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ABSTRACT

A variety of methodologies developed in our research group has inspired the three
separate projects reported. First, the total synthesis of (±)-quebrachamine was performed
in 13 steps and 17.8% overall yield. Highlights of the synthesis include an efficient
preparation of a functionalized indole core via a [3+2] annulation cycloaddition reaction
between a functionalized nitrile and donor-acceptor cyclopropane and a photo induced 9membered ring closure.
Secondly, we have reported the most efficent and highest yielding route to several
tetrahydroisoquinocarbazoles, where the core was prepared in six steps from tryptophol
in 51% overall yield. This work highlights for the first time the synthetic utility of the
dipolar C-2 alkylation of 3-substituted indoles with 2-alkoxycyclopropanoate esters. The
synthesis also features a selective SmBr2-HMPA promoted ring closure of an aldehyde
onto a sterically congested trisubstituted alkene.
Lastly, we have developed efficient syntheses towards several fragments of
biselide A, which could be used to explore both ring closing metathesis and relay ring
closing metathesis to construct the 14-membered macrolactone. The trans-THF ring was
furnished by using our second generation Co(nmp)2 catalyst in a Mukaiyama oxidative
cyclization, while the chloroalkene moiety was introduced with a chloropalladation
reaction. Key steps in the synthesis of the southern fragment included a Sharpless
asymmetric kinetic resolution, or a diastereoselective aldol reaction. Significant synthetic
efforts toward biselide E have also been reported. We have designed an efficient method
to access the western fragment, which also employed our second generation Co(nmp)2
catalyst in a Mukaiyama oxidative cyclization to furnish the trans-THF ring. A proficient
method towards the eastern fragment was also designed, using a Suzuki coupling reaction
as the key step.
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INTRODUCTION: Importance of Total Synthesis
In order to appreciate total synthesis, one needs to consider how synthetic
chemistry has impacted the world around us. Everything from pharmaceuticals, high-tech
materials, polymers, fertilizers, pesticides, personal care products, and even our food, has
been impacted by organic chemistry. One of the main driving forces for chemists is
having the ability to create molecules that have some useful application.
Synthetic chemists take inspiration from Mother Nature, with the hopes that we
can access molecules found in nature, but to also access derivatives of those molecules,
which can be tremendously useful. Since most natural products are found in miniscule
amounts and are often difficult to obtain, accessing them through synthetic means can be
incredibly important in obtaining useful quantities so that we can study their properties.
This leads to their development as useful compounds or potential pharmaceuticals.
When isolation chemists find a natural product that has an interesting biological
activity, the structure of that molecule can be determined using the numerous tools to
facilitate structural elucidation, like NMR, IR, UV-Vis, and HRSM. While these
techniques can be used to determine a compound’s structure with great deal of certainty,
we can only be sure of its absolute structure through synthetic means.
Once we have an efficient way to access a target molecule, we can use that route
to also access derivatives, providing a collection of related molecules that we can study
for their unique properties and biological activity, which is the basis of drug design.
Arguably, one of the most important opportunities that total synthesis offers
chemists the chance to discover and invent new chemistry. During the course of a total
synthesis, you are bound to come across challenges that must be overcome to ultimately
reach your goal. We oftentimes refer to chemical transformations as tools in our synthetic
toolbox. But what if your toolbox doesn’t provide the specific tool you require? It’s these
times that provide chemists with the greatest opportunity to develop new ideas and
methods to achieve a synthetic goal. This is how synthetic chemisty grows and develops.
Lastly, total synthesis, in my opinion is one of the most rigorous ways to train a
synthetic chemist because it challenges their creative thinking, while continually problem
solving, and exposes them to a wide variety of chemical transformations and techniques.
1
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CHAPTER 1: The Total Synthesis of (±)-Quebrachamine

1.1 Introduction

The primary objectives of the Pagenkopf research group are methodology
development and application in the synthesis of natural products. Of particular interest is
the construction of various heterocycles such as pyrroles and indoles due to their
abundance in biologically active compounds. A powerful strategy for the synthesis of
these heterocycles has been developed by our group involving a formal [3+2] dipolar
cycloaddition of donor-acceptor 2-alkoxycyclopropanoate esters.1
The first application of this cycloaddition methodology was demonstrated in the
total synthesis of (±)-goniomitine (1-4), where a [3+2] dipolar cycloaddition between
functionalized nitrile 1-1 and donor acceptor (DA) cyclopropane 1-2 was utilized to
construct the indole core (Scheme 1.1).2 We believed the utility of this methodology
could be further demonstrated by building on these initial discoveries and synthesizing
(±)-quebrachamine (1-5), which is another member of the aspidosperma family.3

Scheme 1.1 Aspidosperma alkaloids

1.2 [3+2] Annulation Reaction

Our interest towards (±)-quebrachamine (1-5) stemmed from the potential
application of our [3+2] dipolar cycloaddition methodology involving DA cyclopropanes.
The versatility and reactivity of cyclopropanes make them useful building blocks in

2

3

organic synthesis. Although there are several known applications with unactivated
cyclopropanes,4 functional groups are more commonly installed around the ring to
increase their reactivity. Electron accepting groups activate the ring opening in a
Michael-type nucleophilic attack, while electron donating substituents do so upon
reaction with an electrophile (Figure 1.1, examples 1 and 2). The most reactive
cyclopropanes contain vicinal acceptor and donor groups5 which promote the formation
of a 1,3-dipole intermediate (Figure 1.1, example 3).

Figure 1.1 Cyclopropane activation

Due to the dual electronic properties exhibited by the 1,3-zwitterionic
intermediate of the opened cyclopropane, the annulation may involve many reaction
partners including nitriles,6 pyridines,7 indoles,8 and other dipolarophiles.9 A general
pyrrole synthesis was developed in our research group where DA cyclopropanes undergo
[3+2] dipolar cycloaddition reactions with nitriles when appropriately activated by a
Lewis acid such as TMSOTf (Scheme 1.2).1,6 The annulation sequence likely consists of
a [3+2] cycloaddition involving the nitrilium ion intermediate, formed in a Ritter type
process where the nitrile attacks the oxocarbenium ion (Scheme 1.2). An intramolecular
cyclization occurs between the enolate and the resulting nitrilium ion, followed by
condensation and tautomerization steps in the construction of the tetrasubstituted pyrrole,
while maintaining absolute regiochemical control.
3

It should be noted that if the

4

cyclopropane contains a fused cyclohexyl ring (R1/R2: -(CH2)4-), the [3+2] annulation
yields a tetrahydroindole which upon oxidation provides access to substituted indoles.

Scheme 1.2 Pyrrole synthesis

1.3 Biological Activity of Quebrachamine

Quebrachamine belongs to a large family of Aspidosperma alkaloids, with only a
few members that possess biological activity. Although quebrachamine is one of the least
structurally complex alkaloids in its class, it exhibits potent bioactivity including αadrenergic blocking behavior in urogenital tissue.10 It was found to reduce smooth muscle
contractions in human prostate, rabbit corpus spongiosum and cavernosum, as well as
guinea pig vas deferens, making quebrachamine a potential drug candidate for erectile
impotence and benign prostatic hyperplasia (BPH).

1.4 Previous Syntheses of Quebrachamine

While quebrachamine (1-5) exhibits attractive pharmacological properties, its
interesting framework has inspired considerable and sustained synthetic efforts, with the
4
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first total synthesis reported in 1963 by Stork and Dolfini.11 The synthesis of this natural
product has continued to challenge chemists as it features a quaternary carbon center,
fused piperidine functionality, and a 9-membered ring. Several previous total syntheses
will be discussed, including the first racemic version, followed by some more recent
asymmetric contributions. Some of the syntheses take inspiration from proposed
biosynthetic pathways towards quebrachamine, which include naturally abundant starting
materials like amino acids and tryptamine.

1.4.1 Previous Syntheses of (±)-Quebrachamine

The first total synthesis of (±)-quebrachamine was described by Stork and Dolfini
in 1963 (Scheme 1.3).11 Their synthesis commenced with a four step sequence from
butyraldehyde 1-6 to form amide 1-7. This crystalline product was reduced to a primary
amine with lithium aluminum hydride and subsequent treatment with acid gave the
bicyclic ketone 1-8. Acylation of the resulting amine with chloroacetyl chloride followed
by treatment with potassium tert-butoxide afforded lactam 1-9. After converting the
lactam to the corresponding amine (1-10) in a three step process, a Fischer indole
cyclization was conducted with phenylhydrazine to give pentacyclic amine 1-11. Finally,
reductive cleavage of 1-11 with potassium borohydride furnished (±)-quebrachamine (15).

Scheme 1.3 Stork and Dolfini’s synthesis of (±)-quebrachamine
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A number of years after the first total synthesis of (±)-quebrachamine, Zoretic and
co-workers published their approach toward the construction of the natural product
(Scheme 1.4).12 Their synthetic efforts began with 4-formylcapronitrile (1-12), and
through a series of functional group manipulations ultimately furnished amine 1-13.
Here, the authors treated the piperidine compound with β-indolylacetyl chloride,
affording a lactam ester which was immediately subjected to saponification reaction
conditions to provide carboxylic acid 1-14 in 44% yield over two steps.

Scheme 1.4 Zoretic’s synthesis of (±)-quebrachamine

Upon heating the carboxylic acid (1-14) in the presence of polyphosphoric acid
(PPA), the desired Friedel-Crafts product was obtained in an excellent 87% yield. It is
interesting to note that PPA catalyzed cyclizations of related β-indolealkanoic acids onto
the C-2 position of the indole typically give the desired products in high yield for 7member ring formation (up to 95%), whereas the 6-, 8-, and 9-membered rings form in
low yields comparatively (30-55%). The authors speculated that the unusually high yield
they observed indicates a possible participation of the amide nitrogen. It is suspected that
perhaps the nitrogen cyclizes on the carboxylic acid first, generating a five membered
transition state and a quaternary ammonium salt, consequently lowering the entropy of
the molecule and promoting the intramolecular cyclization onto the C-2 of the indole.
The synthesis was completed upon reduction of 1-15 with lithium aluminum hydride in
refluxing dioxane in 6% yield. Although (±)-quebrachamine was obtained in low yield,
the synthesis demonstrated an interesting approach to the 9-membered ring via a FriedelCrafts acylation.
6
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A more recent synthesis was reported in 2007 by the Coldham research group.13
Their work relied on the construction of tricyclic amine 1-23 via a highly efficient
cyclization/cycloaddition cascade methodology, which they applied to the synthesis of
(±)-quebrachamine (Scheme 1.5). The synthesis began with acetal protection of
dibromoketone 1-16; followed by a base induced elimination to furnish protected enone
1-17 in 82% yield over two steps. Alkylation of butanenitrile with LDA proceeded
smoothly to give nitrile 1-18, which was subsequently alkylated with 1-bromo-3chloropropane, constructing the quaternary center in 1-19. The resulting nitrile was
reduced with DIBAL in 82% yield, providing the pivotal cyclization precursor (1-20).

Scheme 1.5 Coldham’s synthesis of (±)-quebrachamine

Treatment of 1-20 with glycine and 10-CSA generated ylide 1-21 in situ, which
participated in an intramolecular cycloaddition to give the tetracyclic product 1-22 in
79% yield. Hydrolysis of the acetal was promoted upon treatment with acid, with
concurrent isomerization of the enolizable carbon center providing the cis/cis ketone 123. (±)-Quebrachamine (1-5) was completed after Fischer indole synthesis gave the
desired fused indole, followed by reductive ring opening in 39% yield over two steps.
7
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1.4.2 Previous Asymmetric Syntheses of Quebrachamine
Nearly two decades after Stork and Dolfini’s first total synthesis of (±)quebrachamine, Takano reported the first asymmetric synthesis of (+)-quebrachamine
using L-glutamic acid as a chiral template (Scheme 1.6).14 L-Glutamic acid (1-24) was
first modified by the same reaction sequence developed by Yamada and co-workers.15
After detritylation of 1-25 under acidic conditions, the resulting lactone was hydrolyzed
using NaOH and oxidized with sodium metaperiodate, which gave hydroxy-lactone 1-26
in 60% over three steps. Condensation with tryptamine in acetic acid gave rise to lactam
1-27 as a 1:1 mixture of epimers in 74% yield. Primary alcohol 1-28 was then generated
after treatment of 1-27 with diborane-dimethyl sulphide in THF followed by oxidation
with basic hydrogen peroxide. Reduction of lactam 1-28 proceeded in 46% yield, and
converted to pentacyclic quaternary amine 1-30 over two steps. The quaternary salt was
then reduced (NH3 (liq), Na), giving rise to (+)-quebrachamine in 65% over three steps.

Scheme 1.6 Takano’s synthesis of (+)-quebrachamine
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One year later in 1981, Takano reported an enantioselective route to both (+) and
(−)-quebrachamine using a single chiral synthon 1-25 (Scheme 1.7).16 He provided a
route to both enantiomers of quebrachamine, while utilizing the sequence of steps to form
1-25 as described in his earlier publication.14 His synthesis of (−)-quebrachamine ((−)-15) began with detritylation of 1-25 under acidic conditions, followed by ozonolysis to
access aldehyde 1-31. A Pictet-Spengler condensation was performed with tryptamine
under acidic conditions, producing lactam 1-32 in 47% yield (1:1 epimeric mixture) over
two steps. After epoxide formation (DEAD, PPh3), a rearrangement was induced to
generate an aldehyde which was immediately reduced to give alcohol 1-34 with lithium
aluminum hydride in 11% yield over three steps. The synthesis then converged with
Takano’s previously reported synthesis for (+)-quebrachamine (see Scheme 1.6) to
ultimately furnish (−)-quebrachamine ((−)-1-5).

Scheme 1.7 Takano’s synthesis of (−)-quebrachamine

Recent advancements in chiral olefin metathesis have inspired an enantioselective
synthesis of (+)-quebrachamine, featuring a catalytic ring closure of an achiral triene as
the key step (Scheme 1.8).17 Synthesis of the RCM precursor is accomplished in a four
step sequence, initiated by a Pictet-Spengler condensation of divinylamide fragment 1-36
(prepared in six steps and 34% overall yield from commercially available αacetylbutyrolactone 1-35) and tryptamine to give tetracycle 1-37 in 79% yield. After
amide reduction with lithium aluminum hydride, the resulting amine 1-38 was acylated
with allyl chloroformate and subsequently reduced with NaCNBH3 to cleave the C-N
9
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bond to give 1-39 in 94% yield. Finally, the tricyclic triene 1-40 was secured in 88%
yield after carbamate 1-39 was treated with 2.0 mol % Pd(PPh3)4. With triene 1-40 in
hand, Schrock, Hoveyda and co-workers efficiently performed the key enantioselective
ring closing metathesis with chiral Mo-monoaryloxide catalyst 1-41 with >98%
conversion, 84% yield and 96% ee. Catalytic hydrogenation with PtO2 under H2
atmosphere of terminal alkene 1-42 afforded (+)-quebrachamine in 97% yield.

Scheme 1.8 Schrock and Hoveyda’s synthesis of (+)-quebrachamine
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1.5 The Total Synthesis of (±)-Quebrachamine

1.5.1 Retrosynthesis

Our initial retrosynthetic analysis identified two bonds in the 9-membered ring as
potential key disconnections, which could be formed using a Friedel-Crafts acylation or
N-alkylation reaction, simplifying the target to advanced intermediate 1-43 (Scheme 1.9).
Previous work from the (±)-goniomitine synthesis2 provided a route to 1-43, which was
obtained by oxidation of the tetrasubstituted pyrrole 1-3, which was generated from the
[3+2] cycloaddition involving functionalized nitrile 1-1 and cyclopropane 1-25.

Scheme 1.9 Retrosynthetic strategy

1.5.2 Functionalized Nitrile

Nitrile 1-1 was prepared in a five step sequence, as previously reported in our
group (Scheme 1.10).2 Commercially available δ-valerolactam underwent a one-pot,
double alkylation to install the ethyl and benzyl groups. Following the installation of the
quaternary center using 2-(2-bromoethoxy)tetrahydro-2H-pyran (1-46), 1-47 underwent
hydrolysis (PTSA, MeOH). The resulting primary alcohol 1-48 was halogenated and
directly converted to the target nitrile 1-1 by a microwave assisted displacement reaction
with sodium cyanide. The microwave reaction (120 °C, 8 h) was found to be an efficient
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alternative to classic displacement conditions (82 °C, 72 h), producing the desired nitrile
with a comparable yield and in a significantly shorter reaction time.

Scheme 1.10 Synthesis of nitrile annulation partner 1-1

1.5.3 Construction of the Core of Quebrachamine

The [3+2] cycloaddition reaction between functionalized nitrile 1-1 and DA
cyclopropane 1-2 in the presence of TMSOTf gave cycloadduct 1-3 in 74% yield
(Scheme 1.11). The cycloaddition reaction was followed by oxidation with palladium on
carbon, which provided the indole core (1-50) in an exceptional 98% yield. The ester, an
artifact from the cycloaddition, was removed via a microwave assisted decarboxylation,
and the resulting lactam (1-51) was deprotected without difficulty, thus setting the stage
for the formation of the 9-membered ring.

Scheme 1.11 Construction of the core of quebrachamine
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1.5.4 Cyclization and Completion

1.5.4.1 Friedel-Crafts Method

The formation of 9-membered rings is notoriously difficult, but armed with a
ready supply of indole 1-43, several approaches were investigated. Our initial synthetic
plan to access the 9-membered ring involved a Friedel-Crafts acylation followed by a
Wolff-Kishner reduction. Preparation of the cyclization precursor involved reduction of
lactam 1-43, N-alkylation of the resulting amine (1-52) with ethyl bromoacetate and
saponification (Scheme 1.12). The resulting carboxylic acid (1-53) was subjected to
typical Friedel-Crafts acylation conditions by screening a wide array of catalysts and
varying the reaction temperatures (−30 °C and 25 °C). Unfortunately, all efforts to
cyclize the precursor using these methods resulted in substrate decomposition.

Scheme 1.12 Synthesis of the Friedel-Crafts precursor and cyclization attempts

1.5.4.2 Mitsunobu Method

Our failure to form the 9-membered ring via a Friedel-Crafts reaction compelled
us to explore a different approach involving a Mitsunobu cyclization. In order to
construct this type of ring closing precursor, a hydroxyethyl side-chain needed to be
introduced at the C-3 position of indole 1-51. Previous work in our research group by
Morales in the synthesis of (±)-goniomitine, involved a two-step sequence where indole
was treated with oxalyl chloride in the presence of base, followed by methanol to obtain
13
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methyl oxoester 1-54 (Scheme 1.13, Method 1).18 However, all attempts to selectively
reduce the oxoester to the corresponding alcohol (1-55) without affecting the lactam were
unsuccessful. An alternative route was utilized involving a Mannich type amine
methylation and displacement with sodium cyanide (1-56), followed by double reduction
to the target alcohol (Scheme 1.13, Method 2). This method was undesirable due to the
lengthy reaction sequence and low overall yields, so an alternative method was pursued
to construct the hydroxyethyl side-chain required to access quebrachamine.

Scheme 1.13 Previous hydroxyethyl installation methods

There are several known examples of ethylene oxide being used in a one-step
alkylation process; however, simple substrates undergo alkylation with modest yields
while more highly functionalized examples, comparable to (±)-quebrachamine, result in
unacceptably low yield.19 Although the literature does not provide much encouragement,
we were confident we could optimize the reaction and began a model study.
Our model study began with the N-silyl protection of 2-methyl indole to ensure C3 selectivity by eliminating competitive N-alkylation (Table 1.1). The trimethylsilyl
protecting group was ideal as it can be conveniently removed during purification on silica
gel, avoiding an additional deprotection step. Initial attempts for the side-chain
installation involved treating protected indole 1-57 with an excess of ethylene oxide in
the presence of a Lewis acid in order to activate the epoxide for ring opening.
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Table 1.1 Hydroxyethyl side-chain model study

Entry

Lewis acida

Solvent

Yield (%)d

1

InBr3

THFb

0

b

0

b

2

Yb(OTf)3

THF

3

Sc(OTf)3

THF

0

4

TMSOTf

THFb

0

5

InBr3

Et2Ob

20

6

InCl3

Et2Ob

19

7

Et2AlCl

Et2Ob

10

b

8

BF3·OEt2

Et2O

20

9

Yb(OTf)3

Et2Oc

23

10

Sc(OTf)3

Et2Oc

21

11

TMSOTf

Et2Oc

0

12

MgI2

Et2Oc

0

13

InBr3

Et2Oc

27

c

14

SnCl4 (50 mol %)

Et2O

45e

15

SnCl4

Et2Oc

26

16

SnCl4 (100 mol %)

Et2Oc

43e

17

AlMe3

Et2Oc

19

18

InBr3

benzene/Et2Oc

17

19

InBr3

c

CH2Cl2/Et2O

24

20

InBr3

MTBEc

36

a

5 mol % unless otherwise noted. b Reaction flask was sealed with a septum. c
Reaction flask was sealed with a plastic cap. d All remaining starting material
recovered, with almost no decomposition observed unless otherwise noted.
e
No starting material recovered.
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While no reaction was observed with THF as the solvent (entries 1-4), switching
to Et2O resulted in small amounts of the desired product (1-58) as well as recovered
starting material (as 2-methyl indole) with little decomposition. Due to the high volatility
of ethylene oxide, we had suspected that it may be escaping the reaction mixture, so the
flasks were capped to provide an air-tight seal which resulted in a 7% increase in yield
(entries 5 vs. 13). In an effort to push the reaction to completion, reaction times were
increased from 12 h up to 7 days with no increase in yield. Further investigation involved
screening several Lewis acids where InBr3 and SnCl4 showed the most promising results
(entries 13-16); however, no starting material was recovered when SnCl4 was used, so
InBr3 was selected as the optimal Lewis acid. Finally, numerous solvent systems were
explored with the highest yield observed when methyl tert-butyl ether (MTBE) was used
(entry 20).
Encouraged by our progress, we applied the optimized conditions from the model
study to the substrate (1-51). Our synthetic strategy began with an attempt to N-silylate
indole 1-51 in order to ensure C-3 selectivity by eliminating competitive N-alkylation.
However, all efforts to protect the indole nitrogen were unsuccessful. As a result, we
suspected that the substrate would undergo the C-3 selectivity we desired without the
need for N-protection. As predicted, the hydroxyethyl side-chain installation was
completely C-3 selective and furnished indole 1-55 in 33% yield, with no recovered
starting material (Table 1.2, entry 1).

Table 1.2 Hydroxyethyl side-chain installation

a

Entry

Base (4 equiv)

1

-

33a

2

NaH

38

3

KH

55

No BHT added.

16

Yield (%)
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We speculated that the low yield could be due to competing radical side reactions,
so a radical scavenger (BHT) was added. In a final effort to optimize the reaction, base
was added to assist the alkylation which resulted in a remarkable 22% increase in overall
yield (Table 1.2, entries 1 vs. 3). At this point we had developed the most efficient and
highest yielding method for C-3 hydroxyethyl installation of an indole compared to other
published methods utilizing ethylene oxide.19 It should also be noted that this one-step
installation was more efficient (one step vs. five steps) and higher yielding (55% vs.
31%) then the alternative synthetic route (Scheme 1.13).18
With the hydroxyethyl side-chain installed, the Mitsunobu cyclization precursor
(1-59) was prepared upon deprotection of indole 1-55 (Scheme 1.14). Lactam 1-59 was
then subjected to Mitsunobu conditions, but the desired cyclization product was not
observed. Instead, the reaction led to the formation of spirocycle 1-60, which was the
result of attack through the C-3 position. Different reaction conditions were employed
including varying reaction temperatures, concentration factors, and addition rate, but all
attempts led to spirocycle formation (1-60). In an effort to make the lactam nitrogen
more nucleophilic, 1-59 was reduced to its corresponding amine 1-61 and subjected to
Mitsunobu reaction conditions; however, this led to substrate decomposition. The
nucleophilicity of the indole was detrimental to the desired cyclization, but attempts to
attenuate the indole nucleophilicity by installing a variety of protecting groups was
unsuccessful due to the sterically hindering side-chain.

Scheme 1.14 Mitsunobu cyclization attempts
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1.5.4.3 SN2 Method
Turning our focus to a possible SN2 reaction to close the ring, indole 1-59 was
converted to halide derivatives (1-62 and 1-63) and treated with a base (Scheme 1.15).
When NaH was employed, only spirocycle 1-60 was isolated, whereas treatment with
t-BuOK promoted substrate decomposition. At this stage, the SN2 approach was
abandoned due to the detrimental and unavoidable nucleophilicity of the indole and a
new route was explored.

Scheme 1.15 SN2 cyclization attempts
1.5.4.4 Literature Inspired Method

Our attention turned to a related example in the literature where Lesma and coworkers constructed a similar 9-membered ring in the total synthesis of (+)-20R-15,20dihydrocleavamine (1-66) from cyclization precursor 1-64 (Scheme 1.16).20 Our
synthesis began by protecting amine 1-52 with a Boc or Cbz group. Using the ethylene
oxide method developed earlier, the hydroxyethyl side-chain was installed on both
protected amine derivatives (1-67 and 1-68). The two primary alcohols 1-69 and 1-70
were then converted to leaving groups with MsCl and the amines were deprotected,
where H2 and Pd/C was used to remove the CBz group, while the Boc group was
18
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removed with TFA. Unfortunately, both reactions resulted in complex mixtures with no
trace of the desired products.

Scheme 1.16 Lesma inspired cyclization attempt

1.5.4.5 Chloroacetamide Method

Given the disappointment with our previous strategies to construct the 9membered ring, another approach was taken. The new synthetic plan was designed to
take advantage of the nucleophilic indole, where we had previously seen attack through
the C-3 position. In our initial approaches, this nucleophilicity was detrimental to the
desired reactivity, whereas it would be required in our new strategy. First, alkylation of
piperidine 1-52 with chloroacetyl chloride was achieved in 96% yield (Scheme 1.17).
Treatment of the resulting chloroacetylated amine 1-71 with NaH or allylmagnesium
bromide both led to complex mixtures with trace amounts of undesired N-cyclization.
This outcome was unexpected since in earlier strategies, the C-3 position of the indole
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was observed to be the most nucleophilic site, and all previous efforts to protect the
indole were unsuccessful due to steric effects of the side-chain.

Scheme 1.17 Chloroacetamide indole cyclization attempt

1.5.4.6 Photocyclization Method

After extensive exploration of classic alkylation and acylation strategies, our final
approach involved a photo induced ring closure. Chloroacetamide photocyclizations can
be utilized in the formation of strained medium-sized lactams.21 A number of Witkop
photocyclizations22 have been reported in the synthesis of Vinca and Strychnos alkaloids
via chloroacetamide indole derivatives (Scheme 1.18).23 It is worth noting that simple
substrates, such as isotryptamine derivatives (1-72),23d cyclize in high yield (example 1),
however, substrates with the complexity comparable to that of (±)-quebrachamine, do so
in low to modest yields (example 2).23b,e,f

Scheme 1.18 Reported photocyclizations of 2-indolylalkyl N-chloroacetamides
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Remarkably, exposure of chloroacetylated amine 1-71 to 254 nm irradiation in
basic solution assembled the 9-membered ring in an unprecedented 85% yield (Scheme
1.19). The cyclization mechanism likely involves photoexcitation and electron transfer
steps leading to an initial diradical species 1-76.24 Upon chloride ionization and
electronic redistribution, cyclization of 1-77 occurs at C-3 which is the most favorable
position based on the geometry between the indole and the side-chain as well as the
calculated spin density.24 Lastly, the indole was rearomatized upon proton loss and the
final cyclization product (1-78) was obtained. Delighted with this result, the synthesis
was completed by reducing lactam 1-78 with LiAlH4, securing (±)-quebrachamine (1-5)
in 93% yield.

Scheme 1.19 Photocyclization and completion

1.6 Summary

In summary, the total synthesis of (±)-quebrachamine (1-5) has been
accomplished in 13 steps and 17.8% overall yield. Highlights of the synthesis include an
efficient preparation of a functionalized indole core via a [3+2] cycloaddition reaction
between a functionalized nitrile and donor-acceptor cyclopropane. This synthesis also
utilized a Witkop photo induced 9-membered ring cyclization in an unprecendented yield,
which demonstrated the utility of this type of ring closure in the total synthesis of
complex natural products.
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1.7 Experimental

1.7.1 General Considerations

All reactions were run under an argon atmosphere unless otherwise indicated.
Flasks were oven dried and cooled in a dessicator prior to use unless water was used in
the reaction. Solvents and reagents were purified by standard methods.1 Acetonitrile,
dichloromethane, tetrahydrofuran, diethylether, dimethylformamide, toluene, and
benzene were purified by passing the solvents through activated alumina columns.
Ethanol and methanol were distilled over magnesium prior to use. Mesitylene, MeNO2,
EtNO2, Et3N, (iPr)2NH, NEt(iPr)2 and hexamethylphosphoramide (HMPA) were dried by
refluxing under CaH2 prior to distillation. The solution of nBuLi was titrated prior to use
by Suffert method.2 LDA was freshly prepared before use by the dropwise addition of
nBuLi in hexane (1.00 mmol, 2.50 M) to a solution of N,N-diisopropylamine (1.05 mmol)
in THF (5.00 ml) at 0 °C. All other chemicals were of reagent quality and used as
obtained from commercial sources unless otherwise noted. The progress of reactions
were monitored by thin layer chromatography (TLC) performed on F254 silica gel plates.
The plates were visualized by staining with ceric ammonium molybdate (CAM)3 or panisaldehyde. Column chromatography was performed with Silica Flash P60 60 Å silica
gel from Silicycle according to the Still method.4
The 1H and
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C NMR data were obtained on Varian INOVA 400 or 600

spectrometers. All spectra were obtained in deuterated chloroform and were referenced to
the singlet at δ 7.25 ppm for 1H spectra and the center peak of the triplet at δ 77.0 ppm for
13

C spectra. When peak multiplicities are given, the following abbreviations are used: s,

singlet; d, doublet; dd, doublet of doublets; ddd, doublet of doublet of doublets; ddt,
doublet of doublet of triplets; dq, doublet of quartets; t, triplet; tt, triplet of triplets; td,
1

Armarego, W.L.F.; Perrin, D. D. Purification of Laboratory Chemicals; 4th Ed.; Oxford;
Boston : Butterworth Heinemann, 1996.
2
Suffert, J. J. Org. Chem. 1989, 54, 509–510.
3
See footnote 50 in: Gao, Y.; Hanson, R.M.; Klunder, J.M.; Ko, S.Y.; Masamune, H.;
Sharpless, K.B. J. Am. Chem. Soc. 1987, 109, 5765.
4
Still, W. C.; Kahn, M.; Mitra, A. J. Org. Chem. 1978, 43, 2923–2925.
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triplet of doublets; q, quartet; quin, quintet; m, multiplet; br, broad; app, apparent. EI
mass spectra were obtained on a Finnigan MAT 8200 spectrometer at an ionizing voltage
of 70 eV. Melting points were obtained in an Electrothermal Mel-Temp and are
uncorrected. The microwave reactions were conducted in an Initiator reactor from
Biotage. The photocyclization was performed in a Rayonet Photochemical Reactor
(Model RPR-100) equipped with 16 quartz tube, low pressure Hg lamps.

1.7.2 Experimental Procedures

3-(1-Benzyl-3-ethyl-2-oxopiperidin-3-yl)-propionitrile (1-1)
Crude chloride 1-49 was dissolved in MeCN (120 mL) and NaCN (5.80 g,
119 mmol) was added. The solution was heated to 120 °C in a microwave
reactor for 8 h (900 rpm stirring). The mixture was allowed to cool to RT and washed
with brine. The organic layer was then dried (MgSO4), filtered through Celite and
concentrated under reduced pressure. Purification by flash chromatography on silica gel
using EtOAc-hexanes for elution provided the title compound as light yellow oil (71%,
9.59 g, over two steps). Rf 0.16 (33% EtOAc/hexanes); 1H NMR (400 MHz, CDCl3) 
7.33–7.26 (m, 3H), 7.24–7.20 (m, 2H), 4.65 (d, J = 14.4 Hz, 1H), 4.44 (d, J = 14.4 Hz,
1H), 3.19 (t, J = 6.0, 2H), 2.52–2.36 (m, 2H), 2.03 (ddd, J = 5.8, 10.3, 13.8 Hz, 1H),
1.90–1.72 (m, 5H), 1.66–1.53 (m, 2H), 0.88 (t, J = 7.4 Hz, 3H);
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C NMR (150 MHz,

CDCl3) 172.8, 137.0, 128.3, 127.6, 127.1, 120.0, 50.2, 47.2, 44.0, 33.4, 30.0, 29.1, 19.0,
12.6, 8.0. HRMS m/z 270.1739 (calcd for C17H22N2O, 270.1732).

2-[2-(1-Benzyl-3-ethyl-2-oxopiperidin-3-yl)-ethyl]-4, 5, 6, 7tetrahydro-1H-indole-3-carboxylic acid ethyl ester (1-3)
To a solution of nitrile 1-1 (6.77 g, 25.0 mmol) and the
cyclopropane 1-2 (14.3 g, 72.0 mmol) in EtNO2 (9.50 mL) at –30 °C, TMSOTf (4.72 mL,
26.3 mmol) was added dropwise. After 16 h, 75.0 mL of EtOAc was added and then the
mixture was poured into a half saturated solution of NaHCO3 (150 mL). The
heterogeneous mixture was separated and the aqueous layer was extracted with EtOAc (3
x 15.0 mL). The combined organic layers were washed with brine, dried (MgSO4),
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filtered through Celite and concentrated under reduced pressure. Purification by flash
chromatography on silica gel using EtOAc-hexanes for elution provided the title
compound as white solid (74%, 8.07 g). Rf 0.28 (33% EtOAc/hexanes); mp 119–120 °C
(hexanes/EtOAc crystal); 1H NMR (400 MHz, CDCl3)  8.42 (br s, 1H), 7.32–7.26 (m,
2H), 7.24–7.19 (m, 3H), 4.62 (d, J = 14.6 Hz, 1H), 4.55 (d, J = 14.6 Hz, 1H), 4.23 (q, J =
7.2 Hz, 2H), 3.29 (ddd, J = 6.4, 10.5, 14.3 Hz, 1H), 3.23–3.18 (m, 2H), 2.69–2.66 (m,
2H), 2.56 (ddd, J = 4.7, 10.5, 14.3 Hz, 1H), 2.48–2.44 (m, 2H), 2.03 (ddd, J = 4.7, 10.5,
13.4 Hz, 1H), 1.86–1.72 (m, 10H), 1.61 (ddd, J = 7.2, 14.3 Hz, 1H), 1.31 (t, J = 7.3 Hz,
3H), 0.88 (t, J = 7.6 Hz, 3H); 13C NMR (100 MHz, CDCl3) 175.3, 166.3, 138.9, 137.5,
128.6, 127.9, 127.8, 127.3, 125.9, 118.1, 108.7, 58.8, 50.6, 47.9, 45.6, 38.3, 31.8, 28.9,
23.6, 23.4, 23.0, 22.6, 19.8, 14.6, 8.6. HRMS m/z 436.2719 (calcd for C27H36N2O3,
436.2726).

(±)-Quebrachamine (1-5)
Lactam 1-78 (9.00 mg, 0.03 mmol) in THF (2.00 mL) was added to
a cooled (0 °C) suspension of LiAlH4 (6.00 mg, 0.15 mmol) in 1.00
mL THF. The solution was allowed to warm to RT slowly and then refluxed for 3 h. The
mixture was cooled to 0 °C and poured into a half saturated solution of Na∙K∙Tartrate
(15.0 mL). After stirring for 1 h at RT, the heterogeneous mixture was separated and the
aqueous layer was extracted with EtOAc (5 x 10.0 mL). The combined organic layers
were washed with brine, dried (MgSO4), filtered through Celite and concentrated under
reduced pressure. Purification by flash chromatography on silica gel using EtOAchexanes for elution provided the title compound as a white solid (93% yield, 8.00 mg). Rf
0.39 (100% EtOAc); 1H NMR (400 MHz, CDCl3)  7.69 (br s, 1H), 7.47 (d, J = 7.0 Hz,
1H), 7.26 (dd, J = 7.0, 1.5 Hz, 1H), 7.08 (td, J = 7.0, 1.5 Hz, 1H), 7.05 (td, J = 7.0, 1.5
Hz, 1H), 3.24 (br d, J = 11.7 Hz, 1H), 2.92 (ddd, J = 4.4, 11.4, 16.0 Hz, 1H), 2.83 (ddd, J
= 2.9, 4.4, 15 Hz, 1H), 2.75–2.64 (m, 2H), 2.46–2.44 (m, 1H), 2.41 (ddd, J = 2.9, 4.4,
11.4 Hz, 1H), 2.32 (td, J = 11.5, 4.4 Hz, 1H), 2.23 (td, J = 11.3, 3.2 Hz, 1H), 1.91 (dd, J =
7.0, 14.0 Hz, 1H), 1.62–1.54 (m, 2H), 1.49 (d, J = 11.7 Hz, 1H), 1.32–1.27 (m, 2H),
1.23–1.20 (m, 1H), 1.17–1.08 (m, 2H), 0.84 (t, J = 7.6 Hz, 3H);

13

C NMR (100 MHz,

CDCl3)  139.9, 134.8, 128.9, 120.2, 118.7, 117.4, 109.9, 108.7, 56.7, 55.1, 53.2, 37.1,
24
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34.8, 33.5, 32.1, 22.7, 22.4, 21.9, 7.8. HRMS m/z 282.2085 (calcd for C19H26N2,
282.2096).

3-Ethyl-3-[2-(1H-indol-2-yl)-ethyl]-piperidin-2-one (1-43)
A solution of lactam 1-51 (100 mg, 0.28 mmol) in THF (7.00
mL) and t-butanol (0.30 mL) was cooled to –78 °C and liquid
ammonia (5.00 mL) was added to the solution. Sodium metal (33.0 mg, 1.43 mmol) was
cut into small portions, washed with dry hexanes and added to the ammonia mixture. The
reaction mixture was stirred at –78 °C for 10 min and then solid NH4Cl (200 mg) was
added. The reaction was allowed to warm up to RT while the ammonia evaporated
completely. Water (10.0 mL) was added and the heterogeneous mixture was separated.
The aqueous layer was extracted with CH2Cl2 (3 x 15.0 mL). The combined organic
layers were washed with brine, dried (MgSO4), filtered through Celite and concentrated
under reduced pressure. Purification by flash chromatography on silica gel using EtOAchexanes for elution provided the title compound as white solid (93% yield, 70.0 mg). Rf
0.12 (80% EtOAc/hexanes); mp 170–172 °C; 1H NMR (400 MHz, CDCl3)  8.44 (br s,
1H), 7.49 (d, J = 7.6 Hz, 1H), 7.27 (d, J = 8.2 Hz, 1H), 7.08 (t, J = 7.6 Hz, 1H), 7.03 (t, J
= 7.6 Hz, 1H), 6.20 (s, 1H), 5.91 (br s, 1H), 3.32–3.29 (m, 2H), 2.86 (ddd, J = 5.8, 11.1,
15.2 Hz, 1H), 2.68 (ddd, J = 4.1, 11.1, 14.6 Hz, 1H), 2.13 (ddd, J = 4.7, 11.7, 14.0 Hz,
1H), 1.86–1.75 (m, 6H), 1.64 (ddd, J = 7.0, 14.6, 28.7 Hz, 1H), 0.91 (t, J = 7.6 Hz, 3H);
13

C NMR (100 MHz, CDCl3)  177.1, 139.9, 136.1, 128.6, 120.8, 119.6, 119.3, 110.5,

99.1, 45.1, 42.7, 37.7, 31.2, 29.1, 23.7, 19.7, 8.5. HRMS m/z 270.1726 (calcd for
C17H22N2O, 270.1732).
1-Benzyl-3-ethylpipidin-2-one (1-45)
A solution of freshly distilled -valerolactam (19.8 g, 200 mmol) in THF
(530 mL) was cooled to –78 °C and nBuLi (2.05 equiv) in hexane was added dropwise.
Iodoethane (12.1 mL, 150 mmol) was then added dropwise and allowed to stir at –78 °C
for 1 h, followed by the addition of benzylbromide (31.6 mL, 266 mmol). The reaction
was then allowed to warm to RT over 16 h. The solution was poured into a half saturated
solution of NH4Cl (530 mL). The heterogeneous mixture was separated and the aqueous
25
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layer was extracted with EtOAc (3 x 100 mL). The combined organic layers were washed
with brine, dried (MgSO4), filtered through Celite and concentrated under reduced
pressure. Purification by flash chromatography on silica gel using EtOAc-hexanes for
elution provided the title compound as light yellow oil (89%, 38.6 g). Rf 0.23 (25%
EtOAc/hexanes); 1H NMR (400 MHz, CDCl3)  7.29–7.19 (m, 5H), 4.55 (s, 2H), 3.14
(dd, J = 4.8, 2.2 Hz, 2H), 2.27 (ddd, J = 5.2, 9.4, 14.0 Hz, 1H), 2.00–1.86 (m, 2H), 1.84–
1.75 (m, 1H), 1.70–1.47 (m, 3H), 0.93 (t, J = 7.4 Hz, 3H); 13C NMR (100 MHz, CDCl3)
172.4, 137.4, 128.3, 127.7, 126.9, 50.0, 47.2, 42.7, 25.6, 24.7, 21.4, 11.3. HRMS m/z
217.1465 (calcd for C14H19NO, 217.1467).

1-Benzyl-3-ethyl-3-[2-(tetrahydropyran-2-yloxy)-ethyl]-piperidin-2-one
(1-47)
Lactam 1-45 (16.3 g, 75.0 mmol) was dissolved in 200 mL of THF and
cooled to –78 °C. A freshly prepared solution of LDA (1.05 equiv) in THF (75.0 mL)
was then added dropwise and allowed to stir for 15 min. The solution was allowed to
warm to –10 °C over 15 min and cooled back to –78 °C. The tetrahydropyranyl ether of
2-bromoethanol (17.3 g, 82.5 mmol) was then added slowly with a dropping funnel and
the resulting solution was allowed to slowly warm to RT 16 h. The mixture was then
poured into an ice cold half saturated solution of NH4Cl (200 mL). The heterogeneous
mixture was separated and the aqueous layer was extracted with EtOAc (3 x 40.0 mL).
The combined organic layers were washed with brine, dried (MgSO4), filtered through
Celite and concentrated under reduced pressure. Purification by flash chromatography on
silica gel using EtOAc-hexanes for elution provided the title compound as yellow oil
(92%, 24.1 g). Rf 0.24 (33% EtOAc/hexanes); 1H NMR (400 MHz, CDCl3)  7.33–7.23
(m, 5H), 4.66–4.48 (m, 3H), 3.89–3.82 (m, 2H), 3.54–3.44 (m, 2H), 3.19–3.16 (m, 2H),
2.13–2.02 (m, 1H), 1.88–1.75 (m, 7H), 1.72–1.65 (m, 1H), 1.63–1.49 (m, 5H), 0.89 (t, J
= 7.3 Hz, 3H);

13

C NMR (100 MHz, CDCl3) 174.3, 137.7, 128.4, 127.9, 127.1, 99.1,

98.8, 64.5, 64.3, 62.5, 62.3, 50.5, 47.6, 44.1, 37.1, 31.6, 30.8, 29.7, 25.4, 19.7, 8.7.
HRMS m/z 345.2297 (calcd for C21H31NO3, 345.2304).
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1-Benzyl-3-ethyl-3-(2-hydroxyethyl)-piperidin-2-one (1-48)
A solution of tetrahydropyranyl lactam 1-47 (34.5 g, 100 mmol) in methanol
(360 mL) was cooled by an ice-brine bath and p-toluenesulphonic acid
monohydrate (2.72 g, 14.7 mmol) was added as a solid and stirred for 4 h. The resulting
solution was neutralized with solid NaHCO3 and the volatiles were removed under
reduced pressure. The yellow residue was dissolved in EtOAc and water (200 mL, 1:1).
The heterogeneous mixture was separated and the aqueous layer was extracted with
EtOAc (3 x 50.0 mL). The combined organic layers were washed with brine, dried
(MgSO4), filtered through Celite and concentrated under reduced pressure. Purification
by flash chromatography on silica gel using EtOAc-hexanes for elution provided the title
compound as yellow oil (92%, 24.0 g). Rf 0.13 (50% EtOAc/hexanes); 1H NMR (400
MHz, CDCl3)  7.33–7.28 (m, 2H), 7.26–7.21 (m, 3H), 4.61 (d, J = 14.7 Hz, 1H), 4.54
(d, J = 14.7 Hz, 1H), 3.97-3.95 (m, 1H), 3.92–3.87 (m, 1H), 3.68–3.60 (m, 1H), 3.20 (t, J
= 5.0 Hz, 2H), 1.92–1.83 (m, 2H), 1.80–1.74 (m, 4H), 1.72–1.58 (m, 2H), 0.85 (t, J = 7.6
Hz, 3H);

C NMR (100 MHz, CDCl3) 176.4, 137.1, 128.6, 127.9, 127.3, 58.9, 50.7,

13

47.8, 44.1, 40.4, 31.2, 29.8, 19.1, 8.1. HRMS m/z 261.1730 (calcd for C16H23NO2,
261.1729).

1-Benzyl-3-(2-chloro-ethyl)-3-ethyl-piperidin-2-one (1-49)
A solution of alcohol 1-48 (13.1 g, 50.0 mmol) in CH2Cl2 (100 mL) was
cooled to 0 °C and Et3N (14.6 mL, 105 mmol) was added dropwise,
following the addition of MsCl (4.12 mL, 52.5 mmol). The ice bath was removed and the
solution was allowed to warm to RT over 3 h. The mixture was then poured into a half
saturated solution of NaHCO3 (80.0 mL). The heterogeneous mixture was separated and
the aqueous layer was extracted with CH2Cl2 (3 x 25.0 mL). The combined organic layers
were washed with brine, dried (MgSO4), filtered through Celite and concentrated under
reduced pressure. The product was immediately converted to nitrile 1-1 without further
purification. Rf 0.40 (33% EtOAc/hexanes); 1H NMR (400 MHz, CDCl3)  7.33–7.26 (m,
2H), 7.24–7.20 (m, 3H), 4.61 (d, J = 14.6 Hz, 1H), 4.50 (d, J = 14.6 Hz, 1H), 3.68–3.56
(m, 2H), 3.18 (t, J = 6.1 Hz, 2H), 2.16 (ddd, J = 5.8, 10.7, 13.7 Hz, 1H), 2.00 (ddd, J =
5.8, 10.7, 13.7 Hz, 1H), 1.86–1.73 (m, 4H), 1.71–1.65 (m, 1H), 1.62–1.53 (m, 1H), 0.88
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(t, J = 7.6 Hz, 3H);

13

C NMR (100 MHz, CDCl3) 173.23, 137.3, 128.5, 127.9, 127.2,

50.4, 47.5, 44.9, 41.3, 41.2, 30.7, 29.8, 19.4, 8.4. HRMS m/z 279.1389 (calcd for
C16H22ClNO, 279.1390).

2-[2-(1-Benzyl-3-ethyl-2-oxopiperidin-3-yl)-ethyl]-1Hindole-3-carboxylic acid ethyl ester (1-50)
Tetrasubstituted pyrrole 1-3 (4.38 g, 10.0 mmol) was added to a
suspension of palladium on carbon (5% Pd/C, 665 mg) in mesitylene (100 mL) and
heated to reflux for 24 h. The mixture was cooled and the palladium was filtered through
a pad of silica gel and Celite.

After the solution was concentrated under reduced

pressure, purification by flash chromatography on silica gel was performed using EtOAchexanes for elution, which provided the title compound as a white solid (98%, 4.24 g). Rf
0.18 (33% EtOAc/hexanes); mp = 134–136 °C (hexanes / EtOAc crystal); 1H NMR (400
MHz, CDCl3)  9.69 (br s, 1H), 8.07 (d, J = 8.2 Hz, 1H), 7.30–7.12 (m, 8H), 4.69 (d, J =
14.6 Hz, 1H), 4.54 (d, J = 14.6 Hz, 1H), 4.39 (q, J = 7.0 Hz, 2H), 3.62 (ddd, J = 6.4, 9.9,
14.0 Hz, 1H), 3.29–3.19 (m, 2H), 2.82 (ddd, J = 5.3, 9.9, 14.6 Hz, 1H), 2.17 (ddd, J =
5.3, 9.9, 14.6 Hz, 1H), 1.93–1.80 (m, 6H), 1.66 (ddd, J = 7.6, 15.2, 28.7 Hz, 1H), 1.45 (t,
J = 7.0 Hz, 3H), 0.89 (t, J = 7.3 Hz, 3H);

13

C NMR (100 MHz, CDCl3)  175.4, 166.2,

149.0, 137.2, 134.9, 128.7, 127.8, 127.4, 126.9, 122.1, 121.3, 111.0, 103.4, 59.3, 50.8,
47.9, 45.9, 37.5, 31.6, 28.9, 22.9, 19.6, 14.6, 8.5. HRMS m/z 432.2419 (calcd for
C27H32N2O3, 432.2413).

1-Benzyl-3-ethyl-3-[2-(1H-indol-2-yl)-ethyl]-piperidin-2-one
(1-51)
Indole 1-50 (4.32 g, 10.0 mmol) was dissolved in ethanol (85.0
mL) and a solution of sodium hydroxide (4.00 g, 100 mmol) in water (85.0 mL) was
added. The mixture was heated to 150 °C in a microwave reactor for 3 h (900 rpm
stirring). The mixture was cooled it was neutralized with 1.00 M HCl. The volatiles were
removed under reduced pressure and the residue was dissolved in 60.0 mL of EtOAc.
The solution was extracted with EtOAc (3 x 60.0 mL). The combined organic layers were
washed with brine, dried (MgSO4), filtered through Celite and concentrated under
28
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reduced pressure. Purification by flash chromatography on silica gel using EtOAchexanes for elution provided the title compound as yellow solid (69%, 2.49 g). Rf 0.27
(33% EtOAc/hexanes); mp 96–98 °C; 1H NMR (400 MHz, CDCl3)  8.46 (br s, 1H),
7.50 (d, J = 8.2 Hz, 1H), 7.32–7.22 (m, 6H), 7.09 (app t, J = 7.6 Hz, 1H), 7.04 (app t, J =
7.6 Hz, 1H), 6.20 (s, 1H), 4.66 (d, J = 14.6 Hz, 1H), 4.53 (d, J = 14.6 Hz, 1H), 3.22 (t, J =
5.3 Hz, 2H), 2.86 (ddd, J = 5.8, 10.5, 15.2 Hz, 1H), 2.66 (ddd, J = 4.7, 10.5, 15.2 Hz,
1H), 2.19 (ddd, J = 4.1, 10.5, 13.5 Hz, 1H), 1.88–1.77 (m, 6H), 1.68 (ddd, J = 7.6, 14.6,
28.7 Hz, 1H), 0.90 (t, J = 7.6 Hz, 3H);

13

C NMR (100 MHz, CDCl3)  174.9, 140.1,

137.5, 136.1, 128.6, 127.9, 127.3, 120.9, 119.6, 119.4, 110.5, 99.1, 50.6, 47.8, 45.6, 37.9,
31.5, 29.2, 23.8, 19.6, 8.5. HRMS m/z 360.2203 (calcd for C24H28N2O, 360.2202).
2-[2-(3-Ethyl-piperidin-3-yl)-ethyl]-1-H-indole (1-52)
A solution of lactam 1-43 (100 mg, 0.28 mmol) in THF (15.0
mL) was cooled to 0 °C and Red-Al (2.80 mmol of 65 wt% in
toluene) was added dropwise. The flask was adapted with a reflux condenser and the ice
bath removed. The solution was allowed to warm to RT slowly and then refluxed for 12
h. The mixture was cooled to 0 °C and poured into a half saturated solution of 15.0 mL
Rochelle’s salt (Na·K·tartrate). After stirring for 1 h at RT, the heterogeneous mixture
was separated and the aqueous layer was extracted with EtOAc (5 x 15.0 mL). The
combined organic layers were washed with brine, dried (MgSO4), filtered through Celite
and concentrated under reduced pressure. Purification by flash chromatography on silica
gel using a gradient solvent system with EtOAc and then MeOH-EtOAc was performed,
which provided the title compound as orange oil (93% yield, 67.0 mg). Rf 0.03 (10%
MeOH in EtOAc); 1H NMR (400 MHz, CDCl3)  9.01 (br s, 1H), 7.51 (dd, J = 1.5, 7.0
Hz, 1H), 7.29 (d, J = 7.9 Hz, 1H), 7.09 (dt, J = 1.9, 7.6 Hz, 1H), 7.04 (dt, J = 1.4, 7.3 Hz,
1H), 6.23 (s, 1H), 4.22 (br s, 1H), 2.96–2.90 (m, 1H), 2.75–2.69 (m, 2H), 2.67–2.62 (m,
2H), 2.50 (d, J = 12.4 Hz, 1H), 1.94 (ddd, J = 6.5, 10.2, 14.1 Hz, 1H), 1.66 (ddd, J = 6.7,
10.2, 14.1 Hz, 2H), 1.55–1.25 (m, 6H), 0.85 (t, J = 5.3 Hz, 3H);

13

C NMR (100 MHz,

CDCl3)  140.3, 136.0, 128.7, 120.7, 119.6, 119.3, 110.4, 99.0, 54.0, 46.6, 34.6, 33.8,
32.9, 28.3, 21.9, 21.5, 7.1. HRMS m/z 256.1931 (calcd for C17H24N2, 256.1939).
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{3-Ethyl-3-[2-(1H-indol-2-yl)-ethyl]-piperidin-1-yl}-acetic
acid ethyl ester (1-52b)
Amine 1-52 (109 mg, 0.42 mmol) was dissolved in MeCN
(30.0 mL) and then NEt(iPr)2 (96.0 μL) was added slowly dropwise followed by
ethylbromoacetate (62.0 μL). The solution was allowed to stir for 14 h and then poured
into 15.0 mL 1.00 M HCl. The heterogeneous mixture was separated and the aqueous
layer was extracted with EtOAc (5 x 10.0 mL). The combined organic layers were
washed with brine, dried (MgSO4), filtered through Celite and concentrated under
reduced pressure. Purification by flash chromatography on silica gel using EtOAchexanes for elution provided the title compound as colorless oil (82% yield, 119 mg). Rf
0.67 (10% MeOH in EtOAc); 1H NMR (400 MHz, CDCl3) δ 8.79 (br s, 1H), 7.53 (d, J =
7.5 Hz, 1H), 7.33 (d, J = 8.0 Hz, 1H), 7.11 (td, J = 7.4, 1.5 Hz, 1H), 7.07 (td, J = 7.3, 1.2
Hz, 1H), 7.25 (d, J =1.2 Hz, 1H), 4.26 (d, J = 8.0 Hz, 1H), 4.22 (d, J = 8.0 Hz, 1H), 3.17
(q, J = 16.0 Hz, 2H), 2.74–2.64 (m, 3H), 2.51 (d, J = 11.0 Hz, 1H), 2.31–2.27 (m, 1H),
2.18–2.11 (m, 1H), 1.99 (d, J = 11.0 Hz, 1H), 1.81–1.71 (m, 1H), 1.68–1.56 (m, 2H),
1.52–1.43 (m, 2H), 1.31 (t, J = 7.1 Hz, 3H), 1.28–1.18 (m, 2H), 0.90 (t, J = 7.5 Hz, 3H);
13

C NMR (100 MHz, CDCl3) δ 171.2, 140.9, 136.1, 128.8, 120.5, 119.5, 119.2, 110.4,

98.8, 62.0, 60.5, 60.0, 54.8, 35.9, 33.6, 33.1, 29.0, 22.1, 21.7, 14.2, 7.2. HRMS: m/z
342.2358 (calcd. for C21H30N2O2, 342.2307).

{3-Ethyl-3-[2-(1H-indol-2-yl)-ethyl]-piperidin-1-yl}-acetic
acid (1-53)
Ester 1-52b (85.0 mg, 0.25 mmol) was dissolved in EtOH
(5.00 mL) and 2.00 M NaOH (0.25 mL) was added slowly dropwise. The solution was
allowed to stir for 8 h and then neutralized with 1.00 M HCl and the solution was
concentrated under reduced pressure. The residue was dissolved in EtOAc and water
(20.0 mL, 1:1) and the aqueous layer was extracted with EtOAc (5 x 10.0 mL). The
combined organic layers were washed with brine, dried (MgSO4), filtered through Celite
and concentrated under reduced pressure. Purification by flash chromatography on silica
gel using EtOAc-hexanes for elution provided the title compound as colorless oil (73%
yield, 57.0 mg). Rf 0.05 (10% MeOH in EtOAc); 1H NMR (400 MHz, CDCl3) δ 10.67
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(br s, 1H), 7.45 (d, J = 7.2 Hz, 1H), 7.33 (br. s, 1H), 7.05–6.94 (m, 2H), 6.12 (br. s, 1H),
3.80–2.62 (m, 1H), 3.58–3.45 (m, 1H), 3.42–2.13 (m, 2H), 2.95–2.76 (m, 1H), 2.54–2.41
(m, 1H), 2.39–2.25 (m, 1H), 2.18–1.82 (m, 2H), 1.16–1.35 (m, 3H), 1.34–1.16 (m, 3H),
0.99–0.83 (m, 2H), 0.75 (br s, 3H); 13C NMR (100 MHz, CDCl3) δ 168.2, 139.9, 136.4,
128.4, 120.5, 119.4, 119.0, 111.0, 98.6, 59.5, 58.7, 53.9, 35.7, 31.6, 30.8, 29.6, 21.6, 18.9,
6.7. HRMS: m/z 314.1988 (calcd. for C19H26N2O2, 314.1994).

1-Benzyl-3-ethyl-3-{2-[3-(2-hydroxy-ethyl)-1H-indol-2-yl]ethyl}-piperidin-2-one (1-55)
Indole 1-51 (25.0 mg, 0.06 mmol) was dissolved in 0.20 mL
MTBE and cooled to −25 °C and potassium hydride (9.60 mg, 0.24 mmol) was added as
a solution in 0.50 mL MTBE. InBr3 (21.0 mg, 0.06 mmol) and BHT (1.00 mg, 0.005
mmol) were then added, followed by 45.0 μL (0.90 mmol) of ethylene oxide in 0.30 mL
MTBE.5 The flask was capped and the solution as allowed to stir at 0 °C for 12 h. The
solution was allowed to warm to RT and the ethylene oxide evaporated. The solution was
poured into 10.0 mL water and the heterogeneous mixture was separated and the aqueous
layer was extracted with EtOAc (5 x 10.0 mL). The combined organic layers were
washed with brine, dried (MgSO4), filtered through Celite and concentrated under
reduced pressure. Purification by flash chromatography on silica gel using EtOAchexanes for elution provided the title compound as yellow oil (55% yield, 13.0 mg). Rf
0.55 (100% EtOAc); 1H NMR (400 MHz, CDCl3) δ 8.59 (br s, 1H), 7.50 (d, J = 7.6 Hz,
1H), 7.32–7.23 (m, 6H), 7.11 (dd, J = 7.5, 1.3 Hz, 1H), 7.07–7.03 (m, 1H), 4.68 (d, J =
14 Hz, 1H), 4.54 (d, J = 14 Hz, 1H), 3.83 (t, J = 6.4 Hz, 2H), 3.29–3.21 (m, 2H), 2.96 (td,
J = 6.4, 2.3 Hz, 2H), 2.91–2.85 (m, 1H), 2.53 (ddd, J = 14, 10, 4.0 Hz, 1H), 2.17 (ddd, J
5

Ethylene oxide is very toxic and great care should be taken when using it. The tank
should be secured inside a fumehood with the appropriate regulator. The set-up
involved connecting the regulator with a tube, equipped with a needle. This needle was
inserted into a 25 mL flask with a septum. The flask was also equipped with needle
connected to a bubbler, which vented to the fumehood. The ethylene oxide gas was
then passed through the flask at −30 °C. Once a small amount of ethylene oxide was
condensed, a known amount of solvent (MTBE) was added and the solution was
brought up in a syringe to determine the total volume. The concentration was then
calculated and the appropriate amount was added to the reaction mixture.
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= 13, 13, 3.9 Hz, 1H), 1.83–1.65 (m, 8H), 0.89 (t, J = 7.5 Hz, 3H); 13C NMR (100 MHz,
CDCl3) δ 175.1, 137.4, 135.6, 128.6, 128.3, 127.9, 127.4, 121.1, 119.0, 117.9, 110.6,
106.6, 62.8, 50.74, 47.9, 45.8, 38.3, 31.6, 28.9, 27.8, 21.6, 19.5, 8.5. HRMS m/z 404.2474
(calcd for C26H32N2O2, 404.2464).
2-Methyl-1-(trimethylsilyl)-1H-indole (1-57)
2-Methylindole (300 mg, 2.28 mmol) was dissolved in 4.00 mL THF and
cooled to −78 °C. nBuLi (0.90 mL, 2.28 mmol, 2.51 M) and allowed to stir
for 1.5 h at −78 °C. TMSCl (0.35 mL, 2.74 mmol) was added and the solution was
allowed to stir at RT for 16 h. The solution was poured into 10.0 mL water and mixture
was separated and the aqueous layer was extracted with EtOAc (5 x 10.0 mL). The
combined organic layers were washed with brine, dried (MgSO4), filtered through Celite
and concentrated under reduced pressure to give the title compound as colorless oil (92%
yield, 427 mg). 1H NMR (400 MHz, CDCl3) δ 7.50-7.47 (m, 2H), 7.09-7.06 (m, 2H),
6.31 (s, 1H), 2.48 (s, 3H), 0.60 (s, 9H).

2-(2-Methyl-1H-indol-3-yl)-ethanol (1-58)
Indole 1-57 (24.0 mg, 0.12 mmol) was dissolved in 0.40 mL MTBE
and cooled to −25 °C. InBr3 (3.20 mg, 0.01 mmol) and BHT (2.00 mg)
were then added, followed by 90.0 μL of ethylene oxide in 0.60 mL MTBE.5 The flask
was capped and the solution as allowed to stir at 0 °C for 12 h. The solution was allowed
to warm to RT and the ethylene oxide evaporated. The solution was poured into 10.0 mL
water and the heterogeneous mixture was separated and the aqueous layer was extracted
with EtOAc (5 x 10.0 mL). The combined organic layers were washed with brine, dried
(MgSO4), filtered through Celite and concentrated under reduced pressure. Purification
by flash chromatography on silica gel using EtOAc-hexanes for elution provided the title
compound as colorless oil (36% yield, 8.00 mg). Rf 0.30 (50% EtOAc/hexanes). 1H NMR
(400 MHz, CDCl3) δ 7.85 (br s, 1H), 7.52 (d, J = 7.6 Hz, 1H), 7.26 (d, J = 7.6 Hz, 1H),
7.15–7.07 (m, 2H), 3.84 (t, J = 6.5 Hz, 2H), 2.97 (t, J = 6.5 Hz, 2H), 3.29 (s, 3H), 1.51
(br s, 1H); 13C NMR (100 MHz, CDCl3) δ 135.3, 132.4, 12.7, 121.1, 119.3, 117.9, 110.3,
107.5, 62.8, 27.7, 11.7.
32

33

3-Ethyl-3-{2-[3-(2-hydroxy-ethyl)-1H-indol-2-yl]-ethyl}piperidin-2-one (1-59)
The title compound was obtained from compound 1-55 using the
standard benzyl deprotection reaction conditions described above in the procedure to
obtain compound 1-43. This procedure provided the title compound as colorless oil (91%
yield). Rf 0.40 (100% EtOAc); 1H NMR (400 MHz, CDCl3) δ 8.85 (br. s, 1 H), 7.50 (d, J
= 7.4 Hz, 1 H), 7.26–7.24 (m, 1 H), 7.10–7.02 (m, 2 H), 6.10 (br. s, 1 H), 3.84 (t, J = 6.4
Hz, 2 H), 3.24–3.20 (m, 2 H), 2.99–2.94 (m, 2 H), 2.83 (ddd, J = 5.9, 12.0, 14.0 Hz, 1 H),
2.49 (ddd, J = 2.3, 12.0, 16.0 Hz, 1 H), 2.42 (br. s, 1 H), 2.10–2.02 (m, 1 H), 1.80–1.68
(m, 5 H), 1.65–1.54 (m, 2 H), 0.86 (t, J = 7.4 Hz, 3H) ppm. 13C NMR (100 MHz, CDCl3)
δ 177.2, 137.2, 135.5, 128.3, 120.9, 118.8, 117.9, 110.6, 106.6, 62.6, 45.1, 42.6, 38.2,
31.4, 28.7, 27.8, 21.4, 19.6, 8.3. HRMS: m/z 314.1985 (calcd. for C19H26N2O2,
314.1994).

3-Ethyl-3-{3-[(E)-2-(1-methyl-cyclopropyl)-phenylimino]propyl}-piperidin-2-one (1-60)
Procedure A: A solution of PPh3 (25.0 mg, 0.09 mmol) and
DIAD (19.0 mg, 0.09 mmol) in 2.00 mL of THF was maintained at RT for 30 min and
then cooled to 0 °C. A solution of indole 1-59 (20.0 mg, 0.063 mmol) in THF (0.75 mL)
was added and stirred for 12 h at RT. The heterogeneous mixture was separated and the
aqueous layer was extracted with EtOAc (5 x 10.0 mL). The combined organic layers
were washed with brine, dried (MgSO4), filtered through Celite and concentrated under
reduced pressure. Purification by flash chromatography on silica gel using
EtOAc/hexanes for elution provided the title compound as yellow oil (56% yield).
Procedure B: A solution of indole 1-62 or 1-63 (0.05 mmol) in THF (8.00 mL) was
added to a slurry of NaH in 1.60 mL of THF. The solution was heated to reflux for 30
min, cooled and then poured into 10.0 mL of water. The heterogeneous mixture was
separated and the aqueous layer was extracted with EtOAc (5 x 10.0 mL). The combined
organic layers were washed with brine, dried (MgSO4), filtered through Celite and
concentrated under reduced pressure. Purification by flash chromatography on silica gel
using EtOAc/hexanes for elution provided the title compound as yellow oil (60% yield).
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Rf 0.18 (5% MeOH in EtOAc). 1H NMR (400 MHz, CDCl3) δ 7.65 (d, J = 7.4 Hz, 1 H),
7.30 (t, J = 7.7 Hz, 1 H), 7.15 (t, J = 7.4 Hz, 1H), 6.95 (d, J = 6.8 Hz, 1 H), 5.61 (br s, 1
H), 3.29 (dt, J = 5.8, 1.9 Hz, 2 H), 2.48 (ddd, J = 5.9, 11.2, 15.1 Hz, 1 H), 2.25 (ddd, J =
5.4, 11.0, 16.0 Hz, 1 H), 2.07–2.01 (m, 2 H), 1.97–1.93 (m, 1 H), 1.90–1.68 (m, 7 H),
1.63–1.54 (m, 2 H), 0.89 (t, J = 7.5 Hz, 3 H);

13

C NMR (100 MHz, CDCl3) δ 177.1,

137.0, 135.3, 127.8, 127.1, 119.1, 117.5, 110.7, 107.0, 45.3, 44.7, 42.7, 37.8, 31.2, 28.9,
28.2, 21.4, 19.5, 8.4.

2-{2-[2-(3-Ethyl-piperidin-3-yl)-ethyl]-1H-indol-3-yl}-ethanol
(1-61)
*Note: The title compound was not confirmed by spectroscopic
characterization, and was only suspected using the following procedure.*
Compound 1-59 was subjected to the reduction reaction conditions described above in the
procedure to obtain compound 1-52. This procedure provided an orange oil (suspected
93% yield). Rf 0.03 (100% EtOAc). NMR or HRMS of this compound was not possible
due to its instability. Characterized by TLC and used immediately.

3-{2-[3-(2-Chloro-ethyl)-1H-indol-2-yl]-ethyl}-3-ethylpiperidin-2-one (1-62)
*Note: The title compound was not confirmed by spectroscopic
characterization, and was only suspected using the following procedure.*
Alcohol 1-59 (30.0 mg, 0.09 mmol) was dissolved in CH2Cl2 (1.00 mL) and cooled to 0
°C. MsCl (10.0 μL, 0.13 mmol) and Et3N (40.0 μL, 0.29 mmol) were added dropwise.
The solution was allowed to stir for 3 h and then poured into a half saturated solution of
NaHCO3 (10.0 mL). The heterogeneous mixture was separated and the aqueous layer was
extracted with EtOAc (5 x 10.0 mL). The combined organic layers were washed with
brine, dried (MgSO4), filtered through a pad of silica over Celite and concentrated under
reduced pressure providing a yellow oil (suspected 52% yield, 48.0 mg). Rf 0.41 (5 %
MeOH in EtOAc). Due to the instability of this compound, NMR and HRMS were not
obtained. Characterized by TLC and used immediately.
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3-{2-[3-(2-Bromo-ethyl)-1H-indol-2-yl]-ethyl}-3-ethylpiperidin-2-one (1-63)
*Note: The title compound was not confirmed by spectroscopic
characterization, and was only suspected using the following procedure.*
Alcohol 1-59 (43.0 mg, 0.13 mmol) was dissolved in CH2Cl2 (0.60 mL), to which CBr4
(68.0 mg, 0.20 mmol) and PPh3 (52.0 mg, 0.19 mmol) were added. The solution was
allowed to stir for 3 h and the solution was concentrated under reduced pressure. The
residue was filtered through a pad of silica over Celite and concentrated under reduced
pressure providing colourless oil (suspected 95% yield, 48.0 mg). Rf 0.2 (5% MeOH in
EtOAc). Due to the instability of this compound, NMR and HRMS were not obtained.
Characterized by TLC and used immediately.

3-Ethyl-3-[2-(1H-indol-2-yl)-ethyl]-piperidine-1-carboxylic
acid benzyl ester (1-67)
Amine 1-52 (17.0 mg, 0.07 mmol) was dissolved in CH2Cl2
(3.00 mL), to which NEt(iPr)2 (23.0 μL, 0.13 mmol) and freshly distilled benzyl
chloroformate (14.0 μL, 0.10 mmol) were added. The solution was allowed to stir for 16
h and then poured into 10.0 mL water. The heterogeneous mixture was separated and the
aqueous layer was extracted with CH2Cl2 (5 x 10.0 mL). The combined organic layers
were washed with brine, dried (MgSO4), filtered through Celite and concentrated under
reduced pressure. Purification by flash chromatography on silica gel using EtOAchexanes for elution provided the title compound as colorless oil (82% yield, 21.0 mg). Rf
0.38 (30% EtOAc/hexanes); 1H NMR (400 MHz, CDCl3) δ 8.84 (br s, 1H), 7.50 (d, J =
7.6 Hz, 1H), 7.37–7.24 (m, 6), 7.10–7.01 (m, 2H), 6.20 (s, 1H), 5.27 (d, J = 12 Hz, 1H),
5.14 (d, J = 12 Hz, 1H), 3.93–3.91 (m, 1H), 3.42–3.38 (m, 0.5H), 3.31–3.27 (m, 0.5H),
3.10–3.07 (m, 0.5H), 3.00–2.94 (m, 0.5H), 2.76–2.58 (m, 3H), 1.75–1.68 (m, 1H), 1.57–
1.25 (m, 7H), 0.91 (t, J = 7.4 Hz, 3H);

13

C NMR (100 MHz, CDCl3) δ 156.2, 140.6,

128.8, 128.5, 128.1, 127.8, 121.0, 120.7, 119.6, 119.2, 110.4, 99.1, 98.9, 67.3, 51.8, 45.2,
36.3, 34.6, 32.8, 28.4, 22.5, 21.4, 7.1. HRMS m/z 390.2291 (calcd for C25H30N2O2,
390.2307).
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3-Ethyl-3-[2-(1H-indol-2-yl)-ethyl]-piperidine-1-carboxylic
acid tert-butyl ester (1-68)
Amine 1-52 (25.0 mg, 0.09 mmol) was dissolved in CH2Cl2
(2.00 mL), to which Et3N (16.0 μL, 0.12 mmol) and Boc2O (21.0 μL, 0.09 mmol) were
added. The solution was allowed to stir for 35 min and then poured into 10.0 mL water.
The heterogeneous mixture was separated and the aqueous layer was extracted with
CH2Cl2 (5 x 10.0 mL). The combined organic layers were washed with brine, dried
(MgSO4), filtered through Celite and concentrated under reduced pressure. Purification
by flash chromatography on silica gel using EtOAc-hexanes for elution provided the title
compound as colorless oil (83% yield, 28.0 mg). Rf 0.66 (100% EtOAc); 1H NMR (400
MHz, CDCl3) δ 8.98 (br s, 1H), 7.50 (d, J = 7.6 Hz, 1H), 7.23 (d, J = 7.6 Hz, 1H), 7.08–
7.00 (m, 2H), 6.19 (s, 1H), 3.97 (d, J = 12 Hz, 1H), 3.90 (d, J = 12 Hz, 1H), 3.39 (br s,
0.5H), 3.18 (br s, 0.5H), 2.86–2.80 (m, 1H), 2.73–2.62 (m, 2H), 2.54 (d, J = 13 Hz, 1H),
1.58–1.54 (m, 4H), 1.52 (s, 9H), 1.50–1.41 (m, 4H), 0.92–0.89 (m, 2H); 13C NMR (100
MHz, CDCl3) δ 146.7, 140.9, 128.7, 120.6, 119.5, 119.0, 110.4, 98.7, 85.2, 59.2, 50.9,
45.6, 34.9, 32.7, 28.7, 28.5, 27.4, 22.6, 21.5, 7.1.. HRMS m/z 356.2468 (calcd for
C22H32N2O2, 356.2464).

3-Ethyl-3-{2-[3-(2-hydroxy-ethyl)-1H-indol-2-yl]-ethyl}piperidine-1-carboxylic acid benzyl ester (1-69)
The title compound was obtained from compound 1-67 using
the alkylation reaction conditions described above in the procedure to obtain compound
1-55. This procedure provided the title compound as colorless oil (34% yield, 65% based
on recovered starting material). Rf 0.25 (30% EtOAc/hexanes); 1H NMR (400 MHz,
CDCl3) δ 9.00 (br s, 1H), 7.51 (d, J = 7.8 Hz, 1H), 7.35–7.30 (m, 6H), 7.12–7.03 (m,
2H), 5.30 (d, J = 12 Hz, 1H), 5.13 (d, J = 12 Hz, 1H), 4.09 (d, J = 13 Hz, 1H), 4.02 (d, J
= 13 Hz, 1H), 3.85–3.82 (m, 2H), 2.97–2.94 (m, 2H), 2.88–2.82 (m, 1H), 2.73–2.69 (m,
1H), 2.59 (d, J = 13 Hz, 1H), 1.66–1.42 (m, 9H), 1.37–1.29 (m, 1H), 0.93 (t, J = 7.4 Hz,
3H);

13

C NMR (100 MHz, CDCl3) δ 156.4, 138.0, 136.5, 135.5, 128.6, 128.4, 128.1,

127.8, 120.9, 118.9, 117.9, 110.5, 109.8, 67.4, 62.9, 51.5, 45.3, 36.5, 34.8, 32.6, 28.9,
27.8, 21.4, 20.4, 7.2. HRMS m/z 434.2536 (calcd for C27H34N2O3, 434.5705).
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3-Ethyl-3-{2-[3-(2-hydroxy-ethyl)-1H-indol-2-yl]-ethyl}piperidine-1-carboxylic acid tert-butyl ester (1-70)
The title compound was obtained from compound 1-67 using the
alkylation reaction conditions described above in the procedure to obtain compound 1-55.
This procedure provided the title compound a colorless oil (21% yield, 63% based on
recovered starting material). Rf 0.51 (100 % EtOAc); 1H NMR (400 MHz, CDCl3) δ
9.08 (br s, 1H), 7.49 (d, J = 7.8 Hz, 1H), 7.23–7.20 (m, 1H), 7.10–7.02 (m, 2H), 4.12–
4.08 (m, 1H), 3.99–3.97 (m, 1H), 3.84 (t, J = 6.6 Hz, 2H), 2.98–2.93 (m, 2H), 2.76–2.64
(m, 2H), 2.46–2.42 (m, 1H), 1.67–1.55 (m, 13H), 1.49–1.40 (m, 6H), 0.92 (t, J = 7.2 Hz,
3H). HRMS m/z 400.2718 (calcd for C24H36N2O3, 400.2726). Due to lack of material, a
13

C NMR spectra was not obtained.

2-Chloro-1-{3-ethyl-3-[2-(1-H-indol-2-yl)-ethyl]piperidin-1-yl}-ethanone (1-71)
To a solution of amine 1-52 (40.0 mg, 0.16 mmol) in
CH2Cl2 (8.00 mL) at 0 °C, tin (IV) chloride solution (0.34 mL, 1.00 M in CH2Cl2) was
added slowly dropwise and allowed to stir for 10 min. Then, chloroacetyl chloride (12.4
μL, 0.16 mmol) and 0.80 mL EtNO2 were added and the resulting solution was allowed
to stir for 12 h at RT. The solution was poured into 15.0 mL of cold water and the
heterogeneous mixture was separated and the aqueous layer was extracted with EtOAc (5
x 15.0 mL). The combined organic layers were washed with brine, dried (MgSO4),
filtered through Celite and concentrated under reduced pressure. Purification by flash
chromatography on silica gel using EtOAc-hexanes for elution provided the title
compound as colorless oil (96% yield, 51.0 mg). Rf 0.57 (100% EtOAc); 1H NMR (400
MHz, CDCl3)  8.70 (br s, 1H), 7.49 (d, J = 7.8 Hz, 1H), 7.32 (d, J = 8.0 Hz, 1H), 7.08
(td, J = 1.2, 7.5 Hz, 1H), 7.02 (td, J = 1.1, 7.4 Hz, 1H), 6.18 (s, 1H), 4.24 (d, J = 13.3 Hz,
1H), 4.16 (q, J = 12.0 Hz, 2H), 3.69 (ddd, J = 3.7, 13.1 Hz, 1H), 3.18 (ddd, J = 3.5, 10.2,
13.8 Hz, 1H), 2.77 (dt, J = 3.1, 12 Hz, 1H), 2.70–2.62 (m, 2H), 1.69–1.58 (m, 5H), 1.53–
1.36 (m, 3H), 0.92 (t, J = 7.5 Hz, 3H);

13

C NMR (100 MHz, CDCl3)  166.0, 140.3,

136.2, 128.7, 120.7, 119.5, 119.2, 110.6, 98.9, 50.3, 47.8, 41.2, 37.1, 34.6, 33.0, 28.5,
22.6, 22.0, 7.1. HRMS m/z 332.1647 (calcd for C19H25N2OCl, 332.1655).
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10-Oxoquebrachamine (1-78)
A solution of chloroacetamide indole 1-71 (58.0 mg, 0.17 mmol)
and Na2CO3 (28.0 mg, 0.26 mmol) in 4.00 mL EtOH and 3.00 mL
water was placed in a quartz vessel (11.0 cm tall, 1.20 cm diameter)
equipped with a septa. The vessel was degassed with Ar for 15 min and then suspended
in the center of a Rayonet Photochemical Reactor. The solution was irradiated for 140
min, and the solution was concentrated under reduced pressure. The residue was
dissolved in EtOAc and water (20.0 mL, 1:1) and the aqueous layer was extracted with
EtOAc (5 x 10.0 mL). The combined organic layers were washed with brine, dried
(MgSO4), filtered through Celite and concentrated under reduced pressure. Purification
by flash chromatography on silica gel using EtOAc-hexanes for elution provided the title
compound as a white solid (85% yield, 43.0 mg). Rf 0.53 (100% EtOAc); 1H NMR (600
MHz, CDCl3)  7.75 (br s, 1H), 7.70 (d, J = 7.02 Hz, 1H), 7.22 (dd, J = 1.7, 7.0 Hz, 1H),
7.10 (m, 2H), 4.63 (dd, J = 2.3, 12.9 Hz, 1H), 4.42 (d, J = 14.0 Hz, 1H), 4.03 (d, J = 14.0
Hz, 1H), 3.60 (d, J = 14.0 Hz, 1H), 2.83–2.79 (m, 2H), 2.64 (ddd, J = 4.7, 10.2, 15.5 Hz,
1H), 2.46 (ddd, J = 3.5, 12.9 Hz, 1H), 1.72–1.67 (m, 2H), 1.63–1.57 (m, 1H), 1.51 (d, J =
15.8 Hz, 1H), 1.46–1.43 (m, 1H), 1.39 (m, 1H), 1.33 (ddd, J = 4.4, 13.3 Hz, 1H), 1.22–
1.16 (m, 1H), 0.86 (t, J = 7.6 Hz, 3H);

13

C NMR (100 MHz, CDCl3)  170.2, 137.7,

134.3, 129.6, 121.4, 119.9, 118.3, 110.0, 105.5, 53.7, 42.8, 38.6, 34.6, 32.3, 30.7, 28.8,
20.8, 20.7, 7.3. HRMS m/z 296.1878 (calcd for C19H24N2O, 296.1889).
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CHAPTER 2: Synthesis of Tetrahydroisoquinocarbazoles

2.1 Introduction

Considerable synthetic attention has been directed at the development of efficient
methods towards the construction and derivatization of indole containing compounds, as
this important subunit is found in a plethora of biologically active natural products.1 Our
research group has recently developed a methodology for C-2 alkylation of 3-substituted
indoles with 2-alkoxycyclopropanoate esters to give useful indole products.2 These
valuable intermediates feature ester and alkene functional group handles capable of
further synthetic manipulation, particularly towards the synthesis of natural products and
other biologically active compounds. Herein, we report the short syntheses of several
related tetrahydroisoquinocarbazoles 2-1, 2-2 and 2-3 (Scheme 2.1) by employing the C2 alkylation of indoles with donor acceptor (DA) cyclopropanes 1-2 and a SmBr2−HMPA
mediated reductive cyclization as key synthetic steps.3

Figure 2.1 Application of C-2 alkylation of indoles with DA cyclopropane 1-2
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2.2 C-2/C-3 Annulation and C-2 Alkylation of Indoles with 2Alkoxycyclopropanoate Esters

Our research group has developed a method for heterocycle synthesis via C-2/C-3
annulation of indoles with 2-alkoxycyclopropanoate esters, affording a wide variety of
substituted indoline compounds with high efficiency and stereocontrol.2 The annulation
process likely involves the initial formation of an oxocarbenium ion promoted via a
cyclopropane ring opening reaction upon treatment with a Lewis acid, such as a silyl
triflate (Scheme 2.1). This zwitterionic intermediate is then attacked by indole, forming
the first carbon-carbon bond. The silyl enolate then attacks the C-2 position of the indole,
completing the annulation process. It is important to note that one of the stereocenters in
the original cyclopropane (denoted by the asterisk) remains unchanged during the course
of the reaction and is responsible for the formation of four new stereocenters.

Scheme 2.1 C-2/C-3 Annulation of indoles with 2-alkoxycyclopropanoate esters

When the annulation conditions were applied to 3-substituted indoles, unexpected
C-2 alkylated products were isolated. The mechanism likely involves the same Lewis
acid activation of the DA cyclopropane and subsequent attack of the indole, again from
the C-3 position (Scheme 2.2). In the case of 3-substituted indoles, C-2 alkylation
products are observed. This reactivity may occur through an indirect process involving
initial attack at the C-3 position followed by C-3 to C-2 migration and deprotonation
42
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steps to give the indole alkylation product (shown in Scheme 2.2).4 However, a more
direct electrophilic substitution attack through the C-2 position of the indole, followed by
a deprotonation step has also been proposed, which takes advantage of the extended πsystem of the indole. This alternative mechanism, while plausible, is energetically
unfavorable because it disturbs the aromaticity of the benzene ring.4 Finally, the C-2
alkylation product is obtained after spontaneous condensation to form the double bond.

Scheme 2.2 C-2 Alkylation of indoles with 2-alkoxycyclopropanoate esters

2.3 Biological Activity

Fused indole compounds such as the Vinca alkaloids have inspired synthetic and
medicinal interest in a large class of related tetrahydroisoquinocarbazole analogs, most of
which exhibit interesting biological activity.5,6 Most members of this class of compounds
have been found to be antiarrhythmic agents, which suppress ischemia induced
ventricular arrhythmias.5 One of the most important clinical problems after acute
myocardial infarction (MI) is sustained ventricular tachycardia (SVT), which often leads
to sudden death. Suppression of SVT in patients is crucial, particularly in the first few
days after an acute MI when the risk is the highest.5 Some members of this novel class of
antiarrhythmic agents have emerged as promising candidates, where they have been
proven to be effective in several animal models, and have attractive cardio hemodynamic
profiles in canines. Among the most potent members of this class, RS-2135 (Figure 2.1,
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(+)-2-4) has attracted the most attention because of its relatively low toxicity and it
demonstrated antiarrhythmic effects lasting for at least 48 h after a coronary embolism
with only 10 mg/kg (oral administration) in canine studies.6

2.4 Previous Syntheses of Tetrahydroisoquinocarbazoles

2.4.1 Previous Recemic Syntheses of Tetrahydroisoquinocarbazoles

Simoji and Hashimoto employed an elegant route towards a series of
tetrahydroisoquinocarbazole compounds that employed an intramolecular Diels-Alder
reaction and Curtius rearrangement to construct the core.5a The general synthesis
commenced with an transesterification with indolylpropenoate (2-5) using allyl alcohol
and sodium hydride (Scheme 2.3). The resulting indole (2-6) was then acylated with acid
chloride 2-7, leading to indole 2-8, as the cyclization precursor. Heating 2-8 promoted the
stereoselective intramolecular Diels-Alder reaction, followed by migration of the double
bond upon treatment with acid, giving carbazole 2-9.

Scheme 2.3 Simoji and Hashimoto’s synthesis towards tetrahydroisoquinocarbazoles
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Deprotection of the ester moiety revealed carboxylic acid 2-10 in a moderate
yield, which was subsequently chlorinated with thionyl chloride and treated with sodium
azide. The resulting carboxylic azide underwent a Curtius rearrangement, benzyl
protection to give a benzyl carbamate, and lastly, hydrogenation conditions were used to
access the functionalized tetrahydroisoquinocarbazole (2-11).

2.4.2 Previous Asymmetric Syntheses of Tetrahydroisoquinocarbazoles

Among the many members of tetrahydroisoquinocarbazoles, RS-2135 ((+)-2-4)
has attracted the most synthetic attention due to its long lasting antiarrhythmic effects and
low toxicity. Simoji and Hashimoto reported the first synthesis of the single enantiomer
of RS-2135 ((+)-2-4) in 1992 (Scheme 2.4).5b A racemic mixture of 2-11 (using the
protocol described in Scheme 2.3) was condensed with Boc protected L-proline with the
use of diethyl phosphoryl cyanide (DEPC) as a coupling reagent and triethylamine in
52% overall yield. The two diastereomers 2-12a and 2-12b were separated by column
chromatography on silica gel and treated with hydrochloric acid to furnish optically pure
enantiomers (+)-2-4 (RS-2135) and (−)-2-4, each in a modest 15% yield.

Scheme 2.4 Simoji and Hashimoto’s synthesis towards (+)-2-4 (RS-2135) and (−)-2-4
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Simoji and Hashimoto improved their original strategy towards optically pure RS2135 ((+)-2-4) in 1996 by utilizing an enantiomerically pure acid chloride (2-14), which
was prepared from an enzymatic kinetic resolution of a 2-substituted cyclohexan-1-ol
followed by several other functional group manipulations (Scheme 2.5).5c The synthetic
strategy began with the acylation of indole 2-13 with a chiral acid chloride (2-14) to
afford cyclization precursor 2-15 in 81% yield. The synthesis followed a similar reaction
sequence as described in their earlier reports,5a,b where indole 2-15 underwent an
intramolecular Diels-Alder reaction when heated, followed by treatment with acid to
promote the double bond migration and ester hydrolysis. Carboxylic acid 2-16 underwent
Curtius rearrangement, formation of a benzyl carbamate and hydrogenation to furnish
(+)-2-4 (RS-2135) in 60% yield over two steps.

Scheme 2.5 Simoji and Hashimoto’s synthesis of RS-2135
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2.5 Synthesis of Tetrahydroisoquinocarbazoles
2.5.1 Retrosynthesis

From our initial retrosynthetic analysis, we identified a key disconnection
between C-12 and C-12a as being strategically important, as it simplified the target core
to indole 2-17, which is readily available from our C-2 alkylation methodology (Scheme
2.6). It was anticipated that ring C could be constructed by several strategies, including
hydrometallation of alkene 2-17, followed by appropriate ring closure conditions. The
same disconnection would also allow radical cyclizations to be explored, such as
selenoester or samarium(II) iodide mediated ring closures. The lactam bond could be
constructed via a base induced cyclization with the indole nitrogen and ester moiety in
intermediate 2-17, which would be accessed from a C-2 alkylation between 3-substituted
indole 2-18 and DA cyclopropane 1-2.

Scheme 2.6 Retrosynthetic analysis

2.5.2 Constructing the Core

2.5.2.1 Investigating the C-2 Alkylation of Various C-3 Substituted Indoles

The synthesis began by examining the C-2 alkylation of several C-3 substituted
indoles with DA cyclopropane 1-2 (Scheme 2.7). The substituent in the C-3 position of
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the indole was particularly significant since it would later serve as a functional handle to
facilitate closure of ring C. This strategy began with the alkylation of indole 2-19, which
proceeded in a modest 50% yield to give 2-20, accompanied with a large amount of
decomposition. However, alkylation of indole 2-21 under the same conditions gave the
desired product (2-22) in an improved 82% yield. Considering our C-2 alkylation
methodology was employed early in our synthetic strategy, we continued our
investigation towards the construction of the tetrahydroisoquinocarbazole core with 2-22.

Scheme 2.7 C-2 Alkylation of 2-substituted indoles

2.5.2.2 Lactam Formation and Hydrometallation Strategy
With indole 2-22 in hand, we opted to form ring D via a lactam cyclization. Upon
treatment of ester 2-22 with DBU, the intramolecular cyclization proceeded smoothly in
91% yield, providing tetracyclic core 2-23 as a key intermediate for the final ring closure.
The initial approach for ring C assembly involved elaborating alkene 2-23 via
hydroboration or hydrometallation strategies, potentially supplying a collection of
suitable handles (OH, I) at C-12a with which to facilitate cyclization (Scheme 2.8).

Scheme 2.8 Hydrometallation strategy
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Initial hydrometallation studies began with hydroboration as a possible route to
ring C. Hydroboration is a highly regioselective reaction which would provide an
intermediate borane at the least substituted carbon of the original alkene preferentially,
allowing access to an alcohol after oxidation. Treatment with alkene 2-23 with BH3∙THF
or 9-BBN, followed by oxidation with H2O2/NaOH led to substrate decomposition (Table
2.1, entries 1 and 2).

Table 2.1 Hydrometallation attempts with 2-23

Entry

Reagent(s)

Result

1

BH3∙THF; H2O2/NaOH

Decomposition

2

9-BBN; H2O2/NaOH

Decomposition

3

BH3∙THF; I2

No reaction

4

9-BBN; I2

No reaction

5

NaBH3OAc/I2

No reaction

6

(Cp)2Zr(H)Cl/I2

No reaction

In an attempt to obtain the alkyl halide as a functional handle instead of the
alcohol, we decided to explore a method by which the intermediate borane can be
quenched with iodine. Unfortunately, treatment of 2-23 with BH3∙THF, NaBH3OAc or 9BBN, followed by an I2 quench gave no reaction (Table 2.1, entries 3-5).
An alternative hydrometallation method applicable towards 2-23 was a possible
hydrozironation reaction. Alkylzironium(IV) complexes such as (η5-C5H5)2Zr(H)Cl have
been shown to be useful intermediates in organic synthesis since they readily react with
olefins in a regioselective manner.7 Regrettably, our hindered alkene 2-23 failed to
participate in the hydrozironation reaction and all of the starting material was recovered
(Table 2.1, entry 6). Unfortunately, all attempts at alkene functionalization with 2-23 led
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to starting material recovery or substrate decomposition, which is likely due to
unfavorable steric interactions of the bulky trisubstituted alkene.

2.5.2.3 Mn(III)-Mediated Oxidative Cyclization Strategy

Our focus then turned to pentacyclic intermediate 2-24, which could be used to
furnish tetrahydroisoquinocarbazole 2-1 by removal of one ester via decarboxylation,
saponification of the remaining ester, and conversion to the amine using a Schmidt
reaction. Then, a Mn(III)-mediated oxidative cyclization strategy could construct
pentacycle 2-24 from diester 2-25 (Scheme 2.9).

Scheme 2.9 Oxidative cyclization strategy

The radical cyclization mechanism is thought to involve initial enolization to give
a Mn(III) enolate, followed by electron transfer with loss of Mn(II), generating an αdiester radical. Typically malonate radicals of this kind demonstrate a preference for 5exo-cyclization with monosubstituted alkenes, whereas disubstituted alkenyl radicals
afford a mixture of 5-exo- and 6-endo-cyclization. Substrates similar to 2-25 featuring a
trisubstituted alkene undergo 6-endo-cyclization exclusively.8
Encouraged by these reports, we began investigating this route by protecting 3methylindole (2-26) with a Boc group, which proceeded smoothly under standard
conditions in near quantitative yield (Scheme 2.10). The resulting indole 2-27 underwent
a radical induced halogenation reaction with AIBN and NBS to install a bromine leaving
group, followed by displacement with dimethylmalonate and NaH providing 2-29 in 78%
yield over two steps. Subsequent removal of the Boc group revealed indole 2-30, setting
the stage for the C-2 alkylation with DA cyclopropane 1-2. Unfortunately, all attempts to
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furnish alkylation product 2-31 resulted in starting material recovery or substrate
decomposition. Since diester 2-30 proved to be a poor reaction partner in the alkylation
reaction, we proposed a similar route where the sequence of chemical transformations
was revised.

Scheme 2.10 Synthetic route towards diester 2-25: method 1

Our new approach involved alkylation of 3-methylindole with DA cyclopropane
1-2, which furnished alkene 2-32 in an excellent 92% yield (Scheme 2.11). Lactam
formation with DBU and dichloromethane proceeded in 98% yield to give 2-33, and
installation of the bromine leaving group was performed upon treatment with AIBN and
NBS. Unlike indole 2-28, the corresponding tetracyclic intermediate 2-34 was completely
unstable, so the displacement reaction with dimethylmalonate was performed
immediately, without isolation. All efforts to construct diester 2-25 in this manner were
ineffective and only substrate decomposition was observed.
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Scheme 2.11 Synthetic route towards diester 2-25: method 2

2.5.2.4 Electrocyclization Strategy

Since our earlier approaches towards ring C were ineffective, we turned our focus
to a possible electrocyclization reaction. Hexatrienes have been shown to readily
participate in thermal or Lewis acid activated disrotatory 6π electrocyclizations, so we
envisioned that this type of ring closure could also be possible with conjugated indole 237

(Scheme

2.12).

Retrosynthetically,

we

envisioned

access

to

tetrahydroisoquinocarbazole 2-3 through a three step process including a 1,4-reduction of
the α,β-unsaturated ester, saponification and Schmidt reaction, which would reveal
pentacyclic intermediate 2-35. This intermediate would likely arise after double bond
isomerization of 2-36, that could be accessed via a 6π electrocyclization of indole 2-37.

Scheme 2.12 Electrocyclization strategy
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This approach to 2-37 began with a stabilized Wittig reaction using indole-3carboxaldehyde (2-38), which furnished a 17:1 E/Z ratio of conjugated indole 2-39
(Scheme 2.13, method 1). This indole was then subjected to C-2 alkylation reaction
conditions with DA cyclopropane 1-2, but all attempts resulted in decomposition and
some starting material recovery. The strategy was then revised by changing the sequence
of chemical transformations where the α,β-unsaturated ester would be installed later in
the synthesis (Scheme 2.13, method 2). Unfortunately, the C-2 alkylation of indole-3carbinol (2-41) did not lead to any desired product (2-42), indicating that the alkylation
methodology was substrate dependent. Failure to access the conjugated indole 2-37 also
precluded the potential 6π electrocyclization as a means for the final ring closure.

Scheme 2.13 Potential synthetic route towards 2-37

2.5.2.5 Radical Cyclization: Selenoester Approach

Since all of the early approaches for ring C assembly involved elaborating the
alkene, reductive cyclization, or electrocyclization strategies, a revised strategy involved
exploring a potential selenoester derived radical-mediated ring closure. Selenoesters have
long been recognized as precursors to acyl radicals that actively participate in inter- and
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intramolecular alkene addition reactions.9 Despite the preference for free radicals to
undergo 5-exo-trig over 6-endo-trig cyclizations, Boger and co-workers demonstrated
that in some cases the latter is favored.9 Where acyl radicals are formed, the radical may
suffer from a competitive decarbonylation reaction, but this may never be observed if the
rate of cyclization is much higher than that of decarbonylation. Typically, this
decarbonylation process is avoided when unactivated alkenes such as 2-43 are used in the
reaction (Scheme 2.14), however, the acyl radical derived from 2-44 provides a
heteroatom stabilized primary radical which does not undergo cyclization, but instead
proceeds through the decarbonylation pathway exclusively to give 2-45. Although our
substrate could undergo competitive decarbonylation, we were encouraged with the
prospect of an intramolecular alkene addition via an acyl radical.

Scheme 2.14 Intramolecular alkene addition reactions via acyl radicals

The synthesis of selenoester 2-47 commenced with the C-2 alkylation of
commercially available tryptophol with cyclopropane 1-2 to give indole 2-50 in a
moderate 70% yield (Scheme 2.15). However, closure of the D-ring with this
intermediate under basic conditions was unsuccessful. Suspecting that the free alcohol
was interfering in the lactamization process, acylated derivative 2-49 was employed
instead, and the C-2 alkylation product was obtained in 86% yield. The resulting indole
(2-51) was effectively converted to the lactam in 90% yield upon treatment with DBU.
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Deprotection of alcohol 2-52 allowed access to indole 2-53, thus setting the stage to
explore ring C construction.

Scheme 2.15 C-2 Alkylation and lactam formation
Selenoester 2-47 was then prepared in a three step sequence commencing with
Swern oxidation of alcohol 2-53 (Scheme 2.16). The resulting aldehyde (2-54) underwent
Pinnick oxidation (NaH2PO4·H2O, NaClO2, 1-methylcyclohexene, tBuOH), and the
resulting carboxylic acid was treated with diphenyl diselenide and tributylphosphine,
providing cyclization precursor 2-47 in 81% yield over three steps. An acyl radical (2-55)
was generated with AIBN and Bu3SnH, but regrettably, stabilized radical 2-56 formed
and promoted rapid decarbonylation, ultimately giving 3-methyl indole derivative 2-33 as
the exclusive product.

Scheme 2.16 Selenoester cyclization approach
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2.5.2.6 Radical Cyclization: Samarium(II) Iodide Approach

Operating through the aldehyde oxidation state appeared to be an attractive means
to further explore a radical cyclization strategy while avoiding the undesired
decarbonylation. In this regard, both inter- and intramolecular carbonyl-alkene/alkyne
reductive coupling reactions mediated by samarium(II) iodide are well documented.10
Both aldehydes and ketones participate as coupling partners, but a large majority of these
radical induced cyclizations with aldehydes employ electrophilic α,β-unsaturated esters
or allylic leaving groups including halides, sulfides, and sulfones.11
The aldehyde cyclization precursor (2-54) was treated with 2.2 equivalents of
0.1 M SmI2 in THF (Scheme 2.17). Two reaction products were obtained, including the
desired secondary alcohol (2-1) and primary alcohol (2-53) resulting from aldehyde
reduction in a 1.2:1.0 ratio and 80% overall yield (Table 2.2, entry 1).

Scheme 2.17 Completion of several tetrahydroisoquinocarbazoles

Efforts to optimize this cyclization involved exploring various additives such as
Lewis bases (HMPA), proton sources (H2O, MeOH), and inorganic salts (LiBr), all of
which have been documented to profoundly affect SmI2 mediated reactions.10 According
to Flowers and co-workers, the oxidation potential of SmI2 alone is −1.33 V (vs.
Ag/AgNO3 in THF), and was found to increase to a maximum of −2.05 V with four
equivalents of added HMPA.12 When these conditions were applied to the intramolecular
coupling reaction, an increase in selectivity toward cyclization over aldehyde reduction
was observed (Table 2.2, entry 2).
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Table 2.2 Optimization data for SmI2 cyclization
Entry

Additives (equiv)a

Ratio of 2-1:2-53

Yield (%)b

1

-

1.2:1.0

80

2

HMPA (8.8)

2.0:1.0

85

3

H2O (22)

>99:1

33

4

MeOH (22)

>99:1

42

5

LiBr (8.8)

1.4:1.0

91

6

LiBr (8.8), HMPA (110)

>99:1

78

a

Relative to aldehyde 2-54, with 2.2 equivalents of 0.1 M SmI2 in each reaction.
Combined isolated yield of 2-1 and 2-53, for both steps starting from alcohol 2-53.

b

Protic additives such as water and methanol have also been shown to influence
similar radical processes, as they likely activate the reagent through metal coordination
and protonate anionic intermediates.13 Although these proton sources improved
selectivity for the cyclization product (2-1) over aldehyde reduction, significantly lower
yields were accompanied with considerable decomposition (entries 3 and 4).
Inorganic salts such as LiBr have been shown to participate in displacement
reactions with SmI2, producing SmBr2.14 Cyclizations with SmBr2 as a reducing agent
provided a 1.4:1.0 mixture of 2-1:2-53, although in excellent 91% combined yield (entry
5). Flowers also found that the addition of 50 equivalents of HMPA significantly
improved the reducing ability of SmBr2 (−2.07 V for SmBr2 versus −2.63 V for SmBr2HMPA).14 Optimal results were achieved by a combination of several known additives,
specifically LiBr and HMPA (entry 6). The SmBr2-HMPA reductant prepared under
Flowers’ conditions displayed excellent selectivity (>99:1) for cyclization to 2-1 in 78%
yield. The relative stereochemistry of 2-1 was confirmed by extensive NMR analysis.15
To further illustrate the utility of this approach additional modifications were
made to the functionalized core (Scheme 2.17). Oxidation of alcohol 2-1 with IBX
proceeded smoothly to afford ketone 2-2, which was advanced to amine 2-3 after
reductive amination. Presumably, other tetrahydroisoquinocarbazoles, including RS2135, can be accessed by elaboration of the starting indole or cyclopropane.
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2.6 Summary
In summary, we have reported the most efficent and highest yielding route to
several tetrahydroisoquinocarbazoles, where the core (2-1) was prepared in six steps from
tryptophol in 51% overall yield. This work highlights for the first time the synthetic
utility

of

the

dipolar

C-2

alkylation

of

3-substituted

indoles

with

2-

alkoxycyclopropanoate esters. The synthesis also features a selective SmBr2-HMPA
promoted ring closure of an aldehyde onto a sterically congested trisubstituted alkene.
This

also

provides

an

attractive

route

to

other

biologically

tetrahydroisoquinocarbazoles including the most potent member, RS-2135.
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2.7 Experimental

2.7.1 General Considerations

General experimental procedures were the same as provided in Chapter 1.

2.7.2 Experimental Procedures

12-Hydroxy-2,3,3a,3a1,4,11,12,12a-octahydroisoquinolino[2,1,8lma]carbazol-5(1H)-one (2-1)
Lithium bromide (107 mg, 1.23 mmol) was dissolved in 3.00 mL
degassed THF and added to a 0.10 M solution of SmI2 (3.10 mL, 0.31 mmol).6 After the
dark purple mixture was allowed to stir for 3 min at RT, freshly distilled HMPA (2.60
mL, 15.4 mmol) was added dropwise and stirred for an additional 5 min. Aldehyde 2-54
(39.0 mg, 0.14 mmol) was then added over 3 min, as a solution in 1.00 mL of degassed
THF, and the dark purple solution turned dark green. After 5 min at RT, the mixture was
poured into a half saturated solution of NaHCO3 (5.00 mL). The heterogeneous mixture
was separated and the aqueous layer was extracted with EtOAc (4 x 10.0 mL). The
combined organic layers were washed with brine, dried (MgSO4), filtered through Celite
and concentrated under reduced pressure. Purification by flash chromatography on silica
gel using EtOAc-hexanes for elution provided the title compound as colorless oil (78%
yield over two steps from alcohol 2-53, 30.0 mg). Rf 0.30 (50% EtOAc/hexanes); 1H
NMR (400 MHz, CDCl3)  8.28-8.26 (m, 1H), 7.40-7.38 (m, 1H), 7.30-7.26 (m, 2H),
3.81 (dt, J = 10.8, 4.5 Hz, 1H), 3.07 (dd, J = 14.8, 4.7 Hz, 1H), 2.80-2.71 (m, 2H), 2.582.47 (m, 2H), 2.31-2.24 (m, 2H), 1.83-1.55 (m, 5H), 1.41-1.35 (m, 1H), 1.19-1.13 (m,
1H);

13

C NMR (100 MHz, CDCl3)  169.2, 137.7, 129.8, 125.9, 124.2, 123.9, 117.9,

116.0, 111.2, 68.1, 42.8, 39.2, 38.1, 37.9, 31.4, 30.2, 24.2, 21.1. HRMS m/z 281.1427
(calcd for C18H19NO2, 281.1416).
6

SmI2 was made according to the following procedures: a) Curran, D. P.; Gu, X.; Zhang,
W.; Dowd, P. Tetrahedron 1997, 53, 9023–9042. b) Concellon J. M.; Rodriguez-Solla,
H.; Bardales, E.; Huerta, M. Eur. J. Org. Chem. 2003, 9, 1775–1778.
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NOESY Interactions:

gCOSY Interactions:

Proton

Chemical Shift

Interactions

a

3.81 (dt, J = 10.8, 4.5 Hz, 1H)

bd, bu, c

bd

3.07 (dd, J = 14.8, 4.7 Hz, 1H)

bu, a

bu

2.58-2.47 (m, 1H)

bd, a

c

2.31-2.24 (m, 1H)

a, f, g

dd

2.80-2.71 (m, 1H)

du, i

du

2.58-2.47 (m, 1H)

dd, i

e

2.31-2.24 (m, 1H)

-

f

2.80-2.71 (m, 1H)

c, i

g

1.83-1.55 (m, 2H)

kd, ku, c

i

1.83-1.55 (m, 1H)

dd, du, jd, ju, f

jd

1.83-1.55 (m, 1H)

ju, i, kd, ku

ju

1.19-1.13 (m, 1H)

jd, i, kd, ku

kd

1.83-1.55 (m, 1H)

ku, g, jd, ju

ku

1.41-1.35 (m, 1H)

kd, g, jd, ju

l

8.28-8.26 (m, 1H)

m

m

7.30-7.26 (m, 2H)

l, n

n

7.30-7.26 (m, 2H)

m, o

o

7.40-7.38 (m, 1H)

n
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1,2,3,3a,4,12a-Hexahydroisoquinolino[2,1,8-lma]carbazole5,12(3a1H,11H)-dione (2-2)
Alcohol 2-1 (15.0 mg, 0.05 mmol) was dissolved in DMSO (1.00 mL)
and IBX (36.0 mg, 0.13 mmol) was added. The mixture was stirred at RT for 9 h. After
the solution was cooled to 0 °C, it was diluted with a half saturated solution of NaHCO3
(5.00 mL). The mixture was filtered through a pad of Celite, and extracted with EtOAc
(4 x 10.0 mL). The combined organic layers were washed with brine, dried (MgSO4),
filtered through Celite and concentrated under reduced pressure provided the title
compound as pale yellow oil. Rf 0.50 (50% EtOAc/hexanes); 1H NMR (400 MHz,
CDCl3)  8.28 (dd, J = 6.9, 1.1 Hz, 1H), 7.37–7.26 (m, 3H), 3.68 (dt, J = 17.4, 1.6 Hz,
1H), 3.37 (d, J = 17.4 Hz, 1H), 3.30-3.18 (m, 2H), 2.76 (dd, J = 17.6, 3.7 Hz, 1H), 2.562.49 (m, 1H), 2.36-2.31 (m, 2H), 1.80-1.70 (m, 2H), 1.55-1.41 (m, 2H), 1.18-1.09 (m,
1H);

13

C NMR (100 MHz, CDCl3)  206.4, 168.9, 135.8, 135.5, 129.1, 124.9, 124.2,

118.1, 116.1, 110.2, 43.2, 42.4, 39.9, 38.6 36.8, 29.2, 22.4, 22.0. HRMS m/z 279.1269
(calcd for C18H17NO2, 279.1259).
NOESY Interactions:

61

62

gCOSY Interactions:

Proton

Chemical Shift

Interactions

bd

3.68 (dt, J = 17.4, 1.6 Hz, 1H)

au

bu

3.37 (d, J = 17.4 Hz, 1H)

ad

c

3.30-3.18 (m, 1H)

f

dd

2.76 (dd, J = 17.6, 3.7 Hz, 1H)

du, i

du

2.56-2.49 (m, 1H)

dd, i

f

3.30-3.18 (m, 1H)

c, i

g

2.36-2.31 (m, 2H)

k

i

1.80-1.70 (m, 1H)

d , j , ju, f

jd

1.80-1.70 (m, 1H)

ju, i, k

ju

1.18-1.09 (m, 1H)

jd, i, k

k

1.55-1.41 (m, 2H)

g, jd, ju

l

8.28 (dd, J = 6.9, 1.1 Hz, 1H)

m

m

7.37–7.26 (m, 1H)

n, l

n

7.37–7.26 (m, 1H)

m, o

o

7.37–7.26 (m, 1H)

n
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u

d
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12-amino-2,3,3a,3a1,4,11,12,12a-octahydroisoquinolino[2,1,8lma]carbazol-5(1H)-one (2-3)
Ammonium acetate (65.0 mg, 0.85 mmol) was added to ketone 2-2
(24.0 mg, 0.08 mmol) in 3.00 mL MeOH and allowed to stir for 2 min. NaCNBH3 (5.00
mg, 0.08 mmol) was then added as a solution in 1.00 mL MeOH and stirred for 22 h. The
reaction mixture was concentrated under reduced pressure, and 5.00 mL H2O was added
to the residue. The mixture was basified with 15% NaOH solution and diluted with 10.0
mL EtOAc. The heterogeneous mixture was separated and the aqueous layer was
extracted with EtOAc (4 x 10.0 mL). The combined organic layers were washed with
brine, dried (MgSO4), filtered through Celite and concentrated under reduced pressure.
Purification by flash chromatography on silica gel using EtOAc-hexanes for elution
provided the title compound as a white solid (69% over two steps from alcohol 2-3, 15.0
mg). Rf 0.30 (50% EtOAc/hexanes); 1H NMR (600 MHz, CDCl3)  8.33 (d, J = 7.0 Hz,
1H), 7.38 (d, J = 5.8 Hz, 1H), 7.30–7.25 (m, 2H), 3.98 (td, J = 9.7, 6.4 Hz, 1H), 3.20
(ddd, J = 15.7, 6.0, 1.7 Hz, 1H), 2.78 (dd, J = 16.7, 3.8 Hz, 1H), 2.58–2.53 (m, 1H), 2.46
(dd, J = 16.9, 12.8 Hz, 1H), 2.36–2.14 (m, 3H), 2.03-2.98 (m, 1H), 1.93–1.83 (m, 2H),
1.74 (bs, 1H), 1.62–1.45 (m, 3H), 1.33–1.27 (m, 1H).

13

C NMR (100 MHz, CDCl3) 

174.7, 129.84, 124.2, 123.8, 122.9, 118.0, 116.2, 115.8, 115.5, 72.2, 46.1, 41.1, 40.9,
38.2, 31.5, 30.9, 27.4, 25.3. HRMS m/z 281.1410 (calcd for C18H20N2O + H+, 281.1654).
NOESY Interactions:
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gCOSY Interactions:

Proton

Chemical Shift

Interactions

a

3.98 (td, J = 9.7, 6.4 Hz, 1H)

bd, bu, c

bd

3.20 (ddd, J = 15.7, 6.0, 1.7 Hz, 1H)

bu, a

bu

2.58-2.53 (m, 1H)

bd, a

c

1.62-1.45 (m, 1H)

a, f, g

dd

2.78 (dd, J = 16.7, 3.8 Hz, 1H)

du

du

2.46 (dd, J = 16.9, 12.8 Hz, 1H)

dd, i

ed

1.74 (bs, 1H)

-

1.62-1.45 (m, 1H)

-

f

2.36-2.14 (m, 1H)

c, i

gd

2.03-2.98 (m, 1H)

k, gu, c

gu

1.62-1.45 (m, 1H)

k, gd, c

i

1.93-1.83 (m, 1H)

du, jd, ju, f

jd

1.93-1.83 (m, 1H)

ju, i, k

ju

1.33-1.27 (m, 1H)

jd, i, k

k

2.36-2.14 (m, 2H)

g, jd, ju

l

8.33 (d, J = 7.0 Hz, 1H)

m

m

7.30–7.25 (m, 1H)

l, n

n

7.30–7.25 (m, 1H)

m, o

o

7.38 (d, J = 5.8 Hz, 1H)

n

e

u
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3-(2-Nitroethyl)-1H-indole (2-19)
NaBH4 (736 mg, 19.0 mmol) was added in two portions to a stirred
solution of 3-(2-nitrovinyl)-1H-indole7 in 20.0 mL dry MeOH at RT. The solution was
allowed to stir for 15 min and subsequently acidified to pH 6 with acetic acid. The
solvent was removed under reduced pressure and the residue was dissolved in 10.0 mL
H2O and 10.0 mL ethyl acetate. The heterogeneous mixture was separated and the
aqueous layer was extracted with EtOAc (5 x 10.0 mL). The combined organic layers
were washed with brine, dried (MgSO4), filtered through Celite and concentrated under
reduced pressure. Purification by flash chromatography on silica gel using EtOAchexanes for elution provided the title compound as a white solid (90% yield, 228 mg). Rf
0.52 (50% EtOAc/hexanes); 1H NMR (400 MHz, CDCl3)  8.05 (br s, 1H), 7.57 (d, J =
7.8 Hz, 1H), 7.38 (d, J = 7.4 Hz, 1H), 7.23 (td, J = 7.7, 1.3 Hz, 1H), 7.15 (td, J = 7.5, 1.1
Hz, 1H), 7.07 (d, J = 2.5 Hz, 1H), 4.67 (t, J = 7.3 Hz, 2H), 3.49 (td, J = 7.3, 0.7 Hz, 2H).
13

C NMR (100 MHz, CDCl3)  136.2, 126.6, 122.5, 119.9, 118.1, 111.41, 110.0, 75.7,

23.6.

Ethyl 2-(2-(3-(2-nitroethyl)-1H-indol-2-yl)cyclohex-2-enyl)acetate
(2-20)
To a solution of indole 2-19 (35.0 mg, 0.18 mmol) and the
cyclopropane 1-2 (47.0 mg, 0.24 mmol) in MeNO2 (1.00 mL) at 0 °C,
TMSOTf (77.0 μL, 0.42 mmol) was added dropwise. After 3 h at 40 °C, the reaction
mixture was cooled to RT and poured into 10.0 mL of a half saturated solution of
NaHCO3. The heterogeneous mixture was separated and the aqueous layer was extracted
with EtOAc (3 x 10.0 mL). The combined organic layers were washed with brine, dried
(MgSO4), filtered through Celite and concentrated under reduced pressure. Purification
by flash chromatography on silica gel using EtOAc-hexanes for elution provided the title
compound as colorless oil (50%, 33.0 mg). Rf 0.53 (35% EtOAc/hexanes); 1H NMR (400
MHz, CDCl3)  8.17 (br s, 1H), 7.52 (d, J = 7.8 Hz, 1H), 7.32 (d, J = 8.0 Hz, 1H), 7.18
7

Commercially available, but can be prepared according to the following procedure: Di
Giacomo, B.; Bedini, A.; Spadoni, G.; Tarzia, G.; Fraschini, F.; Pannacci, M.; Lucini,
V. Bioorg. Med. Chem. 2007, 15, 4643–4650.
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(td, J = 7.5, 1.4 Hz, 1H), 7.12 (td, J = 7.4, 1.2 Hz, 1H), 6.00 (td, J = 3.9, 1.6 Hz, 1H),
4.63–4.58 (m, 2H), 4.04–3.95 (m, 2H), 3.60–3.52 (m, 1H), 3.48–3.41 (m, 1H), 3.06–3.00
(m, 1H), 2.26–2.20 (m, 4H), 1.96–1.93 (m, 1H), 1.74–1.63 (m, 3H), 1.15 (t, J = 7.1 Hz,
3H).

13

C NMR (100 MHz, CDCl3)  136.9, 135.3, 132.3, 132.1, 128.1, 122.6, 120.2,

118.1, 111.23, 106.5, 75.5, 60.8, 38.9, 34.6, 28.3, 26.0, 23.7, 19.2, 14.3. HRMS m/z
356.1739 (calcd for C20H24N2O4, 356.1736).

Methyl 3-(1H-indol-3-yl)propanoate (2-21)
To a solution of indole (100 mg, 0.85 mmol) dissolved in MeCN
(2.00 mL), methyl acrylate (154 μL, 1.70 mmol) was added,
followed by TMSOTf (201 μL, 1.10 mmol) added dropwise. After 3 h at RT, the reaction
mixture was poured into 10.0 mL of a half saturated solution of NaHCO3. The
heterogeneous mixture was separated and the aqueous layer was extracted with EtOAc (3
x 10.0 mL). The combined organic layers were washed with brine, dried (MgSO4),
filtered through Celite and concentrated under reduced pressure. Purification by flash
chromatography on silica gel using EtOAc-hexanes for elution provided the title
compound as white solid (90%, 155 mg). Rf 0.45 (40% EtOAc/hexanes); 1H NMR (400
MHz, CDCl3)  8.60 (br s, 1H), 7.62 (dd, J = 7.9, 0.7 Hz, 1H), 7.34 (d, J = 8.0 Hz, 1H),
7.21 (td, J = 7.6, 1.3 Hz, 1H), 7.14 (td, J = 7.4, 1.2 Hz, 1H), 6.98 (d, J = 2.3 Hz, 1H), 3.69
(s, 3H), 3.13 (t, J = 7.6 Hz, 2H), 2.75 (t, J = 7.4 Hz, 2H). 13C NMR (100 MHz, CDCl3) 
173.9, 136.2, 127.1, 121.9, 121.4, 119.3, 118.6, 114.8, 111.1, 51.5, 34.7, 20.6.

Methyl 3-(2-(6-(2-ethoxy-2-oxoethyl)cyclohex-1-enyl)-1H-indol3-yl)propanoate (2-22)
To a solution of indole 2-21 (48.0 mg, 0.26 mmol) and the
cyclopropane 1-2 (94.0 mg, 0.47 mmol) in MeNO2 (1.50 mL) at 0
°C, TMSOTf (174 μL, 0.96 mmol) was added dropwise. After 1.5 h at RT, the reaction
mixture was poured into 10.0 mL of a half saturated solution of NaHCO3. The
heterogeneous mixture was separated and the aqueous layer was extracted with EtOAc (3
x 10.0 mL). The combined organic layers were washed with brine, dried (MgSO4),
filtered through Celite and concentrated under reduced pressure. Purification by flash
66
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chromatography on silica gel using EtOAc-hexanes for elution provided the title
compound as colorless oil (82%, 85.0 mg). Rf 0.53 (40% EtOAc/hexanes); 1H NMR (400
MHz, CDCl3)  8.03 (br s, 1H), 7.54 (d, J = 7.8, 0.8 Hz, 1H), 7.29 (dt, J = 7.9, 1.0 Hz,
1H), 7.14 (td, J = 7.5, 1.2 Hz, 1H), 7.08 (td, J = 7.2, 1.2 Hz, 1H), 5.99 (td, J = 3.9, 1.6
Hz, 1H), 4.06–3.94 (m, 2H), 3.68 (s, 3H), 3.17–3.01 (m, 3H), 2.72–2.57 (m, 2H), 2.30–
2.18 (m, 4H), 1.94–1.88 (m, 1H), 1.72–1.63 (m, 3H), 1.15 (t, J = 7.1 Hz, 3H). 13C NMR
(100 MHz, CDCl3)  173.8, 173.1, 135.4, 135.2, 132.22, 131.1, 128.3, 121.8, 119.4,
118.5, 111.4, 110.7, 60.4, 51.6, 38.7, 35.2, 34.1, 27.9, 25.8, 20.3, 18.9, 14.1.

Methyl 3-(6-oxo-2,3,4,4a,5,6-hexahydroindolo[2,1-a]isoquinolin12-yl)propanoate (2-23)
DBU (1.20 mL, 8.10 mmol) was added to a stirred solution of
indole 2-22 (1.00 g, 2.70 mmol) in 50.0 mL CH2Cl2 at RT. The solution was allowed to
stir for 18 h and then poured into a 10% solution of CuSO4 and stirred for 20 min. The
heterogeneous mixture was separated and the aqueous layer was extracted with CH2Cl2 (3
x 10.0 mL). The combined organic layers were washed with brine, dried (MgSO4),
filtered through Celite and concentrated under reduced pressure. Purification by flash
chromatography on silica gel using EtOAc-hexanes for elution provided the title
compound as a white solid (91% yield, 838 mg). Rf 0.58 (35% EtOAc/hexanes); 1H NMR
(400 MHz, CDCl3)  8.49–8.46 (m, 1H), 7.51–7.49 (m, 1H), 7.34–7.26 (m, 2H), 6.34–
6.31 (m, 1H), 3.70 (s, 3H), 3.26–3.19 (m, 1H), 3.15–3.08 (m, 1H), 2.86 (dd, J = 16, 4.6
Hz, 1H), 2.80–2.68 (m, 2H), 2.63–2.56 (m, 1H), 2.51 (dd, J = 16, 13 Hz, 1H), 2.39–2.29
(m, 2H), 2.12–2.05 (m, 1H), 1.88–1.82 (m, 1H), 1.63–1.53 (m, 1H), 1.39–1.30 (m, 1H).
13

C NMR (100 MHz, CDCl3)  173.2, 168.8, 133.9, 133.5, 130.6, 127.9, 127.7, 125.0,

123.8, 118.1, 116.5, 115.8, 51.8, 41.3, 33.9, 33.7, 29.9, 26.3, 20.6. HRMS m/z 323.1517
(calcd for C20H21NO3, 323.1521).

tert-Butyl-3-methyl-1H-indole-1-carboxylate (2-27)
3-Methylindole (367 mg, 2.80 mmol) was dissolved in 10.0 mL THF, and
Boc anhydride (733 mg, 3.40 mmol) was added, followed by DMAP (34.0 mg, 0.28).
The solution was allowed stir for 16 h at RT and poured into 10.0 mL of H2O. The
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heterogeneous mixture was separated and the aqueous layer was extracted with EtOAc (3
x 10.0 mL). The combined organic layers were washed with brine, dried (MgSO4),
filtered through Celite and concentrated under reduced pressure. Purification by flash
chromatography on silica gel using EtOAc-hexanes for elution provided the title
compound as a white solid (99% yield, 642 mg). Rf 0.57 (35% EtOAc/hexanes); 1H NMR
(400 MHz, CDCl3)  8.10 (br s, 1H), 7.51–7.47 (m, 1H), 7.34–7.21 (m, 3H), 2.27–2.26
(m, 3H), 1.66–1.65 (m, 9H). 13C NMR (100 MHz, CDCl3)  169.1, 143.6, 135.3, 124.2,
122.8, 122.2, 188.9, 116.3, 115.1, 28.2, 27.4, 9.6.

tert-Butyl-3-(bromomethyl)-1H-indole-1-carboxylate (2-28)
Indole 2-27 (600 mg, 2.60 mmol) was dissolved in 40.0 mL
cyclohexanone (dried over 4Å molecular sieves), and brought to reflux. NBS (554 mg,
3.10 mmol) and AIBN (19.0 mg, 11.0 mmol) were added in 3 portions over 3 min. After
30 min at reflux, and another portion of AIBN (19.0 mg, 11.0 mmol) was added at once.
After 2 h at reflux, the mixture was cooled to RT and the solids were filtered off and
washed with hexanes. The solvent was removed under reduced pressure and the title
compound was isolated as a yellow solid (98% yield, 790 mg). Rf 0.45 (35%
EtOAc/hexanes); 1H NMR (400 MHz, CDCl3)  8.14 (d, J = 8.2 Hz, 1H), 7.68–7.66 (m,
2H), 7.38–7.29 (m, 2H), 4.68 (s, 2H), 1.69–1.66 (m, 9H). Due to the instability of this
compound, only 1H NMR was obtained and it was used immediately after preparation
and TLC analysis.

Dimethyl 2-((1-(tert-butoxycarbonyl)-1H-indol-3-yl)methyl)
malonates (2-29)
NaH (19.0 mg, 0.79 mmol) in 5.00 mL THF was added dimethylmalonate (96.0 μl, 0.84
mmol) and stirred at RT for 3 h. Indole 2-28 (130 mg, 0.42 mmol) was added as a
solution in 2.00 mL THF and allowed to stir at reflux for 36 h. The mixture was cooled to
RT and poured into 20.0 mL H2O. The heterogeneous mixture was separated and the
aqueous layer was extracted with EtOAc (3 x 10.0 mL). The combined organic layers
were washed with brine, dried (MgSO4), filtered through Celite and concentrated under
reduced pressure. Purification by flash chromatography on silica gel using EtOAc68
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hexanes for elution provided the title compound as colorless oil (80% yield, 120 mg). Rf
0.25 (35% EtOAc/hexanes); 1H NMR (400 MHz, CDCl3)  8.10 (d, J = 7.2 Hz, 1H), 7.52
(d, J = 8.4 Hz, 1H), 7.40 (br s, 1H), 7.30 (td, J = 7.7, 1.4 Hz, 1H), 7.23 (td, J = 7.4, 0.8
Hz, 1H), 3.80–3.77 (m, 1H), 3.71 (s, 6H), 3.32 (d, J = 7.6 Hz, 1H), 1.65 (s, 9H).

13

C

NMR (100 MHz, CDCl3)  169.2, 149.5, 129.9, 124.4, 123.5, 122.4, 118.6, 116.6, 115.2,
109.7, 83.5, 52.6, 51.8, 28.1, 24.2. HRMS m/z 361.1525 (calcd for C19H23NO6,
361.1525).

Dimethyl 2-((1H-indol-3-yl)methyl)malonates (2-30)
Indole 2-29 (30.0 mg, 0.08 mmol) was dissolved in 3.00 mL
CH2Cl2 with 300 mg SiO2, and solvent removed under reduced pressure. The silica with
indole adhered onto the surface was heated to 50 °C while under reduced pressure (0.20
mm Hg) for 1.5 h. The reaction mixture was cooled to RT and 10.0 mL CH2Cl2 added.
The solution was filtered through Celite and the solution was concentrated under reduced
pressure. Purification by flash chromatography on silica gel using EtOAc-hexanes for
elution provided the title compound as colorless oil (95% yield, 20 mg). Rf 0.31 (35%
EtOAc/hexanes); 1H NMR (400 MHz, CDCl3)  8.02, (br s, 1H), 7.60 (d, J = 7.8 Hz,
1H), 7.34 (d, J = 8.0 Hz, 1H), 7.19 (td, J = 7.5, 1.2 Hz, 1H), 7.13 (dd, J = 7.5, 1.1 Hz,
1H), 7.03 (d, J = 2.3 Hz, 1H), 3.80 (t, J = 7.7 Hz, 1H), 3.69 (s, 6H), 3.40 (d, J = 7.6 Hz,
1H).

13

C NMR (100 MHz, CDCl3)  169.6, 136.1, 126.9, 122.5, 122.1, 119.5, 118.5,

112.1, 111.1, 52.7, 52.5, 24.6. HRMS m/z 261.1010 (calcd for C14H15NO4, 261.1001).

Ethyl 2-(2-(3-methyl-1H-indol-2-yl)cyclohex-2-enyl)acetate (2-32)
To a solution of 3-methylindole (270 mg, 2.10 mmol) and the
cyclopropane 1-2 (816 mg, 4.10 mmol) in MeNO2 (5.00 mL) at 0 °C,
TMSOTf (1.50 mL, 8.20 mmol) was added dropwise. After 3 h at RT, the solution was
poured into 20.0 mL of a half saturated solution of NaHCO3. The heterogeneous mixture
was separated and the aqueous layer was extracted with EtOAc (3 x 10.0 mL). The
combined organic layers were washed with brine, dried (MgSO4), filtered through Celite
and concentrated under reduced pressure. Purification by flash chromatography on silica
gel using EtOAc-hexanes for elution provided the title compound as colorless oil (92%,
69
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565 mg). Rf 0.55 (35% EtOAc/hexanes); 1H NMR (400 MHz, CDCl3)  7.96, (br s, 1H),
7.51 (d, J = 7.8 Hz, 1H), 7.28 (d, J = 8.0 Hz, 1H), 7.14 (dd, J = 7.5, 1.3 Hz, 1H), 7.08 (td,
J = 7.4, 1.1 Hz, 1H), 6.00 (td, J = 3.9, 1.5 Hz, 1H), 4.05–3.97 (m, 2H), 3.14–3.12 (m,
1H), 2.36–2.31 (m, 1H), 2.30 (s, 3H), 2.55–2.19 (m, 3H), 1.93–1.88 (m, 1H), 1.72–1.66
(m, 1H), 1.16 (t, J = 7.1 Hz, 3H).

13

C NMR (100 MHz, CDCl3)  173.1, 135.1, 134.7,

132.5, 130.3, 129.5, 121.6, 119.1, 118.4, 110.5, 108.3, 60.4, 38.7, 33.6, 27.9, 25.8, 18.6,
14.1, 9.6.

12-Methyl-3,4,4a,5-tetrahydroindolo[2,1-a]isoquinolin-6(2H)-one (233)
A solution of phenyl selenoester 2-47 (30.0 mg, 0.07 mmol) and AIBN
(0.60 mg, 0.004 mmol) in benzene (8.00 mL) was heated to reflux. Tributyltin hydride
(22.0 μL, 0.08 mmol) was then added to the reaction mixture, as a solution in 0.80 mL
benzene over 1 h. After refluxing for 1.5 h, the solution was cooled to RT and
concentrated under reduced pressure. The residue was purification by flash
chromatography on silica gel using EtOAc-hexanes for elution, to provide the title
compound as white solid (72% yield, 12.0 mg). Rf 0.53 (33% EtOAc/hexanes). 1H NMR
(400 MHz, CDCl3)  8.47-8.45 (m, 1H), 7.48-7.46 (m, 1H), 7.33-7.26 (m, 2H), 6.31-6.30
(m, 1H), 2.85 (dd, J = 15.8, 4.5 Hz, 1H), 2.81-2.73 (m, 1H), 2.49 (dd, J = 15.9, 12.9 Hz,
1H), 2.36 (s, 3H), 2.34-2.23 (m, 2H), 2.12-2.04 (m, 1H), 2.1.89-1.81 (m, 1H), 1.61-1.52
(m, 1H), 1.35 (ddd, J = 12.8, 9.7, 2.9 Hz, 1H);

13

C NMR (100 MHz, CDCl3)  168.8,

133.8, 133.1, 131.8, 128.3, 127.9, 124.8, 123.7, 118.2, 116.4, 113.0, 41.4, 33.8, 30.0,
26.2, 20.8, 10.7. HRMS m/z 251.1304 (calcd for C17H17NO, 251.1310).

(E)-Ethyl-3-(1H-indol-3-yl)acrylate (2-39)
To a solution of indole-3-carboxaldehyde (174 mg, 1.20 mmol)
dissolved in 20.0 mL toluene and 3.00 mL CH2Cl2, freshly prepared Ph3PCHCO2Et was
added as a solid under a N2(g) cone. The reaction mixture was stirred at RT for 16 h and
the solvent was removed under reduced pressure. The residue was purified by flash
chromatography on silica gel using EtOAc-hexanes for elution provided the title
compound as white solid (72%, 186 mg). Rf 0.55 (80% EtOAc/hexanes); 1H NMR (400
70
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MHz, CDCl3)  8.60 (br s, 1H), 7.94–7.90 (m, 2H), 7.47 (d, J = 2.7 Hz, 1H), 7.42–7.40
(m, 1H), 7.30–7.22 (m, 2H), 6.47 (d, J = 16 Hz, 1H), 4.27 (q, J = 7.0 Hz, 1H), 1.35 (t, J =
7.1 Hz, 1H).

13

C NMR (100 MHz, CDCl3)  168.3, 138.2, 137.1, 128.7, 125.3, 123.3,

121.5, 120.5, 113.6, 113.5, 111.7, 60.1, 14.4.

Se-phenyl-2-(6-oxo-2,3,4,4a,5,6-hexahydroindolo[2,1a]isoquinolin-12-yl)ethaneselenoate (2-47)
To a solution of aldehyde 2-54 (50.0 mg, 0.18 mmol) in tBuOH
(1.26 mL), H2O (1.26 mL), and THF (1.00 mL), was added 0.90 mL 1-methylcyclohexene. NaH2PO4·H2O (124 mg, 0.90 mmol) and NaClO2 (49.0 mg, 0.54 mmol)
were then added to the reaction mixture as solids. The solution was stirred for 1 h, and
then poured a half saturated solution of NaCl (10.0 mL). The heterogeneous mixture was
separated and the aqueous layer was extracted with EtOAc (5 x 10.0 mL). The combined
organic layers were washed with brine, dried (MgSO4), filtered through Celite and
concentrated under reduced pressure. The carboxylic acid was dissolved in 3.00 mL
CH2Cl2 and a solution of diphenyl diselenide (84.0 mg, 0.27 mmol) in 10.0 mL CH2Cl2
was added and cooled to 0 °C. Tributylphosphine (67.0 μL, 0.27 mmol) was then added
dropwise, as a solution in 0.40 mL CH2Cl2. The reaction mixture was stirred at RT for 4
h, and then poured into 10.0 mL H2O. The heterogeneous mixture was separated and the
aqueous layer was extracted with CH2Cl2 (4 x 10.0 mL). The combined organic layers
were washed with brine, dried (MgSO4), filtered through Celite and concentrated under
reduced pressure. Purification by flash chromatography on silica gel using EtOAchexanes for elution provided the title compound as white solid (81% yield, three steps
from alcohol 2-53, 66.0 mg). Rf 0.65 (50% EtOAc/hexanes). 1H NMR (400 MHz, CDCl3)
 8.53-8.51 (m, 1H), 7.58-7.56 (m, 1H), 7.46-7.44 (m, 2H), 7.40-7.33 (m, 5H), 6.51-6.46
(m, 1H), 4.19 (d, J = 16.8 Hz, 1H), 4.03 (d, J = 16.8 Hz, 1H), 2.92 (dd, J = 16.2, 4.5 Hz,
1H), 2.88-2.78 (m, 1H), 2.59 (dd, J = 16.3, 13.2 Hz, 1H), 2.40-2.30 (m, 2H), 2.14-2.08
(m, 1H), 1.91-1.83 (m, 1H), 1.63-1.52 (m, 1H), 1.41-1.32 (m, 1H).
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3-(2-Acetoxyethyl)indole (2-49)
Tryptophol (806 mg, 5.00 mmol) was dissolved in 10.0 mL pyridine
and acetic anhydride (662 μL, 7.00 mmol) was added dropwise and allowed to stir for 15
h at RT. The solution was poured into 40.0 mL H2O solution and stirred for 20 min. The
heterogeneous mixture was separated and the aqueous layer was extracted with CH2Cl2 (4
x 10.0 mL). The combied organic layers were washed with brine, dried (MgSO4), filtered
through Celite and concentrated under reduced pressure. Purification by flash
chromatography on silica gel using EtOAc-hexanes for elution provided the title
compound as colorless oil (99% yield, 1.00 g). Rf 0.46 (50% EtOAc/hexanes); 1H NMR
(400 MHz, CDCl3)  8.17 (br s, 1H), 7.68 (d, J = 8.2 Hz, 1H), 7.36 (d, J = 8.0 Hz, 1H),
7.24 (dt, J = 7.5, 1.3 Hz, 1H), 7.18 (dt, J = 7.5, 1.1 Hz, 1H), 7.01 (d, J = 2.3 Hz, 1H), 4.40
(t, J = 7.1 Hz, 1H), 3.14 (dt, J = 7.2, 0.8 Hz, 1H), 2.10 (s, 3H);

13

C NMR (100 MHz,

CDCl3)  171.2, 136.1, 127.3, 121.9, 119.3, 118.7, 111.8, 111.1, 64.6, 24.7, 21.0.

{2-[3-(2-Hydroxyethyl)-1H-indol-2-yl]-cyclohex-2-enyl}-acetic acid
methyl ester (2-50)
To a solution of tryptophol (80.0 mg, 0.49 mmol) and the
cyclopropane 1-2 (127 mg, 0.64 mmol) in MeNO2 (2.00 mL) at 0 °C,
TMSOTf (206 μL, 1.13 mmol) was added dropwise. After 1 h at RT, 5.00 mL of EtOAc
was added and the mixture was poured into a half saturated solution of NaHCO3 (15.0
mL). The heterogeneous mixture was separated and the aqueous layer was extracted with
EtOAc (4 x 10.0 mL). The combined organic layers were washed with brine, dried
(MgSO4), filtered through Celite and concentrated under reduced pressure. Purification
by flash chromatography on silica gel using EtOAc-hexanes for elution provided the title
compound as pale yellow oil (70% yield, 112 mg). Rf 0.44 (50% EtOAc/hexanes); 1H
NMR (400 MHz, CDCl3)  8.07 (br s, 1H), 7.58 (dd, J = 7.8, 1.2 Hz, 1H), 7.30 (dt, J =
8.0, 0.9 Hz, 1H), 7.15 (ddd, J = 8.1, 7.0, 1.3 Hz, 1H), 7.09 (ddd, J = 7.9, 6.9, 1.1 Hz,
1H), 6.06 (td, J = 4.0, 1.6 Hz, 1H), 3.99-3.88 (m, 4H), 3.13-2.96 (m, 3H), 2.33-2.17 (m,
4H), 1.93-1.88 (m, 1H), 1.72-1.62 (m, 4H), 1.11 (t, J = 7.1 Hz, 3H); 13C NMR (100 MHz,
CDCl3)  173.1, 136.49, 135.2, 132.2, 131.4, 128.8, 121.9, 119.5, 118.7, 110.7, 108.8,
63.0, 60.5, 38.8, 34.2, 28.3, 25.8, 18.9, 14.0.
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{2-[3-(2-Acetoxyethyl)-1H-indol-2-yl]-cyclohex-2-enyl}-acetic acid
methyl ester (2-51)
To a solution of indole 2-49 (100 mg, 0.49 mmol) and cyclopropane
1-2 (127 mg, 0.64 mmol) in MeNO2 (2.00 mL) at 0 °C, TMSOTf (206
μL, 1.13 mmol) was added dropwise. After 1 h at RT, 5.00 mL of EtOAc was added and
the mixture was poured into a half saturated solution of NaHCO3 (15.0 mL). The
heterogeneous mixture was separated and the aqueous layer was extracted with EtOAc (4
x 10.0 mL). The combined organic layers were washed with brine, dried (MgSO4),
filtered through Celite and concentrated under reduced pressure. Purification by flash
chromatography on silica gel using EtOAc-hexanes for elution provided the title
compound as colorless oil (86% yield, 155 mg). Rf 0.63 (50% EtOAc/hexanes); 1H NMR
(400 MHz, CDCl3)  8.09 (br s, 1H), 7.60 (d, J = 7.2 Hz, 1H), 7.30 (d, J = 8.0 Hz, 1H),
7.15 (td, J = 7.6, 1.3 Hz, 1H), 7.09 (td, J = 7.4, 1.3 Hz, 1H), 6.04 (td, J = 3.9, 1.4 Hz,
1H), 4.33-4.23 (m, 2H), 4.04-3.96 (m, 2H), 3.17-2.99 (m, 3H), 2.32-2.19 (m, 4H), 2.04
(s, 3H), 1.95-1.89 (m, 1H), 1.72-1.64 (m, 3H), 1.15 (t, J = 7.1 Hz, 3H);

13

C NMR (100

MHz, CDCl3)  171.9, 171.1, 136.2, 135.1, 132.0, 131.4, 128.7, 121.9, 119.5, 118.7,
110.7, 108.4, 64.6, 60.4, 38.6, 34.1, 27.9, 25.7, 24.3, 21.1, 18.8, 14.1.

2-(6-Oxo-2,3,4,4a,5,6-hexahydroindolo[2,1-a]isoquinolin-12yl)ethyl acetate (2-52)
The title compound was obtained from indole 2-51 using the
cyclization reaction conditions as described above in the procedure to obtain compound
2-23. This procedure provided the title compound as a white solid (90% yield). Rf 0.54
(50% EtOAc/hexanes); 1H NMR (400 MHz, CDCl3)  8.49-8.47 (m, 1H), 7.56-7.54 (m,
1H), 7.34-7.28 (m, 2H), 6.46 (dt, J = 4.7, 2.7 Hz, 1H), 4.38-4.28 (m, 2H), 3.26-3.18 (m,
1H), 3.16-3.09 (m, 1H), 2.27 (dd, J = 16.2, 4.5 Hz, 1H), 2.85-2.74 (m, 1H), 2.52 (dd, J =
16.2, 13.1 Hz, 1H), 2.40-2.26 (m, 2H), 2.12-2.06 (m, 1H), 2.05 (s, 3H), 1.90-1.82 (m,
1H), 1.63-1.52 (m, 1H), 1.40-1.31 (m, 1H); 13C NMR (100 MHz, CDCl3)  171.0, 168.8,
134.6, 133.9, 131.1, 127.9, 127.8 125.1, 123.9, 118.3, 116.5, 112.8, 63.4, 41.4, 34.0, 29.9,
26.3, 24.7, 21.0, 20.7. HRMS m/z 323.1529 (calcd for C20H21NO3, 323.1521).
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12-(2-Hydroxyethyl)-3,4,4a,5-tetrahydroindolo[2,1-a]isoquinolin6(2H)-one (2-53)
To a solution of indole 2-52 (70.0 mg, 0.22 mmol) in 8.00 mL MeOH
was added 2.00 mL of 0.50 M K2CO3 solution (4.70 mmol). The solution was allowed
stir at RT for 30 min. The solution was concentrated under reduced pressure, and then
residue was dissolved in 10.0 mL EtOAc and 10.0 mL H2O. The heterogeneous mixture
was separated and the aqueous layer was extracted with EtOAc (4 x 10.0 mL). The
combined organic layers were washed with brine, dried (MgSO4), filtered through Celite
and concentrated under reduced pressure. Purification by flash chromatography on silica
gel using EtOAc-hexanes for elution provided the title compound as white solid (85%
yield, 52.6 mg). Rf 0.35 (50% EtOAc/hexanes); 1H NMR (400 MHz, CDCl3)  8.47-8.45
(m, 1H), 7.54-7.52 (m, 1H), 7.34-7.27 (m, 2H), 6.58-6.56 (m, 1H), 4.04-3.93 (m, 2H),
3.18-3.07 (m, 2H), 2.84-2.71 (m, 2H), 2.40 (dd, J = 16.0, 12.9 Hz, 1H), 2.34-2.28 (m,
2H), 2.10-2.04 (m, 1H), 1.87-1.80 (m, 1H), 1.70-1.68 (m, 1H), 1.61-1.50 (m, 1H), 1.361.27 (m, 1H);

13

C NMR (100 MHz, CDCl3)  168.9, 134.8, 133.9, 131.3, 128.0, 127.6,

125.0, 123.9, 118.5, 116.6, 113.9, 62.3, 41.2, 33.9, 29.9, 28.5, 26.3, 20.7. HRMS m/z
281.1408 (calcd for C18H19NO2, 281.1416).

2-(6-Oxo-2,3,4,4a,5,6-hexahydroindolo[2,1-a]isoquinolin-12-yl)
acetaldehyde (2-54)
To a solution of oxalyl chloride (24.0 μL, 0.28 mmol) in 0.60 mL
CH2Cl2 at −78 °C, DMSO (40.0 μL, 0.56 mmol) as a solution in 0.40 mL CH2Cl2 was
added over 10 min. The solution was stirred at −78 °C for 1 h. A solution of alcohol 2-53
(39.0 mg, 0.14 mmol) in 0.40 mL CH2Cl2 was then added over 15 min, and stirred at −78
°C for 2 h. After the slow addition of Et3N (137 μL, 0.98 mmol) over 15 min, the solution
was allowed to stir at −78 °C for 1 h, and then warmed to RT over 30 min. The reaction
mixture was diluted with 5.00 mL CH2Cl2 and then poured into a half saturated solution
of NaCl (15.0 mL). The heterogeneous mixture was separated and the aqueous layer was
extracted with CH2Cl2 (5 x 10.0 mL). The combined organic layers were dried (MgSO4)
and filtered through Celite. After the solution was concentrated under reduced pressure,
the title compound was isolated as colorless oil and used immediately. Rf 0.61 (50%
74

75

EtOAc/hexanes). 1H NMR (400 MHz, CDCl3)  9.74 (t, J= 2.1, Hz, 1H), 8.50 (d, J = 8.0
Hz, 1H), 7.43 (d, J = 7.8 Hz, 1H), 7.37-7.28 (m, 2H), 6.27 (bs, 1H), 3.96 (dd, J = 16.6,
1.7, Hz, 1H), 3.81 (dd, J = 16.8, 2.3, Hz, 1H), 2.89 (dd, J = 16.3, 4.6, Hz, 1H), 2.86-2.75
(m, 1H), 2.53 (dd, J = 16.1, 13.2, Hz, 1H), 2.36-2.22 (m, 2H), 2.10-2.07 (m, 1H), 1.871.83 (m, 1H), 1.61-1.50 (m, 1H), 1.37-1.28 (m, 1H);

13

C NMR (100 MHz, CDCl3) 

198.5, 168.7, 135.9, 133.9, 130.6, 128.9, 127.7, 125.5, 124.2, 117.9, 116.6, 107.5, 41.3,
40.6, 33.9, 29.8, 26.2, 20.6.
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CHAPTER 3: Progress Towards the Total Synthesis Biselide A and E

3.1 Introduction
Many research groups have developed efficient methods for the synthesis and
derivatization of 2,5-trans-tetrahydrofuran (THF) rings due to their presence in a wide
array of biologically active natural products, including biselide A and E (Figure 3.1).1
One particularly useful strategy to form trans-THF rings was developed by Mukaiyama
in 1990, which involves the oxidative cyclization of pentenols with a variety of cobalt
catalysts.2

Figure 3.1 Natural products containing trans-THF rings

The utility of the Mukaiyama oxidative cyclization has already been shown in our
research group through the total synthesis of (−)-aplysiallene3 and bullatacin,4 where we
envisioned the methodology could also be used to access biselide A and E (Figure 3.1).
The cobalt catalysts employed by Mukaiyama (first generation catalysts) are effective in
the methodology; however, our research group recently reported a second generation
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catalyst that has been shown to provide the desired trans-THF products in higher yields
and with significantly simplified purification compared to the first generation catalysts.5
Herein, we report the progress towards the total synthesis of biselide A and E, where the
second generation cobalt catalyst is employed for the formation of the trans-THF core in
each target molecule.

3.2 Mukaiyama Oxidative Cyclization

3.2.1 First Generation Cobalt Catalysts

The Mukaiyama oxidative cyclization of pentenols has become one of the most
useful methods for constructing trans-THF rings in good yields and excellent
diastereoselectivity (>99:1 dr).2 While the mechanistic details of the oxidative cyclization
are not well understood, Hartung has made significant mechanistic contributions and has
proposed a generally accepted radical mechanism.6 The three cobalt catalysts employed
by Mukaiyama are known as the first generation catalysts, and they feature ligands with
acetylacetonate (acac) and amide moieties, with substituents including a piperidine ring
(piper, 3-5), morpholine unit (modp, 3-6) and dibenzyl linkages (diBn, 3-7) (Figure 3.2).

Figure 3.2 First generation cobalt catalysts
Our research group has applied the Mukaiyama oxidative cyclization of pentenols
to generate the trans-THF rings found in two natural products, including bullatacin (33),4 that contains a bridged bis-THF core (Scheme 3.1), and (−)-aplysiallene (3-4),3 which
features a fused bis-THF ring core (Scheme 3.2). The total synthesis of bullatacin began
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with a double allylation of diepoxide (R,R)-3-8, which was mono-acylated to
desymmetrize the molecule. This cyclization precursor (3-9) underwent an efficient
oxidative cyclization, catalyzed by Co(modp)2 in 82% yield. Protection of the resulting
primary alcohol as the silyl ether, followed by removal of the acetate protecting group
gave rise to another cyclization precursor, which furnished the second trans-THF ring (311) in 79% yield and with complete stereocontrol. This advanced intermediate was then
carried through a variety of chemical transformations to ultimately give bullatacin in 17
total steps from epoxide (R,R)-3-8 and 13.3% overall yield.

Scheme 3.1 Total synthesis of bullatacin
To further demonstrate the utility of the Mukaiyama oxidative cyclization, our
group used the methodology to complete the first total synthesis of (−)-aplysiallene
(Scheme 3.2).3 The core of the natural product was constructed in a similar fashion to the
bullatacin synthesis, beginning with a double vinylation of diepoxide (S,S)-3-8. Monoacylation gave pentenol 3-12 which underwent the first Co(modp)2 catalyzed Mukaiyama
oxidative cyclization to give trans-THF 3-13 in 80% yield. Following some protecting
group manipulations, the second trans-THF ring (3-14) was also efficiently constructed
using the oxidative cyclization. With the unique fused bis-THF ring core in place, the rest
of the natural product was completed to give (−)-aplysiallene in 16 total steps in 2.3%
overall yield.
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Scheme 3.2 Total synthesis of (−)-aplysiallene

3.2.2 Second Generation Cobalt Catalyst

Although the first generation cobalt catalysts (Figure 3.2) used in the Mukaiyama
oxidative cyclization of pentenols provide trans-THF ring products in good yield and
diastereoselectivity, there were oftentimes difficulties associated with the catalysts.
During the course of the reaction, the first generation catalysts decompose into other
active cobalt residues that catalyze undesired side-reactions, producing over-oxidation
products and lowering the overall yield. After the reaction is complete, these cobalt
residues are very difficult to remove from the trans-THF product even after purification
by

column

chromatography,

which

result

in

difficulties

with

spectroscopic

characterization due to the paramagnetic nature of cobalt. The problems associated with
purifying the THF products from the first generation cobalt catalysts, urged our group to
develop a new catalyst.5
Our initial approach towards a second generation cobalt catalyst involved using
the first generation catalysts as a template, and modifying the amide substituent of the
ligand to exhibit increased polarity. This method has been successful in a variety of areas
including water soluble ligands and reagents, sulphonated phosphines, fluorous phases,
ionic liquids.7 This strategy led us to replace the neutral morpholine unit found in the
modp ligand (3-6) with a basic N-methyl piperazine (3-15), henceforth known as nmp
(Figure 3.3, protonated ligands shown). The tertiary amine in nmp could be protonated by
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acid or quaternarized by alkylation which would provide a convenient method of removal
from the reaction mixture by aqueous work-up.

Figure 3.3 First generation modp and second generation nmp ligands

The synthesis of Co(nmp)2 began with reaction of ethyl oxalyl chloride with Nmethyl piperazine and triethylamine, which furnished glyoxyalate 3-18 in 99% yield
(Scheme 3.3). Claisen condensation of 3-18 with pinacolone followed by a non-aqueous
acidic quench gave a 95% yield of the nmp ligand. Finally, complexation of the nmp
ligand to cobalt was achieved in near quantitative yield using a modified procedure
involving the addition of four equivalents of water. The second generation catalyst for the
Mukaiyama oxidative cyclization, Co(nmp)2, is readily accessible as it can be prepared
quickly on gram scale from inexpensive commercially available starting materials, using
centrifugation as the only method of purification.8

Scheme 3.3 Synthesis of Co(nmp)2
When Co(nmp)2 is employed in a cyclization reaction, purification can be
accomplished using one of three methods, each catering to specific functional group
sensitivity. The first two purifications involve the ligand’s ability to quaternize, due to the
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basic N-methyl piperazine unit in Co(nmp)2. One method involves an acidic (pH 4) buffer
wash,9 which allows the catalyst to move from the organic to the aqueous layer upon
work-up. Alternatively, a neutral procedure was introduced for acid sensitive substrates
which involve methylation using MeI followed by neutral aqueous workup.
The third purification method was developed after our group serendipitously
discovered that Co(nmp)2 had an Rf of 0.00 in 100% ethyl acetate, whereas the first
generation catalysts had similar Rf’s to the trans-THF products formed in the reaction.
This finding allowed us to avoid an aqueous workup completely, by first removing the
solvent from the reaction mixture under reduced pressure, dissolving the residue in ethyl
acetate, and directly filtering the heterogeneous mixture through a pad of silica over
Celite. This third purification method is the most convenient, results in the highest yields,
and also caters to substrates that contain functionalities that are incompatible with acidic
or methylating conditions. With all three work-up methods, trans-THF products are
obtained in high purity as crude reaction mixtures. Additionally, pre-activation of
Co(nmp)2 can be performed in order to facilitate the oxidative cyclization of peroxide
sensitive substrates.10
The performance of the second generation catalyst Co(nmp)2 was compared to the
first generation catalysts, and in all cases, cyclization reactions performed with Co(nmp)2
resulted in increased yields and with fewer side-products. This second generation catalyst
system also features a mild and simple isolation and purification procedure, proving to be
a vast improvement over the first generation catalysts where removal of the cobalt
residues are difficult or impossible. This highlights the superiority of our second
generation catalyst Co(nmp)2, and its value in the synthesis of natural products containing
trans-THF rings.
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3.3 Biological Activity
The first members of the haterumalide family of natural products were isolated in
1999 from an Okinawan sea sponge Ircinia sp. and ascidian Didemnidae sp. off of the
coast of Japan,11 while several members of the biselide family were isolated years later
from an Okinawan ascidian Didemnidae sp.12 Many of the haterumalides and biselides
have been investigated for thier biological activity, where haterumalide NA (3-19) has
attracted the most attention (Figure 3.4). Biselide A and E are closely related analogs,
where a possible biosynthetic pathway to 3-1 from 3-2 may involve lactone disconnection
of the 14-membered macrocycle where the carbonyl at C-1 may cyclize onto the alcohol
at C-20 along with condensation to form the unsaturation at C-2/C-3 in Biselide E.

Figure 3.4 Biselide A and E, haterumalide NA and haterumalide NA methyl ester

Haterumalide NA (3-19) was found to exhibit strong cytotoxity against murine
lymphoma cell lines (P388 cells) with an IC50 of 0.32 μg/mL, while also demonstrating
acute toxity with an LD99 of 0.24 g/kg in mice.11 The artificial analogue of 3-19, the C-19
methyl ester of haterumalide NA (3-20), was also screened for its bioactivity and was
found to demonstrate an IC50 of 0.14 μg/mL against human lung cancer cells (NCIH460).11 Biselide A (3-1), however, was shown to be most cytotoxic against human colon
cancer cells (DLD-1) with an IC50 of 0.51 μg/mL.11 Unfortunately, the bioactivity of
biselide E has yet to be explored.12b
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3.4 Previous Syntheses of the Haterumalides and the Biselides

3.4.1 Previous Syntheses Towards Haterumalide NA and its Derivatives

Among the related members of the haterumalide and biselide families,
haterumalide NA (3-19) continues to attract the most synthetic attention due to its
biological activity.13 Initially, spectroscopic analysis helped elucidate the relative
stereostructure of 3-19, and the absolute stereochemistry was revised following the total
synthesis of ent-haterumalide NA methyl ester (ent-3-20) in 2003 by Kigoshi and coworkers.13a

Scheme 3.4 Kigoshi’s progress towards ent-haterumalide NA methyl ester
Kigoshi’s synthesis began with the coupling of THF 3-22 (derived from
commercially available (+)-2,3-O-isopropylidene-L-threitol) and Z-alkenylsilane 3-21,
which was prepared from 3-butyn-1-ol (Scheme 3.4). The resulting substrate 3-23
underwent a variety of chemical transformations to functionalize the side-chain (3-24),
prior to TBS removal and acylation of the resulting alcohol. Acidic deprotection of the
allylic alcohol and DMP oxidation furnished 3-25 in good yield.
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Scheme 3.5 Kigoshi’s total synthesis of ent-haterumalide NA methyl ester

Intramolecular Reformatsky-type reaction of 3-25, followed by DDQ oxidation of
the PMB ether revealed the desired cyclized product 3-26 in a low 8% yield over the two
steps (Scheme 3.5). Nozaki-Hiyama-Kishi coupling reaction of iodide 3-27 and the
aldehyde derived from a DMP oxidation of 3-26 afforded ent-haterumalide NA methyl
ester (ent-3-20) in 57% over two steps in an 11:1 diasteromeric ratio. Unfortunately, all
attempts to hydrolyze the methyl ester to the carboxylic acid found in the natural product
were unsuccessful. As such, the synthetic material was compared to the methyl ester
derivative of haterumalide NA and was found to be its enantiomer. This discrepancy
between the synthetic and natural material allowed Kigoshi to assign the correct absolute
stereochemistry of the natural product.
It wasn’t until 2005 that Hoye and co-workers reported the first total synthesis of
haterumalide NA as the natural enantiomer (Scheme 3.6).13c In this report, advanced
intermediate ene-yne 3-28 underwent an efficient Pd(II)-mediated chloroallylative
cyclization in an overall 91% yield, albeit in a low isomeric ratio (1:1.4 Z/E, 38% of the
desired Z-isomer 3-29). Luche reduction of the α,β-unsaturated ester (3-29) gave the
desired alcohol as a single diastereomer, which was followed by protection of the
secondary alcohol as an acetate and removal of the PMB ether under oxidative conditions
to give ent-3-26 (the enantiomer of Kigoshi’s intermediate in Scheme 3.5) in 84% yield
over three steps. Oxidation of the resulting primary alcohol set the stage for the Nozaki86
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Hiyama-Kishi coupling reaction with iodide 3-30. Hoye’s choice of iodoalkene, which
featured a PMB ester instead of the methyl ester (3-27) used by Kigoshi was crucial to
the completion of the molecule because he could successfully hydrolyze it, where
Kigoshi failed to do so. This final transformation allowed Hoye and co-workers to
complete the first total synthesis of haterumalide NA (3-19).

Scheme 3.6 Hoye’s total synthesis of haterumalide NA

3.4.2 Previous Attempts Toward the Synthesis of the Biselides

One year after Kigoshi and co-workers confirmed the absolute stereochemistry of
haterumalide NA (3-19), they began to isolate several members of a related family of
natural products, the biselides, from an Okinawan ascidian Didemnidae sp. Using
spectroscopic analysis, the biselides were found to be oxygenated derivatives of the
haterumalides, based on analogy to the haterumalide family.12

12

Although the absolute

stereochemistry of the biselides has yet to be confirmed by synthetic methods, there have
been attempts towards their synthesis. Cossy and co-workers constructed the unique C1-
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C8 fragment of biselide E, where they envisioned a Suzuki-Miyaura coupling reaction to
access the natural product.14

Scheme 3.7 Cossy’s synthesis of RCM precursor 3-34
The synthesis of the fragment began with commercially available βtrichloromethyl-β-propiolactone 3-31, which was converted to iodoalkene 3-32 in four
steps (Scheme 3.7). This coupling partner then participated in a Stille cross-coupling
reaction and was reduced with DIBAL to give diene 3-33. The alcohol was then
functionalized with acryloyl chloride to give RCM precursor 3-34 in 91% yield.

Scheme 3.8 Cossy’s synthesis of the C1-C8 fragment of biselide E
Acrylate 3-34 underwent efficient ring closing metathesis to afford γ-alkylidene
α,β-unsaturated δ-lactone 3-35 in 77% yield (Scheme 3.8). Protection of the carbonyl
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group (3-35) as a methyl acetal was achieved in two steps, which simultaneously
removed the TES ether to reveal a secondary alcohol that was subsequently protected as
an acetate group (3-36). The C1-C8 fragment of biselide E was then completed with a
SmI2–mediated elimination reaction to form gem-dichloroalkene 3-37.
Kigoshi and co-workers have also recently reported the synthesis of the carbon
backbone of biselide A, B, and E (Scheme 3.9),15 which was closely related to their
previous syntheses towards the haterumalides.13d Their first approach involved
functionalizing the aldehyde sidechain in 65% yield over a three step sequence from 3-38
(Horner-Wadsworth-Emmons olefination, DIBAL reduction, and silyl protection), to
furnish iodo olefin 3-39 (Scheme 3.9, route 1).15a The iodo alkene then participated in a
Stille coupling reaction with tributyl(vinyl)tin, which gave terminal olefin 3-40.
Dihydroxylation with OsO4 in aqueous acetone resulted in low regioselectivity at the
terminal olefin over the internal variant, but still provided the desired diol 3-41 in 30%
yield over the two steps. Oxidative cleavage of the diol (3-41) gave rise to aldehyde 3-42,
which was carried forward to furnish the framework of the biselides.
Since their initial Stille/dihydroxylation protocol did not give an efficient route to
the biselide core, Kigoshi and co-workers described an alternative approach (Scheme 3.9,
route 2).15b This new method began with advanced intermediate (3-38), which underwent
a Horner-Wadsworth-Emmons olefination followed by DIBAL reduction, as described in
their previous haterumalide syntheses.13d After protection of the allylic alcohol 3-43 as a
p-nitrobenzoyl group in 89% yield, a regioselective allylic oxidation installed the alcohol
in 3-45 in 35% yield. Finally, a three step protocol was followed to give aldehyde 3-42,
involving protection of the allylic alcohol as a TBDPS ether, cleavage of the PNB group,
and DMP oxidation.
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Scheme 3.9 Kigoshi’s studies toward aldehyde 3-42
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Kigoshi and co-workers then utilized aldehyde 3-42 as a precursor to the carbon
backbone found in biselide A, B, and E (Scheme 3.10). The aldehyde was taken through
the same chemical transformations as in the haterumalide syntheses, to access
macrolactone 3-46.15b Aldehyde 3-42 also underwent a series of transformations
including a Wittig olefination, Stille cross-coupling and cyclization to form the α,βunsaturated lactone 3-47. Both intermediates (3-46 and 3-47) could be used to access
biselide A, B, and E, as well as members of the haterumalide family.

Scheme 3.10 Kigoshi’s studies toward the biselide framework from aldehyde 3-42
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3.5 Progress Towards the Total Synthesis of Biselide A

3.5.1 Retrosynthesis

Upon retrosynthetic analysis, biselide A could be disconnected into three
fragments, including β-hydroxyacids 3-48 or 3-49 (the southern fragments), the transTHF core 3-50 or 3-51 (the northern fragments), and the side-chain 3-54 (Scheme 3.11).
An esterification reaction followed by a RCM (with 3-48 and 3-50) or RRCM (with 3-49
and 3-51) was envisioned to construct the 14-membered ring, while the side-chain (3-54)
could be appended using the Nozaki-Hiyama-Kishi reaction as demonstrated in the
haterumalide syntheses.13 The chloroalkenes (3-50 and 3-51) could be accessed via a
chloropalladation reaction of 3-52, while the trans-THF ring could be furnished using the
second generation cobalt catalyzed Mukaiyama oxidative cyclization with syn-diol 3-53.

Scheme 3.11 Retrosynthesis of biselide A
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3.5.2 Constructing the Northern Fragment

3.5.2.1 Asymmetric Aldol Reactions

Chiral auxiliary mediated asymmetric aldol addition reactions have become a
powerful method for asymmetric carbon-carbon bond formation.16 A key contribution in
this field was supplied by Evans, in the development of the oxazolidinone aldol
reaction.17 This highly diastereoselective method allows access to Evans’ syn and nonEvans syn aldol products depending on the reaction conditions (Figure 3.5).

Figure 3.5 Oxazolidinone aldol products

Asymmetric aldol reactions have seen a great deal of success when employing
propionates (Figure 3.6, R1= Me), whereas acetate aldol reactions remain a challenge
(R1= H). N-Acyloxazolidinones are among the most commonly used chiral auxiliaries to
construct β-hydroxy acid derivatives. The α-substituent in the auxiliary (R1= Me) plays a
key role in facial differentiation, which ultimately results in a single diastereomer
product. Using boron enolates 3-55a and 3-55b, the aldol reaction can proceed via four
Zimmerman-Traxler transition states. Assuming the aldehyde substituent R2 remains in
the equatorial position, it must approach the enolate opposite to the bulky isopropyl
substituent of the auxiliary, favoring transition states 1 and 4. Although undesirable
dipole interactions somewhat disfavor transition state 4, unfavorable allylic strain
interactions play a more influencial role in the resulting diastereoselectivity. The allylic
strain observed between the isopropyl group and R1 disfavor transition state 4 over
transition state 1 with the propionic enolate 3-55a, resulting in the formation of the Evans
syn product exclusively (>20:1 of Evans syn:non-Evans syn). In the case of an acetate
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aldol (3-55b, where R1= H), the aforementioned unfavorable allylic strain interactions are
absent and poor selectivity is observed.

Figure 3.6 Influence of the α-substituent in boron mediated aldol reactions

The poor diastereoselectivity observed with acetate aldol reactions (where R= H)
has led to the development of several chiral auxiliaries that are designed to overcome the
lack of α-substitution. Based on work developed by Evans, Nagao introduced a new class
of N-acetyl-1,3-thiazolidine-2-thione auxiliaries that were shown to give aldol products
with high diastereocontrol using tin(II) triflate as the Lewis acid (Figure 3.7).18 The same
thiazolidinethione auxiliaries were later extended to give highly selective acetate aldols
with dichlorophenylborane as the Lewis acid using sparteine as the base.19

Figure 3.7 Chiral aldol auxiliaries
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Crimmins extended the use of Nagao’s auxiliary to include N-propionyl
oxazolidinethiones and thiazolidinethiones with titanium(IV) chloride, where both the
Evans syn and non-Evans syn products could be obtained by controlling the amount and
nature of the base and Lewis acid.20 Based on those results, Olivo explored the same
conditions to include acetate aldols while also employing a titanium enolate (Figure
3.8).21 A closed transition state is formed when one or less than one equivalent of base
relative to titanium(IV) chloride is employed, ultimately leading to the acetate syn
product. However, if an excess of base is used, the thiocarbonyl of the chiral auxiliary is
no longer coordinated to the titanium which leads to an open transition state that
generates the acetate anti product.

Figure 3.8 Titanium mediated aldol reactions

3.5.2.2 Examining Asymmetric Aldol Reactions
In order to explore Olivo’s titanium mediated aldol addition in our synthesis, we
first set out to synthesize a small set of thiazolidinethione auxiliaries, as described in the
literature (Scheme 3.12). The synthesis of mesityl substituted auxiliary 3-58 began by
treating (R)-tBuSONH2 (3-56) with anhydrous α-chloroacetylaldehyde and CuSO4 to
generate imine 3-57 in 82% yield. Grignard addition with excess mesityl magnesium
bromide in toluene followed by cyclization with carbon disulfide in basic water gave the
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auxiliary in 58% over two steps.22 Two additional thiazolidinethione auxiliaries (3-61 and
3-62) were prepared by a different method involving the reflux of amino alcohols 3-59
and 3-60 with carbon disulfide in a basic ethanol solution.18 The chiral auxiliaries (3-58,
3-61

and

3-62)

were

all

subjected

to

acylation

conditions

to

give

acetylthiazolidinethiones 3-63, 3-64 and 3-65 in good yields.

Scheme 3.12 Synthesis of thiazolidinethione auxiliaries

The synthesis of the northern fragment began with a titanium mediated aldol
reaction with acetylthiazolidinethione 3-64 and aldehyde 3-67, which was prepared by
mono-silylation23 and oxidation of 1,3-propanediol (Scheme 3.13). The asymmetric aldol
gave the desired alcohol in 87% yield and modest diasteroselectivity (7:1 dr).
Fortunately, the diastereomers were separable by column chromatography, allowing for
isolation of diastereomerically pure 3-68. Cleavage of the auxiliary with N,Odimethylhydroxylamine hydrochloride gave rise to Weinreb amide 3-69 in 92% yield,
with full recovery of auxiliary 3-61. The amide was subsequently treated with vinyl
magnesiumbromide to furnish α,β-unsubstituted ester 3-70. Unfortunately, a synreduction under Prasad reduction conditions (Et2BOMe, NaBH4) led to an inseparable
mixture of diols (3-71 and 3-72), promoted by an uncontrollable silyl migration.
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Scheme 3.13 Initial asymmetric aldol and silyl migration

To circumvent the silyl migration problem, an alternative route to the northern
fragment of biselide A was explored. Rather than a protected alcohol as a
functionalizable handle, we envisioned a more efficient substituent such as an alkyne that
could be directly converted to the chloroalkene in the natural product. This new approach
involved the use of acetylthiazolidinethione 3-64 again, but this time employed
commercially available pent-4-ynal, in the asymmetric aldol reaction (Scheme 3.14).
While the aldol reaction proceeded in modest diastereoselectivity (6:1 dr), the product (374) was only obtained in 27% yield.

Scheme 3.14 Aymmetric aldol with terminal alkyne present

We speculated that the terminal alkyne was interfering with the reaction process,
so we investigated the same approach while employing a silyl protected alkyne (Scheme
3.15). In this case, aldehyde 3-76 and acetylthiazolidinethione 3-64 furnished alcohol 377 in 85% yield with modest diastereoselectivity (6:1 dr). In an attempt to increase the
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diastereoselectivity, bulkier acetylthiazolidinethiones were used in the aldol reaction,
where the best results were observed with tert-butyl substituted auxiliary 3-65 which
gave a 10:1 ratio of diastereomers and similar yield. Interestingly, mesityl substituted
acetylthiazolidinethione 3-63 produced the lowest diastereomeric ratio, suggesting that
extensive steric bulk on the auxiliary may be detrimental to the diastereoselectivity in a
titanium mediated aldol reaction when operating through an open transition state. While
satisfied with the yield and selectivity observed with the tert-butyl substituted auxiliary 365, separation of the diastereomers (3-78) proved to be tedious on large scale reactions
(>2 mmol), so additional methods were explored.

Scheme 3.15 Asymmetric aldol with 3-76 and a variety of acetylthiazolidinethiones
3.5.2.3 Examining Braun’s HYTRA Auxiliary
We then turned our attention to Braun’s (S)-2-hydroxy-1,2,2-triphenylethyl
acetate (HYTRA) auxiliary.24 This chiral auxiliary has been shown to provide excellent
enantiofacial differentiation with doubly deprotonated HYTRA to a variety of aldehydes,
obtaining β-hydroxy carboxylic acids in high yield and enantiopurity.
As such, we envisioned the use of Braun’s asymmetric aldol addition as a
potential strategy towards the northern fragment of biselide A. Synthesis of the HYTRA
auxiliary was performed according to Braun’s method of double Grignard addition into
(S)-mandelate with freshly prepared phenylmagnesium bromide (Scheme 3.16).25a
Esterification with acetic anhydride and scandium (III) triflate provided HYTRA acetate
3-82 from diol 3-81 in 77% yield.25b
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Scheme 3.16 Synthesis of Braun’s HYTRA acetate auxiliary

Braun

found

that

moderate

diastereoselectivities

were

obtained

upon

deprotonation with LDA at −78 °C, however, selectivity markedly improved when the
lithium enolate was transmetallated with magnesium bromide and temperatures were
decreased to −115 °C. With HYTRA acetate 3-82 in hand, the auxiliary was treated with
two equivilents of LDA, transmetallated with magnesium bromide to form dianion 3-83,
and treated with aldehyde 3-76 at −115 °C (Scheme 3.17). The aldol addition proceeded
with superior diastereoselectivity (>20:1 dr), but only provided diol 3-84 in 53% yield, so
alternative asymmetric aldol protocols were explored.

Scheme 3.17 Asymmetric aldol with 3-76 and the HYTRA acetate auxiliary
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3.5.2.4 Examining Evans’ Oxazolidinone Auxiliary

Having explored several asymmetric aldol reactions, we had found that
thiazolidinethione auxiliaries gave relatively low diastereoselectivity in good yield, while
HYTRA acetate auxiliaries gave superior selectivity in low yield. Encouraged that we
could find a protocol that featured the best of both methods, we turned our attention to
Evans’ well known boron mediated oxazolindinone aldol addition reaction.17 As
previously mentioned, acetyloxazolindinone aldol reactions lack the allylic strain
between the α-position and the auxiliary required to achieve high diastereoselectivity
(Figure 3.6). One solution to this problem involves the temporary incorporation of an αsubstituent to afford high selectivity, but can be easily removed after the aldol reaction.
Both methylthioacetate17 and chloroacetate26 oxazolindinones serve as effective
auxiliaries in boron mediated asymmetric aldol reactions with a variety of aldehydes,
furnishing β-hydroxy carbonyl adducts in high yield and diastereoselectivity. Removal of
the temporary α-substituents under mild reductive conditions followed by cleavage of the
recyclable auxiliary provides access to optically pure products.
To investigate this alternative to acetate aldols, we began by constructing both
auxiliaries (R)- and (S)-3-86 from (R)- and (S)-phenylalanine (3-85) according to Evans’
original method (Scheme 3.18).27 Acetylation of the auxiliaries with chloroacetyl chloride
proceeded to give (R)- and (S)-3-87, both in 92% yield.28

Scheme 3.18 Synthesis of chloroacetate oxazolidinone auxiliaries
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The boron mediated aldol reaction was performed with (S)-3-87 and aldehyde 376, and we were pleased to find the asymmetric transformation provided the desired αchloro-β-hydroxy product (3-88) in 78% yield as a single diastereomer (Scheme 3.19).
Reductive cleavage of the α-chloro substituent with zinc dust and ammonium chloride
provided

alcohol

3-89

in

near

quantitative

yield.29

Treatment

with

N,O-

dimethylhydroxylamine hydrochloride salt and Me3Al provided Weinreb amide 3-90 in
80% yield and full recovery of auxiliary (S)-3-86. Finally, displacement of amide 3-90
with vinyl magnesiumbromide furnished α,β-unsubstituted ester 3-91, which was
converted to syn-diol 3-92 via Prasad reduction in 68% yield over two steps.

Scheme 3.19 Synthesis of Mukaiyama cyclization precursor 3-92
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Mukaiyama cyclization precursor 3-92 was subjected to our second generation
catalyst, Co(nmp)2, and tBuOOH in an oxygen atmosphere at 55 °C for 16 h, which
furnished the trans-THF ring in 91% yield, with filtration as the only means of
purification (Scheme 3.20). Protection of diol 3-93 as the PMP acetal proceeded in 93%
yield, and terminal alkyne 3-95 was accessed upon treatment with basic methanol in near
quantitative yield.

Scheme 3.20 Synthesis of alkyne 3-95

Recalling the retrosynthetic plan, we envisioned either a RCM (involving 3-97) or
RRCM (involving 3-99) to construct the 14-membered ring. Working towards RCM
partner 3-97 first, alkyne 3-95 underwent successful chloropalladation with PdCl2, LiCl,
and allyl chloride in 83% yield (Scheme 3.21). Then, regioselective PMP acetal cleavage
of 3-96 with NaBH3CN in TFA/DMF cosolvent gave the desired RCM coupling partner
(3-97) in trace amounts, along with significant substrate decomposition.30
Our attention then turned to accessing the RRCM coupling partner (3-99) from
the same alkyne (3-95) which was used to access the RCM precursor 3-97. Beginning
again with a chloropalladation reaction, except this time employing 3-chlorobut-1-ene,
gave rise to the desired chloroalkene 3-98 in 46%. Unfortunately, attempts to execute the
same acetal cleavage with 3-98 resulted in decomposition. Reproductivity issues with this
approach along with lack of advanced material did not allow for further exploration of
these potential coupling partners.
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Scheme 3.21 Synthesis of northern fragments 3-97 and 3-99

3.5.3 Construction of the Southern Fragment

3.5.3.1 Sharpless Asymmetric Kinetic Resolution

The synthesis of the southern fragment required for a RCM (3-107) began by
performing a Baylis-Hillman reaction with methyl acrylate and formaldehyde (Scheme
3.22). The allylic alcohol 3-101 was subsequently protected as the TBS ether in 89%
yield over two steps. Reduction of ester 3-102 with DIBAL, followed by Swern oxidation
gave rise to allylic aldehyde 3-104, which underwent aldol addition with ethyl acetate to
furnish racemic alcohol 3-105 in 74% yield over three steps.
To resolve the material, the racemic mixture was then subjected to Sharpless
asymmetric kinetic resolution reaction conditions (Ti(OiPr)4, (+)-DET, TBHP).
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Unfortunately, the desired enantiopure material ((R)-3-105) was obtained in a low 60%
enantiomeric excess.31 Although the material did not have the level of enantiopurity that
we desired, it could allow insight into the outcome of the ring closing metathesis reaction
when coupled to northern fragment 3-97, so the material was carried forward. The allylic
alcohol (R)-3-105 was protected as a TBS silyl ether (95%) and ester 3-106 was
saponified under basic conditions to give coupling partner 3-107 in 96% yield.

Scheme 3.22 Synthesis of southern fragment 3-107

3.5.3.2 Constructing Aldehyde 3-114

While constructing RCM precursor 3-107, we concurrently worked towards
making a related southern fragment (3-114) featuring a diene functionality designed to
facilitate a relay ring closing metathesis reaction. Our approach towards 3-114 involved a
Baylis-Hillman reaction between methyl acrylate and hex-5-enal (Scheme 3.23).
While Baylis-Hillman reactions are a powerful method to couple unsaturated
carbonyl compounds with aldehydes, they often suffer from poor reaction rates
particularly with unactivated aldehydes. Various methods have been employed to
increase the rate of the reaction, including elevated temperature32 and pressure,33
ultrasound32 and microwave irradiation,34 introduction of hydrogen bond donors (eg.
104

105

MeOH),35 phosphines,36 and quinuclidine based catalysts.37 A variety of these methods
were examined with our substrates (Scheme 3.23), however, very low reaction
conversions were observed. The optimal conditions were obtained with DABCO,
Sc(OTf)3, and diethyl tartrate, a strategy developed by Aggarwal.38 Our Baylis-Hillman
proceeded in 49% yield after 7 days of stirring at room temperature to furnish allylic
alcohol 3-110.

Scheme 3.23 Baylis-Hillman route toward aldehyde 3-114

This material was subjected to Mitsunobu reaction conditions (PNBOH, DIAD,
PPh3) to give allylic alcohol 3-110. This reactivity could be described as an SN2'
Mitsunobu, which could be the result of a tight ion pair. At this point, the PNB protecting
group on 3-111 was exchanged for a more robust p-methoxybenzyl group in 68% yield
over two steps. The resulting α,β-unsaturated ester 3-113 was then converted to aldehyde
3-114 after reduction with DIBAL and Swern oxidation (72% yield over two steps).
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While pleased with the overall effectiveness of our initial route towards aldehyde
3-114, we concurrently explored other methods to ultimately find the most efficient
synthesis. Our second approach first involved PMB protection of α,β-unsaturated ester 3101 (previously synthesized in Scheme 3.22) in 82% yield using 4-methoxybenzyl-2,2,2trichloroacetimidate under acidic conditions (Scheme 3.24). The resulting ester 3-115
was subjected to DIBAL reduction in 86% yield followed by Swern oxidation in near
quantitative yield.
Aldehyde 3-116 was then treated with pent-4-enylmagnesium bromide to give
allylic alcohol 3-117 in 75% yield. Interestingly, alcohol 3-117 did not undergo the
expected SN2' reactivity under Mitsunobu reaction conditions, to give 3-118. Instead, the
substrate followed the traditional SN2 pathway, resulting in p-nitrobenzoyl substituted
alcohol 3-119, suggesting that the ester moiety in substrate 3-110 (Scheme 3.23) played a
crucial role in directing the SN2' Mitsunobu reactivity.

Scheme 3.24 Unsuccessful grignard addition route toward aldehyde 3-114

Our third and final approach toward aldehyde 3-114 began with a Wittig reaction
between

commercially

available

2,2-dimethyl-1,3-dioxan-5-one

(3-120)

and

hexenyltriphenylphosphonium iodide 3-121 (generated from 6-iodohex-1-ene in 94%
yield), which led to acetal protected allylic diol 3-122 in 95% yield (Scheme 3.25).
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Scheme 3.25 Synthesis of allylic alcohols as isomeric mixtures

Removal of the acetal under acidic conditions revealed diol 3-123 in near
quantitative yield. From this point, we made attempts to selectively differentiate the
alcohols through a variety of protecting group strategies. Silyl protection with a bulky
TBS group provided a mixture of products, including a 3:1 inseparable mixture of E:Z
alcohols (3-124). Bulkier silyl groups including TIPS and TBDPS did not significantly
increase the ratio of products. Although this route produced an inseperable mixture of
isomers, this method was high yielding and efficient, where large amounts of material
could be carried forward.
Lastly, PMB protection was explored through treatment of diol 3-123 with 4methoxybenzyl-2,2,2-trichloroacetimidate

under

acidic

conditions;

however,

no

discrimination between the (E) and (Z)-alcohols was observed (Scheme 3.25, Method 1).
Protecting the diol as a PMP acetal prior to DIBAL reduction however, produced a 2:1
mixture of E:Z alcohols in 92% overall yield (Method 2). Although the geometric isomers
were separable, these methods would not be an efficient way to access aldehyde 3-114.
Although both working routes (Baylis-Hillman method in Scheme 3.23 and
alcohol differentiation method in Scheme 3.25) were not as efficient as we had hoped,
they had given access to considerable amounts of 3-114, so we decided to continue our
synthesis towards the southern fragment of biselide A.
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3.5.3.3 Asymmetric Aldol Approach to the Southern Fragment

Analagous to the synthesis of the northern fragment, we envisioned accessing the
southern

piece

via

an

asymmetric

aldol

while

employing

the

same

acetylthiazolidinethiones, but this time operating through the closed transition state to
access acetate syn products (see Figure 3.8). The reaction with aldehyde 3-114 and
acetylthiazolidinethiones 3-64 and 3-65, provided allylic alcohols 3-126 and 3-127,
respectively, in modest yields and diastereomeric ratios (Scheme 3.26). The best results
were achieved with tert-butyl auxiliary 3-65, where a 7:1 ratio of diastereomers (3-127)
was obtained in 64% yield.

Scheme 3.26 Asymmetric aldol with 3-114 and acetylthiazolidinethiones
Attempts to improve the asymmetric aldol involved exploring Braun’s HYTRA
acetate auxiliary next, where the stereochemistry at the alcohol would require inversion
(Scheme 3.27). Although 3-128 was obtained with exceptional diastereoselectivity, the
reaction proceeded in poor yield, which was analogous to our previous findings with
Braun’s auxiliary (see Scheme 3.17).

Scheme 3.27 Asymmetric aldol with 3-114 and the HYTRA acetate auxiliary
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Given that superior yields and diastereoselectivities were achieved with
chloroacetate oxazolidinone (S)-3-87 for the synthesis of the northern fragment, we were
confident that a similar approach could also be utilized to access the southern fragment.
Initial attempts involved an aldol addition between aldehyde 3-129 and auxiliary (R)-387, which did not generate the desired adduct 3-130 but resulted in substrate
decomposition (Scheme 3.28). It was suspected that silyl protecting groups were not
compatible with the reaction conditions, so alternative protecting groups were explored.

Scheme 3.28 Chloroacetate oxazolidinone auxiliary approach with aldehyde 3-129

Fortunately, aldehyde 3-114 containing a p-methoxybenzyl protecting group
participated in the boron mediated asymmetric aldol reaction with (R)-3-87, furnished
chlorohydrin 3-131 in 75% yield as a single diastereomer (Scheme 3.29). Pleased with
the diastereoselectivity of this reaction, we decided to use this material to further explore
the synthesis of southern fragment.

Scheme 3.29 Chloroacetate oxazolidinone auxiliary approach with aldehyde 3-114
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3.5.3.4 Attempts to Construct 3-134

Efforts toward the southern fragment of biselide A continued by subjecting the
aldol adduct (3-131) to dehalogenation reaction conditions (Scheme 2.30). Unfortunately,
a mixture of products was obtained from the reductive reaction including the desired
product (3-132) and suspected ene-yne 3-133 as a 3:1 ratio, in an overall 86% yield.39
Attempts to attenuate the production of the suspected ene-yne 3-133 by varying
the reaction temperature (−20 °C to RT), reaction times (10 seconds, 1 and 5 minutes),
and water content (anhydrous and reagent grade MeOH), were all unsuccessful.
Regrettably, further studies towards the southern fragment of biselide A (3-134) was not
possible due to lack of material and time constraints.

Scheme 3.30 Dechlorination of chlorohydrin 3-131
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3.5.4 Future Work
With viable routes towards all four fragments (RCM partners 3-97 and 3-107 and
RRCM partners 3-99 and 3-134), formation of the 14-membered macrocycle (3-135)
could be investigated via an esterification and metathesis reactions (Scheme 3.31).

Scheme 3.31 Future work towards biselide A
Regarding the methathesis ring closing strategy, Hoye and Wang have made
contributions towards a very similar 14-membered macrocycle in their work towards the
total synthesis of haterumalide NA.13c,40 Hoye’s initial attempts involved ring closing
metathesis substrate 3-136 and relay substrate 3-137 but all of their attempts with Grubbs
II catalyst failed to produce the desired macrocycle and were only met with starting
material recovery (with RCM substrate 3-136), or substrate truncation with RRCM
substrate 3-137 to give 3-138 (Scheme 3.32). Substrate truncation is the result of initial
metathesis or relay event, where the corresponding ring closing event does not occur.
With both RCM and RRCM reactions, dimerization was also detected.
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Scheme 3.32 Hoye’s RCM and RRCM attempts

In order to investigate the effect of ring strain during the metathesis ring closing
reaction, Hoye explored a similar macrocycle formation with “relaxed” substrates (3-139,
3-140, and 3-141) that did not contain the trans-THF ring (Scheme 3.33). Remarkably,
all of the “relaxed” substrates closed to the desired 14-membered lactones (3-142, 3-143,
and 3-144). These results suggest that the there is significant ring strain in the bridged
bicycle found due to the trans-THF ring.

Scheme 3.33 Hoye’s RRCM with “relaxed” substrates
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In the event that our RCM/RRCM attempts do not give rise to our desired 14membered macrocycle, the use of a tether (3-145) would be employed in order to
circumvent the suspected ring strain (Scheme 3.34). This 4-atom tether would expand the
RRCM reaction to give an 18-membered macrocycle, which would likely have a
significant decrease in ring strain, even with the trans-THF intact. Expanded substrate 3145 would give rise to macrocycle 3-146, which could then undergo saponification
reaction to release the tether. The resulting substrate could furnish the required 14membered macrocycle (3-135) via lactonization. The synthesis would then conclude with
a Nozaki-Hiyama-Kishi reaction to append the side-chain, followed by some protecting
group manipulations.

Scheme 3.34 Tethered RRCM reaction and completion of biselide A
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3.6 Progress Towards the Total Synthesis of Biselide E

3.6.1 Retrosynthesis

Synthetic efforts towards biselide A and E were performed concurrently, where
we employed similar strategies to execute fragments of each natural product. Upon
retrosynthetic analysis, biselide E was divided into three fragments, including the γalkylidene α,β-unsaturated δ-lactone piece 3-147 (western fragment), the trans-THF core
3-149 (eastern fragment), and side-chain 3-54 (Scheme 3.35). A Suzuki-Miyaura
coupling reaction was envisioned between the eastern and western fragments, and the
side-chain could be appended using the Nozaki-Hiyama-Kishi reaction as demonstrated
in the haterumalide syntheses.13 The γ-alkylidene α,β-unsaturation in the western piece
could be installed using a Pd-mediated cross-coupling reaction such as a Stille or Suzuki,
while esterification could construct the lactone, simplifying the synthesis to haloalkene 3148. Finally, the eastern fragment could be furnished using the second generation cobalt
catalyzed Mukaiyama oxidative cyclization with syn-diol 3-150.

Scheme 3.35 Retrosynthesis of biselide E
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3.6.2 Constructing the Western Fragment

3.6.2.1 Stille Cross-Coupling Attempt

The synthesis of the western fragment began by mono-protecting 1,3-propanediol
with p-methoxybenzyl bromide followed by oxidation to aldehyde 3-151 (Scheme 3.36).
Wittig reaction with (carboethyoxy)iodomethylenephosphorane41 provided iodoalkene 3152, which was functionalized to the silyl ether (3-153) in 90% yield over two steps.
Unfortunately, all attempts to perform a Stille cross-coupling reaction with either vinyl
stannane 3-154 or stannylpropenoate 3-15542 resulted in recovery of starting material.
Varying the palladium sources (Pd(MeCN)2Cl2 or Pd(PPh3)4), reaction temperatures, and
introducing additives such as CuI, had no effect. In an effort to employ Cossy’s
approach,14 ester 3-152 was subjected to Stille reaction conditions, however no reaction
was observed. Given that 3-152 and 3-153 were resistant to Stille reaction conditions, a
different Pd-catalyzed cross-coupling was explored.

Scheme 3.36 Stille cross-coupling attempts
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3.6.2.2 Suzuki Cross-Coupling

With vinyl iodide 3-153 in hand, we set out to explore the Suzuki cross-coupling
reaction. Fortunately, our first attempt at coupling with vinyl borane43 (3-159) afforded
the γ-alkylidene α,β-unsaturated ester (3-160) with complete stereoselectivity in 84%
yield (Scheme 3.37). Treatment of ester 3-160 under acidic conditions resulted in silyl
deprotection and concomitant cyclization to furnish the desired lactone 3-161 in
quantitative yield. A two step procedure to protect the lactone as a methyl acetal (3-162)
was then performed in 97% overall yield. Regrettably, this material could not be used to
access the western fragment 3-164 because all attempts to remove the p-methoxybenzyl
protecting group (both oxidative and lewis acidic conditions) caused substrate
decomposition. At this time, we decided to explore a different protecting group that could
accommodate the sensitive diene system.

Scheme 3.37 Suzuki cross-coupling approach

To circumvent product decomposition observed previously, a TBDPS group was
envisioned since it could prove robust enough to survive the subsequent chemistry, but
labile enough to remove using mild conditions (TBAF). Propanediol was first
desymmetrized by mono-silyl protection,23 followed by oxidation to access access
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aldehyde 3-165 (Scheme 3.38). Similarly to the PMB derivative, the iodoalkene (3-166)
was formed via stabilized Wittig olefination in 80% yield, followed by reduction of the
ester and TBS protection of the resulting alcohol, giving 3-167 in 71% over three steps.

Scheme 3.38 Synthesis of iodoalkene 3-167

With iodoalkene 3-167 in hand, the Suzuki cross-coupling reaction with vinyl
borane 3-159 was executed in 80% yield with complete stereoselectivity to afford the γalkylidene α,β-unsaturated ester 3-168 (Scheme 3.39). Cyclization to the lactone (3-169)
was accomplished under acidic conditions in near quantitative yield. After protecting the
lactone as a methyl acetal in a two step sequence, primary alcohol 3-163 was accessed
effortlessly upon silyl deprotection with TBAF in 87% yield over three steps.

Scheme 3.39 Progress toward western fragment 3-164
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In order to prepare the western fragment for Suzuki-Miyaura coupling to the
eastern piece, an oxidation followed by a Horner-Wadsworth-Emmons reaction to install
the dichloroalkene was required. Alcohol 3-163 was subjected to a variety of oxidation
conditions (Swern, IBX, DMP), but unfortunately, substrate decomposition was observed
in all cases, which may have been promoted by the instability of the diene system.

3.6.3 Constructing the Eastern Fragment
3.6.3.1 Evans’ Aldol
The strategy toward the eastern fragment of biselide E began with an Evans’
aldol, involving aldehyde 3-171, prepared in a two step sequence from ethylene glycol
(Scheme 3.40). Standard boron mediated aldol conditions (Bu2BOTf, NEt(iPr)2, CH2Cl2)
were employed with aldehyde 3-171 and chloroacetyloxazolidinone (S)-3-87, but
substrate decomposition was observed. The labile silyl ether was suspected to be
incompatible with the reaction conditions, so another protecting group was explored.

Scheme 3.40 Evans’ aldol with aldehyde 3-171
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In order to circumvent product decomposition due to the unstable silyl ether, a
PMB group was employed since it was suspected to be robust enough to survive the aldol
reaction conditions. The synthesis began by desymmetrizing ethylene glycol by PMB
mono-protection followed by IBX oxidation to give aldehyde 3-173 in 84% yield over
two steps (Scheme 3.41). The aldol reaction in this case underwent a diastereoselective
addition to give alcohol 3-176, not the desired 3-174, which could be used to access
eastern fragment 3-175. This outcome was the result of aldehyde fragmentation to give 4methoxybenzaldehyde, which participated in the aldol reaction (Eq. 1).

Scheme 3.41 Evans’ aldol with aldehyde 3-173
The unexpected setbacks with the Evans’ aldol prompted us to explore a
protecting group that would provide even greater stability than a PMB. The pmethoxyphenyl (PMP) group is quite robust and also lacks the methylene unit required
for fragmentation. The synthesis began with a displacement reaction involving 4methoxyphenol and 2-chloroethanol, followed by oxidation of the resulting alcohol,
giving aldehyde 3-178 in 84% yield over two steps (Scheme 3.38). Fortunately, the aldol
reaction with oxazolidinone (S)-3-87 proceeded in 74% yield of the desired α-chloro
aldol adduct 3-179 in >20:1 diastereoselectivity.
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Scheme 3.42 Evans’ aldol with aldehyde 3-178

3.6.3.2 trans-THF Formation

With aldol product 3-179 in hand, reduction with Zn dust and NH4Cl in MeOH
rapidly removed the α-chloro substituent to give alcohol 3-180 in 93% yield (Scheme
3.43). Cleavage of the auxiliary with N,O-dimethylhydroxylamine hydrochloride salt and
Me3Al gave rise to Weinreb amide 3-181, which was converted to α,β-unsaturated ketone
3-182 in good overall yield. A Prasad reduction (Et2BOMe, NaBH4) was then performed
to reveal syn-diol 3-183 as the Mukaiyama oxidative cyclization precursor.

Scheme 3.43 Progress towards eastern fragment 3-163
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Initial attempts to cyclize pentenol 3-183 under our standard cyclization
conditions, were met with decomposition. Although cyclization reactions using Co(nmp)2
have been shown to tolerate PMP substituents, we suspected it may be unstable under the
oxidative conditions with this particular substrate. To circumvent this problem,
preactivated catalyst was employed and the desired trans-THF product 3-184 was
obtained in 87% yield. Protection of the diol as TBS ethers then provided the fully
protected trans-THF fragment 3-185 in 90% yield. Unfortunately, complications with
PMP removal and time constraints prevented further exploration of this route toward the
Suzuki-Miyaura coupling partner 3-175.

3.6.4 Future Work
With viable routes towards 3-163 and 3-185, future work would involve
exploration of the remaining steps to ultimately access eastern and western fragments (3164 and 3-175, respectively, Scheme 3.44).

Scheme 3.44 Future work towards biselide E
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To complete the total synthesis of biselde E would then involve investigation of
the Suzuki-Miyaura coupling reaction between the two fragments, followed by side-chain
installation via a Nozaki-Hiyama-Kishi reaction and some protecting group manipulation.

3.7 Summary
In summary, we have developed efficient syntheses towards several fragments of
biselide A, which could be used to explore both ring closing metathesis and relay ring
closing metathesis to construct the 14-membered macrolactone. The trans-THF ring
found in each northern component (3-97 and 3-98) was furnished by using our second
generation Co(nmp)2 catalyst in a Mukaiyama oxidative cyclization, while the
chloroalkene moiety was introduced with a chloropalladation reaction. Key steps in the
synthesis of the southern fragment 3-107 included a Sharpless asymmetric kinetic
resolution, while a diastereoselective aldol reaction was utilized in our studies towards
fragment 3-134.
Significant synthetic efforts toward biselide E have also been reported. We have
designed an efficient method to access the western fragment using our second generation
Co(nmp)2 catalyst in a Mukaiyama oxidative cyclization to furnish the trans-THF ring (3185). We have also developed a proficient method to an advanced intermediate of the
eastern fragment (3-163) involving a Suzuki coupling reaction as the key step.
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3.8 Experimental

3.8.1 General Considerations

General experimental procedures were the same as provided in Chapter 1.

3.8.2 Experimental Procedures

(Z)-2-Hydroxy-5,5-dimethyl-1-(4-methylpiperazin-1-yl)hex-2ene-1,4-dione (nmp ligand, 3-15)
A 500-mL round-bottomed one neck flask is charged with Nmethylpiperazine (8.90 mL, 80.0 mmol), diluted with 200 mL of CH2Cl2, and cooled to 0
°C. To the cooled solution was added Et3N (11.2 mL, 80.0 mmol). Ethyl oxalyl chloride
(8.90 mL, 80.0 mmol) is added dropwise via syringe over 10 min to the vigorously stirred
solution. After the addition, the heterogeneous solution is stirred at room temperature for
16 h, and then poured slowly into a rapidly stirred solution of half saturated sodium
bicarbonate (200 mL). The solution is transferred to a 500 mL separatory funnel and the
aqueous layer is extracted with CH2Cl2 (2 x 100 mL). The combined organic layers are
washed with 100 mL of brine, dried over anhydrous MgSO4, filtered through a pad of
Celite and concentrated by rotary evaporation (35 °C, 40 mmHg). The residue is then
evacuated at 1.5 mmHg for 30 min to afford the title compound as colorless oil (99 %
yield, 15.8 g). Rf 0.10 (66% EtOAc/Hex); 1H NMR (400 MHz, CDCl3) δ 4.30 (q, J = 7.2
Hz, 2H), 3.64-3.61 (m, 2H), 3.43-3.41 (m, 2H), 2.42-2.40 (m, 4H), 2.29 (s, 3H), 1.33 (t, J
= 7.1 Hz, 3H). 13C NMR (100 MHz, CDCl3) δ 162.7, 160.0, 62.0, 54.8, 54.1, 41.9, 41.2,
14.0. IR (neat, cm-1): 2973, 2798, 1646, 1599, 1463, 1293, 1262, 1001, 737. HRMS
[m/z+H+] 200.1163 (calcd for C9H16N2O3, 200.1161).
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Ethyl 2-(4-methylpiperazin-1-yl)-2-oxoacetate (3-18)
A 500-mL round-bottomed flask equipped with a 3-cm egg shaped stir
bar containing glyoxyalate 3-15 (12.0 g, 60.0 mmol), was diluted with
50.0 mL of THF, pinacolone (7.50 mL, 60.0 mmol) was added and the flask cooled to 0
°C. A separate 500-mL round-bottomed flask was charged with tBuOK (13.4 g, 120
mmol) and diluted with 250 mL of THF. The tBuOK solution was added to the cooled
glyoxyalate/pinacolone solution via cannula over 10 min. After the addition, the solution
was stirred at room temperature for 16 h. A solution of AcOH in CH2Cl2 (1.00 M, 150
mL, 150 mmol) was added in one portion and the reaction was stirred for an additional 30
min.

The reaction mixture was filtered through Celite and concentrated by rotary

evaporation (35 °C, 40 mmHg). The residue was then evacuated at 1.5 mmHg for 30 min
to afford the title compound as pale yellow oil (90 % yield, 13.7 g). Rf 0.15 (5%
MeOH/EtOAc); 1H NMR (400 MHz, CDCl3) δ 5.95 (s, 1H), 3.66-3.58 (m, 4H), 2.46-2.43
(m, 4H), 2.31 (s, 3H), 1.19 (s, 9H). 13C NMR (100 MHz, CDCl3) δ 200.9, 185.3, 163.8,
95.3, 55.1, 54.3, 45.8, 41.6, 27.2. IR (neat, cm-1): 3445, 2965, 2362, 1649, 1560, 1540,
1458, 1108. HRMS [m/z+H+] 254.1644 (calcd for C13H22N2O3, 254.1630).

(S,E)-N-(2-Chloroethylidene)-2-methylpropane-2-sulfinamide (3-57)
2-Methyl-2-propanesulfinamide (1.00 g, 8.25 mmol) in 16.5 mL CH2Cl2
was added CuSO4 (8.22 g, 51.5 mmol) followed by chloroacetaldehyde
(777 mg, 9.90 mmol). The solution was allowed to stir for 24 h at RT, and then filtered
through a pad of Celite and concentrated under reduced pressure. Purification by flash
chromatography on silica gel using EtOAc-hexanes for elution provided the title
compound as colorless oil (82% yield, 1.23 g). Rf 0.58 (50% EtOAc/hexanes). 1H NMR
(400 MHz, CDCl3)  8.03 (t, J = 4.5, 1H), 4.31 (d, J = 4.7, 2H), 1.21 (s, 9H); 13C NMR
(100 MHz, CDCl3)  162.4, 57.5, 43.6, 22.4.
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(R)-4-Mesitylthiazolidine-2-thione (3-58)
To a solution of 1.34 M mesitylmagnesium bromide in Et2O (25.0 mL, 33.6
mmol) at −78 °C was added imine 3-57 as a solution in 22.0 mL toluene
over 45 min. The reaction mixture was then stirred for 3 h at −78 °C,
quenched with 4.00 M HCl (16.8 mL, 67.3 mmol), warmed to RT and stirred for 3 h. The
organic layer was then extracted with H2O (2 x 30.0 mL), and the combined aqueous
layers were cooled to 0 °C, and 2.00 M NaOH solution was added until pH 11 was
achieved. The aqueous layers were then extracted with EtOAc (3 x 50.0 mL), and the
combined organic layers were washed with brine, dried (MgSO4), filtered through Celite
and concentrated under reduced pressure. The residue was then dissolved in 33.7 mL of
1.00 M KOH (33.7 mmol), and carbon disulfide (2.03 mL, 33.7 mmol) was added
dropwise while stirring. The solution was heated to reflux for 16 h. Upon cooling to RT,
30.0 mL CH2Cl2 was added. The aqueous layer was then extracted with CH2Cl2 (3 x 20.0
mL), and the combined organic layers were washed with brine, dried (MgSO4), filtered
through Celite and concentrated under reduced pressure. Purification by flash
chromatography on silica gel using EtOAc-hexanes for elution provided the title
compound as a white solid (58% yield over two steps, 925 mg). Rf 0.53 (50%
EtOAc/hexanes). 1H NMR (400 MHz, CDCl3)  7.70 (bs, 1H), 6.86 (s, 2H), 5.82 (t, J =
10.4, 1H), 3.63 (d, J = 3.6, 2H), 2.39 (s, 6H), 2.25 (s, 3H); 13C NMR (100 MHz, CDCl3)
 199.3, 138.5, 136.6, 130.7, 129.4, 63.6, 37.5, 20.7, 20.5.

(S)-4-Isopropylthiazolidine-2-thione (3-61)
L-Valinol (16.2 g, 0.16 mol) in 715 mL of 5.00 M KOH (3.57 mol), was added
carbon disulfide (76.0 mL, 1.26 mol) dropwise while stirring. The solution was
heated to reflux for 3 days. Upon cooling to RT, 300 mL CH2Cl2 was added. The aqueous
layer was then extracted with CH2Cl2 (3 x 100 mL), and the combined organic layers
were washed with brine, dried (MgSO4), filtered through Celite and concentrated under
reduced pressure. Purification by flash chromatography on silica gel using EtOAchexanes for elution provided the title compound as a white solid (70% yield, 17.7 g). Rf
0.62 (50% EtOAc/hexanes). 1H NMR (400 MHz, CDCl3)  8.66 (bs, 1H), 4.07−4.02 (m,
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1H), 3.48−3.43 (m, 1H), 3.28−3.23 (m, 1H), 0.97 (d, J = 7.0 Hz, 3H), 0.94 (d, J = 6.6 Hz,
3H); 13C NMR (100 MHz, CDCl3)  200.5, 69.9, 35.5, 31.7, 18.5, 17.9.

(S)-4-tert-Butylthiazolidine-2-thione (3-62)
The title compound was obtained from L-tert-leucinol using the same
procedure that was used to obtain compound 3-61. This procedure provided
the title compound as a white solid (68% yield). Rf 0.63 (50% EtOAc/hexanes). 1H NMR
(400 MHz, CDCl3)  7.22 (bs, 1H), 4.00 (t, J = 8.8 Hz, 1H), 3.41 (dd, J = 8.9, 1.6 Hz,
2H), 1.00 (s, 9H); 13C NMR (100 MHz, CDCl3)  201.7, 73.3, 34.5, 34.4, 25.9.

(R)-1-(4-Mesityl-2-thioxothiazolidin-3-yl)ethanone (3-63)
The title compound was obtained from thiazolidin-2-thione 3-58 after an
acylation reaction, as described above in the procedure to obtain compound
3-64. This procedure provided the title compound as pale yellow solid (85%
yield). Rf 0.73 (50% EtOAc/hexanes). 1H NMR (400 MHz, CDCl3)  6.84 (s, 2H), 6.34
(t, J = 9.9, 1H), 3.54 (d, J = 11.3, 10.6, 1H), 3.33 (d, J = 11.3, 10.2, 1H), 2.69 (s, 3H) 2.39
(bs, 6H), 2.24 (s, 3H); 13C NMR (100 MHz, CDCl3)  201.4, 171.9, 137.8, 132.6, 128.8,
127.2, 67.9, 32.4, 27.7, 20.8.

(S)-1-(4-Isopropyl-2-thioxothiazolidin-3-yl)ethanone (3-64)
Thiazolidin-2-thione 3-61 (4.00 g, 20.2 mmol) dissolved in 100 mL THF at
−78 °C was added nBuLi (9.25 mL, 22.2 mmol, 2.40 M in hexanes) and
stirred at −78 °C for 30 min. Acetyl chloride (1.58 mL, 22.2 mmol) was
added dropwise and the solution was allowed to stir for 1 h at −78 °C, and then at RT for
30 min. The reaction mixture was then quenched with 100 mL half saturated aqueous
NH4Cl solution. The solution was allowed to warm to RT and the aqueous layer was then
extracted with EtOAc (3 x 50.0 mL), and the combined organic layers were washed with
brine, dried (MgSO4), filtered through Celite and concentrated under reduced pressure.
Purification by flash chromatography on silica gel using EtOAc-hexanes for elution
provided the title compound as yellow oil (97% yield, 3.90 g). Rf 0.74 (50%
EtOAc/hexanes). 1H NMR (400 MHz, CDCl3)  8.66 (bs, 1H), 5.15−5.12 (m, 1H), 3.50
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(dd, J = 11.3, 7.8 Hz, 1H), 3.00 (d, J = 11.3 Hz, 1H), 2.76 (s, 3H), 2.36 (dq, J = 13.5, 6.8
Hz, 1H), 1.05 (d, J = 7.0 Hz, 3H), 0.96 (d, J = 7.0 Hz, 3H); 13C NMR (100 MHz, CDCl3)
 203.2, 170.7, 71.3, 30.8, 30.4, 26.9, 19.0, 17.7.

(S)-1-(4-tert-Butyl-2-thioxothiazolidin-3-yl)ethanone (3-65)
The title compound was obtained from thiazolidin-2-thione 3-62 after an
acylation reaction, as described above in the procedure to obtain compound
3-64. This procedure provided the title compound as yellow oil (94% yield).
Rf 0.75 (50% EtOAc/hexanes). 1H NMR (400 MHz, CDCl3)  5.30 (d, J = 8.2 Hz, 1H),
3.52 (dd, J = 11.7, 8.2 Hz, 1H), 3.09 (d, J = 11.7 Hz, 1H), 2.77 (s, 3H), 1.02 (s, 9H); 13C
NMR (100 MHz, CDCl3)  205.3, 170.3, 72.0, 37.9, 30.4, 26.8.

3-(tert-Butyldimethylsilyloxy)propan-1-ol (3-67a)
To a flask containing dry NaH (1.10 g, 45.9 mmol) and 100 mL THF at 0 °C was added
freshly distilled propanediol (3.50 g, 45.9 mmol) dropwise. After stirring for 45 min at
RT, TBSCl (6.93 g, 45.9 mmol) was added slowly dropwise and allowed to stir for
another 45 min. The solution was quenched with 100 mL 10% aqueous Na2CO3. The
aqueous layer was then extracted with EtOAc (3 x 50.0 mL), and the combined organic
layers were washed with brine, dried (MgSO4), and filtered through Celite. The solution
was then concentrated under reduced pressure to give the title compound as colorless oil
(100% yield, 8.75 g). Rf 0.50 (40% EtOAc/hexanes). 1H NMR (400 MHz, CDCl3)  3.863.79 (m, 4H), 2.61−2.59 (m, 1H), 1.77 (quin, J = 5.6 Hz, 2H), 0.89 (s, 9H), 0.07 (s, 6H);
13

C NMR (100 MHz, CDCl3)  62.9, 62.5, 34.2, 25.9, 18.2, −5.5.

3-(tert-Butyldimethylsilyloxy)propanal (3-67)
To a solution of oxalyl chloride (452 μL, 5.25 mmol) in 5.00 mL CH2Cl2
at −78 °C, DMSO (747 μL, 10.5 mmol) as a solution in 3.00 mL CH2Cl2 was added over
10 min. The solution was stirred at −78 °C for 40 min. A solution of alcohol 3-67a (500
mg, 2.63 mmol) in 3.00 mL CH2Cl2 was then added over 15 min, and stirred at −78 °C
for 40 min. After the slow addition of Et3N (2.56 mL, 18.4 mmol) over 15 min, the
solution was allowed to stir at −78 °C for 40 min, and then warmed to RT over 30 min.
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The reaction mixture was diluted with 10.0 mL CH2Cl2 and then poured into a half
saturated solution of NaCl (20.0 mL). The heterogeneous mixture was separated and the
aqueous layer was extracted with CH2Cl2 (5 x 10.0 mL). The combined organic layers
were dried (MgSO4) and filtered through Celite. After the solution was concentrated
under reduced pressure, the title compound was isolated as pale yellow oil (96% yield).
Rf 0.72 (40% EtOAc/hexanes). 1H NMR (400 MHz, CDCl3)  9.79 (t, J = 2.2 Hz, 1H),
3.97 (t, J = 6.1 Hz, 1H), 2.59 (td, J = 6.0, 2.2 Hz, 1H), 0.87 (s, 9H), 0.05 (s, 6H);
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NMR (100 MHz, CDCl3)  202.0, 57.4, 46.6, 25.8, 18.2, -5.5.

(R)-5-(tert-Butyldimethylsilyloxy)-3-hydroxy-1-((S)-4isopropyl-2-thioxothiazolidin-3-yl)pentan-1-one (3-68)
TiCl4 (148 μL, 1.36 mmol) and NEt(iPr)2 (473 μL, 2.72 mmol)
are added sequentially to a solution of auxilliary 3-64 (254 mg, 1.25 mmol) in 5.00 mL
CH2Cl2 at −40 °C. After 1.5 h at −40 °C, the solution was cooled to −78 °C, and the
aldehyde 3-67 (144 mg, 0.76 mmol) is added slowly dropwise. After 10 min at −78 °C,
the reaction is quenched with the addition of 5.00 mL 1.00 M NaH2PO4·H2O and the
solution was allowed to warm to RT. The aqueous layer was then extracted with CH2Cl2
(3 x 10.0 mL), and the combined organic layers were washed with brine, dried (MgSO4),
filtered through Celite and concentrated under reduced pressure. Purification by flash
chromatography on silica gel using EtOAc-hexanes for elution provided the title
compound as pale yellow oil (87% yield, 7:1 dr, 259 mg). Rf 0.53 (66% EtOAc/hexanes).
1

H NMR (400 MHz, CDCl3)  5.16−5.13 (m, 1H), 4.40−4.34 (m, 1H), 3.88−3.77 (m,

2H), 3.53−3.46 (m, 3H), 3.29 (dd, J = 17.6, 8.9 Hz, 1H), 3.00 (d, J = 11.3 Hz, 1H),
2.40−2.32 (m, 1H), 1.80−1.67 (m, 2H), 1.04 (d, J = 6.6 Hz, 3H), 0.96 (d, J = 7.0 Hz, 3H),
0.87 (s, 9H), 0.05 (s, 6H); 13C NMR (100 MHz, CDCl3)  202.9, 172.4, 71.5, 67.3, 61.4,
45.6, 38.1, 30.8, 30.6, 25.9, 19.0, 17.7, −5.5. HRMS [m/z+H+] 392.8066 (calcd for
C17H33NO3S2Si, 391.1671).
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(R)-5-(tert-Butyldimethylsilyloxy)-3-hydroxy-N-methoxy-Nmethylpentanamide (3-69)
Imidazole

(85.0

mg,

1.25

mmol)

and

N,O-

dimethylhydroxylamine hydrochloride salt (49.0 mg, 0.50 mmol) were added
sequentially to a stirred solution of alcohol 3-68 (97.0 mg, 0.25 mmol) in 3.00 mL
CH2Cl2. The solution was allowed to stir for 20 h and then quenched with 10.0 mL half
saturated aqueous NH4Cl solution. The aqueous layer was then extracted with CH2Cl2 (3
x 10.0 mL), and the combined organic layers were washed with brine, dried (MgSO4),
filtered through Celite and concentrated under reduced pressure. Purification by flash
chromatography on silica gel using EtOAc-hexanes for elution provided the title
compound as colorless oil (92% yield, 67.0 mg). Rf 0.25 (50% EtOAc/hexanes). 1H NMR
(400 MHz, CDCl3)  4.27−4.20 (m, 1H), 3.95 (d, J = 2.7 Hz, 1H), 3.86−3.77 (m, 2H),
3.68 (s, 3H), 3.18 (s, 3H), 2.66−2.57 (m, 2H), 1.77−1.57 (m, 2H), 0.88 (s, 9H), 0.06 (s,
6H); 13C NMR (100 MHz, CDCl3)  173.4, 66.6, 61.2, 60.8, 38.7, 38.6, 31.8, 25.8, 18.2,
−5.5. HRMS [m/z+H+] 292.1937 (calcd for C13H29NO4Si, 291.1866).

(R)-7-(tert-Butyldimethylsilyloxy)-5-hydroxyhept-1-en-3-one
(3-70)
A 1.00 M solution of vinylmagnesium bromide in THF (1.53 mL, 1.53 mmol) was added
to a solution of amide 3-69 (147 mg, 0.51 mmol) in 5.00 mL THF at −40 °C. After 4 h at
0 °C, the reaction was quenched with 10.0 mL half saturated aqueous NH4Cl solution.
The aqueous layer was then extracted with EtOAc (3 x 10.0 mL), and the combined
organic layers were washed with brine, dried (MgSO4), filtered through Celite and
concentrated under reduced pressure. Purification by flash chromatography on silica gel
using EtOAc-hexanes for elution provided the title compound as colorless oil (77% yield,
100 mg). Rf 0.67 (50% EtOAc/hexanes). 1H NMR (400 MHz, CDCl3)  6.36 (dd, J =
17.6, 10.6 Hz, 1H), 6.36 (dd, J = 17.6, 10.6 Hz, 1H), 6.23 (d, J = 17.6 Hz, 1H), 5.87 (d, J
= 10.2 Hz, 1H), 4.35−4.28 (m, 1H), 3.88−3.75 (m, 2H), 3.63 (d, J = 2.7 Hz, 1H),
2.85−2.72 (m, 2H), 1.73−1.58 (m, 2H), 0.88 (s, 9H), 0.06 (s, 6H); 13C NMR (100 MHz,
CDCl3)  200.5, 136.9, 128.9, 67.2, 61.5, 46.3, 38.3, 25.9, 18.3, −5.5. HRMS [m/z+H+]
259.1726 (calcd for C13H26O3Si, 258.1651).
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(3R,5R)-3-(tert-Butyldimethylsilyloxy)hept-6-ene-1,5-diol
(3-71)
(3R,5R)-7-(tert-Butyldimethylsilyloxy)hept-1-ene-3,5-diol
(3-72)
Ketone 3-70 (50.0 mg, 0.19 mmol) in 2.00 mL THF and 0.50 mL MeOH was cooled to
−78 °C, and Et2B(OMe) (213 μL, 1.00 M in THF, 0.21 mmol) was added. After stirring
for 1 h at −20 °C, the solution was cooled to −78 °C, and NaBH4 (8.00 mg, 0.21 mmol)
was added in portions. After stirring for 3 h at −78 °C, the reaction was quenched with
5.00 mL half saturated aqueous NaHCO3 solution. The solution was allowed to warm to
RT and the aqueous layer was then extracted with EtOAc (3 x 10.0 mL), and the
combined organic layers were washed with brine, dried (MgSO4), filtered through Celite
and concentrated under reduced pressure. Purification by flash chromatography on silica
gel using EtOAc-hexanes for elution provided the title compound as a white solid (96%
yield, 1:1 mixture of isomers, 48.0 mg). Desired isomer (3-72): Rf 0.48 (50%
EtOAc/hexanes). 1H NMR (600 MHz, CDCl3)  5.82 (ddd, J = 16.9, 10.5, 5.3 Hz, 1H),
5.30 (d, J = 16.9 Hz, 1H), 5.11 (d, J = 10.5 Hz, 1H), 4.44−4.42 (m, 1H), 4.15−4.11 (m,
1H), 3.84−3.80 (m, 1H), 3.75−3.72 (m, 1H), 1.96 (dt, J = 14.0, 2.9 Hz, 1H), 1.72−1.64
(m, 2H), 1.41 (dt, J = 14.1, 11.4 Hz, 1H), 0.89−0.87 (m, 12H), 0.68 (q, J = 8.0 Hz, 1H),
0.05 (s, 6H); 13C NMR (100 MHz, CDCl3)  139.1, 114.5, 114.5, 71.9, 67.9, 58.9, 40.2,
39.1, 25.9, 18.4, 7.8, −5.5. HRMS [m/z+H+] 261.1893 (calcd for C13H28O3Si, 260.1808).

(R)-3-Hydroxy-1-((S)-4-isopropyl-2-thioxothiazolidin-3yl)hept-6-yn-1-one (3-74)
The title compound was obtained from auxilliary 3-64 and pent4-ynal using the aldol reaction conditions described above in the
procedure to obtain compound 3-68. This procedure provided the title compound as pale
yellow oil (27% yield, 6:1 dr). Rf 0.43 (50% EtOAc/hexanes). 1H NMR (400 MHz,
CDCl3)  5.15 (t, J = 6.6 Hz, 1H), 4.28-4.24 (m, 1H), 3.64 (dd, J = 17.8, 2.5 Hz, 1H),
3.51 (dd, J = 11.5, 8.0 Hz, 1H), 3.15 (dd, J = 17.6, 9.4 Hz, 1H), 3.02 (d, J = 11.7 Hz, 1H),
2.92 (bs, 1H), 2.39−2.30 (m, 3H), 1.95 (t, J = 2.5 Hz, 1H), 1.80−1.66 (m, 2H), 1.05 (d, J
= 7.0 Hz, 3H), 0.97 (d, J = 7.0 Hz, 1H); 13C NMR (100 MHz, CDCl3)  202.9, 172.8,
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83.8, 71.3, 68.9, 68.2, 66.6, 45.3, 34.7, 30.8, 30.6, 14.8. HRMS [m/z+H+] 286.0934 (calcd
for C13H19NO2S2, 285.0857).

5-(Trimethylsilyl)pent-4-yn-1-ol (3-76a)
4-Pentyn-1-ol (5.20 g, 56.0 mmol) dissolved in 200 mL THF at 0 °C
was added nBuLi (56.0 mL, 123 mmol, 2.19 M in hexanes) over 30 min. The solution
was allowed to stir for 3 h at 0 °C, and then TMSCl (15.7 mL, 123 mmol) was added to
the reaction mixture dropwise. After stirring for 16 h at RT, 1 M HCl (200 mL, 200
mmol) was added and the solution was allowed to stir at RT for another 16 h. The
aqueous layer was then extracted with EtOAc (3 x 50.0 mL), and the combined organic
layers were washed with 5 % NaHCO3, brine, dried (MgSO4), filtered through Celite and
concentrated under reduced pressure which provided the title compound as colorless oil
(100% yield, 8.75 g). 1H NMR (400 MHz, CDCl3)  3.79−3.73 (m, 2H), 2.34 (t, J = 6.8
Hz, 2H), 1.81−1.73 (m, 2H), 1.55 (bs, 1H), 0.14 (s, 9H); 13C NMR (100 MHz, CDCl3) 
106.6, 85.3, 63.3, 61.9, 31.2, 16.6, 0.1

5-(Trimethylsilyl)pent-4-ynal (3-76)
Alcohol 3-76a (5.00 g, 32.0 mmol) in 200 mL EtOAc was added IBX
(17.9 g, 64.0 mmol) and heated to reflux for 3 h. After allowing the
solution to cool to room temperature, the solution was filtered through Celite and
concentrated under reduced pressure, which provided the title compound as colorless oil
(92% yield, 4.50 g). Rf 0.76 (50% EtOAc/hexanes). 1H NMR (400 MHz, CDCl3)  9.78
(s, 1H) 2.69−2.65 (m, 2H), 2.55−2.51 (m, 2H), 0.13 (s, 9H);

13

C NMR (100 MHz,

CDCl3)  200.4, 104.7, 42.5, 13.1, 0.0, −3.5.

(R)-3-Hydroxy-1-((S)-4-isopropyl-2-thioxothiazolidin-3yl)-7-(trimethylsilyl)hept-6-yn-1-one (3-77)
The title compound was obtained from auxilliary 3-64 and
aldehyde 3-76 using the aldol reaction conditions described
above in the procedure to obtain compound 3-68. This procedure provided the title
compound as pale yellow oil (85% yield, 6:1 dr). Rf 0.47 (50% EtOAc/hexanes). 1H
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NMR (400 MHz, CDCl3)  5.13−5.10 (m, 1H), 4.22−4.18 (m, 1H), 3.58 (dd, J = 17.8, 2.5
Hz, 1H), 3.49 (dd, J = 11.5, 8.0 Hz, 1H), 3.11 (dd, J = 17.8, 9.2 Hz, 1H), 2.99 (d, J = 11.7
Hz, 1H), 2.96 (bs, 1H), 2.37−2.27 (m, 3H), 1.75−1.62 (m, 2H), 1.02 (d, J = 6.6 Hz, 3H),
0.94 (d, J = 7.0 Hz, 3H), 0.09 (s, 9H);

13

C NMR (100 MHz, CDCl3)  202.8, 172.6,

106.5, 71.2, 66.8, 45.3, 34.9, 30.7, 30.5, 19.0, 17.7, 16.2, 0.0. HRMS m/z 357.1246 (calcd
for C16H27NO2S2Si, 357.1252).

(R)-1-((S)-4-tert-Butyl-2-thioxothiazolidin-3-yl)-3hydroxy-7-(trimethylsilyl)hept-6-yn-1-one (3-78)
The title compound was obtained from auxilliary 3-65 and
aldehyde 3-76 using the aldol reaction conditions described above in the procedure to
obtain compound 3-68. This procedure provided the title compound as pale yellow oil
(86% yield, 10:1 dr). Rf 0.50 (50% EtOAc/hexanes). 1H NMR (400 MHz, CDCl3)  5.31
(d, J = 8.2 Hz, 1H), 4.23−4.21 (m, 1H), 3.62 (dd, J = 17.6, 2.3 Hz, 1H), 3.54 (dd, J =
11.7, 8.2 Hz, 1H), 3.15 (dd, J = 17.6, 8.9 Hz, 1H), 3.11 (d, J = 11.7 Hz, 1H), 2.97 (d, J =
3.5 Hz, 1H), 2.39 (td, J = 7.2, 2.3 Hz, 1H), 1.76−1.69 (m, 2H), 1.03 (s, 9H), 0.13 (s, 9H);
13

C NMR (100 MHz, CDCl3)  205.1, 172.4, 106.6, 85.1, 72.1, 67.2, 45.0, 37.9, 35.0,

30.6, 26.9, 16.4, 0.1. HRMS m/z 371.1410 (calcd for C17H29NO2S2Si, 371.1409).

(R)-3-Hydroxy-1-((R)-4-mesityl-2-thioxothiazolidin-3-yl)7-(trimethylsilyl)hept-6-yn-1-one (3-79)
The title compound was obtained from auxilliary 3-63 and
aldehyde 3-76 using the aldol reaction conditions described
above in the procedure to obtain compound 3-68. This procedure provided the title
compound as pale yellow oil (52% yield, 5:1 dr). Rf 0.69 (50% EtOAc/hexanes). 1H
NMR (400 MHz, CDCl3)  6.90−6.84 (m, 2H), 6.36 (t, J = 9.9 Hz, 1H), 4.00−3.94 (m,
1H), 3.60−3.51 (m, 2H), 3.32 (dd, J = 11.1, 9.6 Hz, 1H), 3.19 (dd, J = 17.4, 2.54 Hz, 1H),
2.94 (bs, 1H), 2.39−2.25 (m, 8H), 2.24 (s, 3H), 1.70−1.59 (m, 2H), 0.11 (s, 9H).
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(S)-1,1,2-Triphenylethane-1,2-diol (3-81)
(S)-Mandelate (37.0 g, 220 mmol) in 200 mL Et2O is added dropwise to a
0 °C solution of phenylmagnesium bromide (300 mL, 880 mmol, 2.93 M
in Et2O), such that the temperature stayed below 10 °C. The solution was
stirred for 2 h at 0 °C and then brought to reflux for 3 h. After allowing to
stand for 16 h at RT, the solution was poured onto 400 g of ice. Concentrated HCl was
then added until the solution reached pH 4 and then stirred at RT for 1 h. The aqueous
layers were then extracted with CH2Cl2 (3 x 200 mL), and the combined organic layers
were washed with brine, dried (MgSO4), filtered through Celite and concentrated under
reduced pressure. The yellow solid was then recrystallized from MeOH to give the title
compound as a white solid (62% yield, 39.6 g, mp 125 °C). Rf 0.13 (50%
EtOAc/hexanes). 1H NMR (400 MHz, CDCl3)  7.69-7.67 (m, 2H), 7.42−7.38 (m, 2H),
7.32−7.29 (m, 1H), 7.18−7.04 (m, 10H), 5.61 (d, J = 2.34 Hz, 1H), 3.15 (s, 1H), 2.47 (d,
J = 3.1 Hz, 1H); 13C NMR (100 MHz, CDCl3)  145.1, 143.3, 138.8, 128.4, 128.1, 127.7,
127.6, 127.5, 127.4, 126.9, 126.7, 126.2, 80.8, 78.0.

(S)-2-hydroxy-1,2,2-triphenylethyl acetate (3-82)
Diol 3-81 (12.7 g, 43.7 mmol) in 170 mL MeCN was added acetic
anhydride (6.69 g, 65.6 mmol) followed by a solution of Sc(OTf)3 (430
mg, 0.87 mmol) in 40 mL MeCN over 30 min. After 4 h of stirring at
RT, the precipitate was filtered, washed with 50.0 mL cold MeCN, and
dried under reduced pressure to give the title compound as a white solid (77% yield, 11.2
g). Rf 0.45 (50% EtOAc/hexanes). 1H NMR (400 MHz, CDCl3)  7.56-7.54 (m, 2H),
7.37−7.33 (m, 2H), 7.29−7.27 (m, 1H), 7.17−7.03 (m, 10H), 6.67 (s, 1H), 2.81 (s, 1H),
1.98 (s, 3H);

13

C NMR (100 MHz, CDCl3)  169.7, 144.8, 142.7, 135.8, 128.4, 128.3,

127.9, 127.8, 127.5, 127.3, 127.0, 126.3, 126.2, 80.3, 78.5, 21.1.
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(R)-((S)-2-Hydroxy-1,2,2-triphenylethyl)-3hydroxy-7-(trimethylsilyl)hept-6-ynoate (3-84)
LDA (prepared by adding nBuLi (1.09 mL, 2.29 M in
hexanes, 2.50 mmol), dropwise to a solution of
iPr2NH (367 μL, 2.60 mmol) in 5.00 mL THF at −78
°C and allowing the solution to warm to 0 °C) was added to a stirring suspension of
auxiliary 3-82 (331 mg, 1.00 mmol) in 9.00 mL THF −78 °C. The reaction mixture was
allowed to warm to 0 °C to give a clear solution, which was added to a solution of
MgBr2·OEt2 (516 mg, 2.00 mmol) in 15.0 mL Et2O at −78 °C. After 1 h, the reaction
mixture was cooled to −115 °C using a EtOH/liquid N2 bath, and aldehyde 3-76 (247 mg,
1.60 mmol) was slowly added as a solution in 2.00 mL THF. After stirring at −115 °C for
40 min, the reaction was quenched with 30.0 mL half saturated aqueous NH4Cl solution.
The solution was allowed to warm to RT and the aqueous layer was then extracted with
EtOAc (3 x 20.0 mL), and the combined organic layers were washed with brine, dried
(MgSO4), filtered through Celite and concentrated under reduced pressure. Purification
by flash chromatography on silica gel using EtOAc-hexanes for elution provided the title
compound as colorless oil (53% yield, >20:1 dr, 150 mg). Rf 0.61 (50% EtOAc/hexanes).
1

H NMR (400 MHz, CDCl3)  7.59−7.56 (m, 2H), 7.39−7.35 (m, 2H), 7.30−7.26 (m,

1H), 7.20−7.06 (m, 10H), 6.73 (s, 1H), 3.99−3.96 (m, 1H), 2.87 (bs, 1H), 2.44−2.39 (m,
2H), 2.27 (t, J = 7.0 Hz, 2H), 1.55−1.49 (m, 2H), 0.15 (s, 9H);

13

C NMR (100 MHz,

CDCl3)  171.0, 144.5, 142.4, 135.4, 128.4, 128.4, 128.1, 127.8, 127.6, 127.5, 127.1,
126.2, 126.1, 106.4, 85.3, 80.2, 79.0, 67.0, 41.6, 34.7, 16.2, 0.1.

(S)- and (R)-4-Benzyloxazolidin-2-one (3-86)
(S)-4-Benzyloxazolidin-2-one was obtained from (S)-phenylalanine
using the procedure described by Evans (70% yield).8 (R)-4Benzyloxazolidin-2-one was prepared in the same fashion, but starting from (R)phenylalanine (72% yield). Rf 0.15 (40% EtOAc/hexanes). 1H NMR (400 MHz, CDCl3) 
7.35−7.16 (m, 5H), 5.01 (bs, 1H), 4.48 (t, J = 8.4, 1H), 4.17−4.06 (m, 2H), 2.92−2.81 (m,
2H); 13C NMR (100 MHz, CDCl3)  159.4, 136.0, 129.0, 129.0, 127.2, 69.6, 53.8, 41.4.
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(S)- and (R)-4-Benzyl-3-(2-chloroacetyl)oxazolidin2-one (3-87)
Oxazolidine-2-one 3-86 (3.54 g, 20.0 mmol) in 300 mL
THF at −78 °C was added nBuLi (9.09 mL, 20.0 mmol, 2.20 M in hexanes) and allowed
to stir for 15 min. The solution was then allowed to warm to RT and stirred for 2.5 h.
After cooling the reaction mixture to −78 °C, chloroacetyl chloride (1.59 mL, 22.0 mmol)
was added dropwise, allowed to stir for 15 min and then warmed to RT for 30 min. The
reaction mixture was then quenched with 10.0 mL half saturated aqueous NH4Cl solution.
The aqueous layer was then extracted with EtOAc (3 x 10.0 mL), and the combined
organic layers were washed with brine, dried (MgSO4), filtered through Celite and
concentrated under reduced pressure. Purification by flash chromatography on silica gel
using EtOAc-hexanes for elution provided the title compound as a white solid (90-95%
yield, 4.71 g). Rf 0.34 (30% EtOAc/hexanes). 1H NMR (400 MHz, CDCl3)  7.36−7.19
(m, 5H), 4.74 (s, 2H), 4.72−4.67 (m, 1H), 4.31−4.23 (m, 2H), 3.34 (dd, J = 13.3, 3.1,
1H), 2.81 (dd, J = 13.3, 9.4, 1H);

13

C NMR (100 MHz, CDCl3)  166.1, 153.2, 134.7,

129.4, 129.1, 127.6, 67.0, 55.4, 43.8, 37.6.

(S)-4-Benzyl-3-((2S,3R)-2-chloro-3-hydroxy-7(trimethylsilyl)hept-6-ynoyl)oxazolidin-2-one (3-88)
EtN(iPr)2 (776 μL, 4.44 mmol) and Bu2BOTf (3.99 mL, 3.99
mmol, 1.00 M in CH2Cl2) were added sequentially to a stirring solution of auxiliary (S)3-87 (845 mg, 3.33 mmol) in 11.0 mL CH2Cl2 (dried and degassed) at −78 °C. After the
solution was allowed to stir at RT for 1.5 h, it was cooled to −78 °C, and aldehyde 3-76
(342 mg, 2.22 mmol) was added dropwise as a solution in 2.00 mL CH2Cl2. The solution
was then allowed to stir for 30 min at −78 °C followed by 2 h at 0 °C. The solution was
then washed with 1.00 M NaHSO4 (4.00 mL, 4.00 mmol) and concentrated under
reduced pressure (rotary evaporator followed by 5 min under 0.1 mm Hg vacuum). The
resulting residue was dissolved in 25.0 mL MeOH, cooled to 0 °C, and 2.00 mL 30%
H2O2 aqueous solution was added and allowed to stir for 1 h. After adding 15.0 mL H2O
and 15.0 mL EtOAc, the aqueous layer was then extracted with EtOAc (3 x 15.0 mL),
8

Gage. J. R.; Evans, D. A. Org. Synth. 1990, 68, 77-80.
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and the combined organic layers were washed with brine, dried (MgSO4), filtered through
Celite and concentrated under reduced pressure. Purification by flash chromatography on
silica gel using EtOAc-hexanes for elution provided the title compound as pale yellow oil
(78% yield, >20:1 dr, 705 mg). Rf 0.50 (40% EtOAc/hexanes). 1H NMR (400 MHz,
CDCl3)  7.35−7.29 (m, 3H), 7.21 (d, J = 7.0 Hz, 2H), 5.67 (d, J = 2.9 Hz, 1H),
4.74−4.70 (m, 1H), 4.28−4.23 (m, 3H), 3.31 (dd, J = 13.5, 3.5 Hz, 1H), 2.86−2.81 (m,
2H), 2.44−2.41 (m, 2H), 1.94−1.88 (m, 1H), 1.81−1.78 (m, 1H), 1.53 (bs, 1H), 0.13 (s,
9H);

13

C NMR (100 MHz, CDCl3)  168.2, 152.5, 134.6, 129.4, 129.0, 127.5, 105.8,

85.5, 70.2, 66.5, 59.4, 55.4, 37.2, 32.7, 16.2, 0.0. HRMS m/z 407.1305 (calcd for
C20H26ClNO4Si, 407.1320).

(S)-4-Benzyl-3-((R)-3-hydroxy-7-(trimethylsilyl)hept-6ynoyl)oxazolidin-2-one (3-89)
Alcohol 3-88 (1.62 g, 3.98 mmol) in 35.0 mL reagent grade
MeOH was added Zn powder (1.04 g, 15.9 mmol) and solid NH4Cl (850 mg, 15.9 mmol).
After 5 min of stirring at RT, the solution was filtered through Celite and concentrated
under reduced pressure. Purification by flash chromatography on silica gel using EtOAchexanes for elution provided the title compound as colorless oil (96% yield, 1.42 g). Rf
0.50 (40% EtOAc/hexanes). 1H NMR (400 MHz, CDCl3)  7.35−7.19 (m, 5H),
4.73−4.67 (m, 1H), 4.26−4.16 (m, 4H), 3.27 (dd, J = 13.3, 3.5 Hz, 1H), 3.13−3.09 (m,
2H), 2.80 (dd, J = 13.7, 9.4 Hz, 1H), 2.41 (t, J = 7.0 Hz, 2H), 1.83−1.69 (m, 2H), 0.14 (s,
9H);

13

C NMR (100 MHz, CDCl3)  172.4, 153.3, 134.9, 129.3, 129.0, 127.3, 106.5,

85.0, 66.6, 66.3, 54.9, 42.5, 37.7, 35.1, 16.2, 0.0. HRMS [m/z+H+] 374.1775 (calcd for
C20H27NO4Si, 373.1709).

(R)-3-Hydroxy-N-methoxy-N-methyl-7(trimethylsilyl)hept-6-ynamide (3-90)
N,O-Dimethylhydroxylamine hydrochloride salt (725 mg,
7.43 mmol) in 40.0 mL THF at 0 °C was added Me3Al (3.71 mL, 7.43 mmol, 2.00 M in
hexanes). After 30 min at 0 °C, the solution was stirred at RT for another 20 min. The
mixture was cooled to −15 °C and alcohol 3-89 (923 mg, 2.47 mmol) in 15.0 mL THF
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was added dropwise and stirred for 4 h at 0 °C. The reaction mixture was then quenched
with 50.0 mL 0.50 M HCl. The aqueous layer was then extracted with EtOAc (3 x 25.0
mL), and the combined organic layers were washed with brine, dried (MgSO4), filtered
through Celite and concentrated under reduced pressure. Purification by flash
chromatography on silica gel using EtOAc-hexanes for elution provided the title
compound as colorless oil (80% yield, 508 mg). Rf 0.28 (40% EtOAc/hexanes). lH NMR
(400 MHz, CDCl3)  4.15−4.09 (m, 1H), 3.82 (d, J = 3.1 Hz, 1H), 3.68 (s, 3H), 3.19 (s,
3H), 2.70−2.68 (m, 1H), 2.51−2.47 (m, 1H), 2.39 (td, J = 7.1, 3.3 Hz, 1H), 1.79−1.63 (m,
2H), 0.13 (s, 9H);

13

C NMR (100 MHz, CDCl3)  173.5, 106.8, 84.7, 66.7, 61.2, 38.0,

35.2, 31.8, 16.2, 0.1. HRMS [m/z+H+] 258.1535 (calcd for C12H23NO3Si, 257.1447). All
of the auxiliary ((S)-3-86) was also recovered from the reaction mixture.

(R)-5-Hydroxy-9-(trimethylsilyl)non-1-en-8-yn-3-one (3-91)
The title compound was obtained from amide 3-90 using the
Grignard addition conditions, as described above in the
procedure to obtain compound 3-70. This procedure provided the title compound as
colorless oil (78% yield). Rf 0.43 (50% EtOAc/hexanes). 1H NMR (400 MHz, CDCl3) 
6.36 (dd, J = 16.0, 10.2 Hz, 1H), 6.21 (dd, J = 17.6, 1.2 Hz, 1H), 5.89 (dd, J = 10.2, 1.2
Hz, 1H), 4.23−4.18 (m, 1H), 3.17−3.16 (m, 1H), 2.84−2.68 (m, 2H), 2.40−2.36 (m, 2H),
1.76−1.65 (m, 2H), 0.12 (s, 9H);

13

C NMR (100 MHz, CDCl3)  200.9, 136.7, 129.2,

129.2, 106.7, 85.1, 66.6, 45.6, 35.0, 16.2, 0.1. HRMS [m/z+H+] 225.1305 (calcd for
C12H20O2Si, 224.1233).

(3R,5R)-9-(Trimethylsilyl)non-1-en-8-yne-3,5-diol (3-92)
The title compound was obtained from ketone 3-91 using the
Prasad reduction reaction conditions, as described above in the
procedure to obtain compound 3-72. This procedure provided the title compound as a
white solid (87% yield). Rf 0.35 (50% EtOAc/hexanes). 1H NMR (400 MHz, CDCl3) 
5.86 (ddd, J = 16.9, 10.5, 5.9 Hz, 1H), 5.24 (dt, J = 17.2, 1.4 Hz, 1H), 5.09 (dt, J = 10.5,
1.2 Hz, 1H), 4.40−4.35 (m, 1H), 4.04−3.98 (m, 1H), 3.33 (bs, 1H), 3.07 (bs, 1H), 2.34 (t,
J = 4.0 Hz, 2H), 1.71−1.56 (m, 4H), 0.13 (s, 9H); 13C NMR (100 MHz, CDCl3)  140.6,
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114.6, 106.8, 85.5, 73.6, 71.5, 42.8, 36.2, 16.2, 0.1. HRMS [m/z+H+] 227.1469 (calcd for
C12H22O2Si, 226.1389).

(2R,3R,5R)-2-(Hydroxymethyl)-5-(4-(trimethylsilyl)but-3ynyl)tetrahydrofuran-3-ol (3-93)
Diol 3-92 (67.0 mg, 0.29 mmol) was added as a solution in 3.40 mL
iPrOH to a flask charged with Co(nmp)2 (25.0 mg, 0.04 mmol) under 1
atm of O2 (balloon). At room temperature, tert-butyl hydroperoxide (8.00 μL, 0.04 mmol,
5.33 M is isooctane) was added in one portion, and the resulting solution was heated at 55
°C for 16 h. The solution was cooled to RT, and the solvent was removed completely
under reduced pressure (rotary evaporator followed by 5 min under 0.1 mm Hg vacuum
while stirring). The resulting residue was then dissolved in 5.00 mL EtOAc and filtered
through a pad of Celite and washed with 10.0 mL EtOAc. Solvent removal under reduced
pressure provided the title compound as pale yellow oil (91% yield, 63.9 mg). Rf 0.13
(50% EtOAc/hexanes). 1H NMR (400 MHz, CDCl3)  4.50 (bs, 1H), 4.37−4.30 (m, 1H),
3.93−3.89 (m, 3H), 3.36 (bs, 1H), 2.66 (bs, 1H), 2.37−2.26 (m, 2H), 2.11 (dd, J = 13.5,
5.9 Hz, 1H), 1.82−1.64 (m, 3H), 0.11 (s, 9H);

13

C NMR (100 MHz, CDCl3)  106.6,

84.7, 80.2, 77.1, 74.3, 61.8, 41.8, 34.8, 16.7, 0.1. HRMS [m/z+H+] 243.8411 (calcd for
C12H22O3Si, 242.1338).

(4-((4aR,6R,7aR)-2-(4-Methoxyphenyl)tetrahydro-4Hfuro[3,2-d][1,3]dioxin-6-yl)but-1-ynyl)trimethylsilane (3-94)
Diol 3-93 (50.0 mg, 0.21 mmol) in 3.00 mL CH2Cl2 was added
p-methoxybenzaldehyde diethylacetal (45.0 μL, 0.23 mmol)
followed by 10-CSA (5.00 mg, 0.02 mmol). After stirring at
room temperature for 3 h, the solution was quenched with 5.00 mL H2O and 5.00 mL
CH2Cl2. The mixture was separated and the aqueous layer was extracted with CH2Cl2 (3
x 5.00 mL). The combined organic layers were washed with brine, dried (MgSO4),
filtered through Celite and concentrated under reduced pressure. Purification by flash
chromatography on silica gel using EtOAc−hexanes for elution provided the title
compound as colorless oil (93% yield, 69.0 mg). Rf 0.64 (50% EtOAc/hexanes). 1H NMR
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(400 MHz, CDCl3)  7.41 (d, J = 8.6 Hz, 2H), 6.87 (d, J = 8.9 Hz, 2H), 5.40 (s, 1H),
4.55−4.51 (m, 2H), 4.36 (d, J = 12.9 Hz, 1H), 4.06 (dd, J = 13.1, 2.2 Hz, 1H), 3.79 (s,
4H), 2.40−2.28 (m, 3H), 1.90−1.81 (m, 1H), 1.79−1.71 (m, 2H), 0.13 (s, 9H); 13C NMR
(100 MHz, CDCl3)  160.0, 130.6, 127.5, 113.6, 106.8, 99.3, 84.6, 78.3, 77.3, 73.4, 67.9,
55.2, 39.8, 35.3, 16.8, 0.1. HRMS m/z 360.1878 (calcd for C20H28O4Si, 360.1757).

(4aR,6R,7aR)-6-(But-3-ynyl)-2-(4methoxyphenyl)tetrahydro-4H-furo[3,2-d][1,3]dioxine (3-95)
Alkyne 3-94 (262 mg, 0.72 mmol) in 6.00 mL MeOH was
added K2CO3 (110 mg, 0.80 mmol) and the solution was
allowed to stir at RT for 6 h. The reaction was quenched by the
addition of 6.00 mL half saturated aqueous NH4Cl, followed by 6.00 mL EtOAc. The
aqueous layer was then extracted with EtOAc (3 x 10.0 mL), and the combined organic
layers were washed with brine, dried (MgSO4), filtered through Celite and concentrated
under reduced pressure. Purification by flash chromatography on silica gel using EtOAchexanes for elution provided the title compound as colorless oil (98% yield, 207 mg). Rf
0.43 (40% EtOAc/hexanes). 1H NMR (400 MHz, CDCl3)  7.40 (d, J = 8.8 Hz, 2H), 6.86
(d, J = 8.8 Hz, 2H), 5.38 (s, 1H), 4.54−4.49 (m, 1H), 4.47−4.46 (m, 1H), 4.33 (d, J = 13.5
Hz, 1H), 4.03 (dd, J = 13.2, 2.1 Hz, 1H), 3.76 (s, 4H), 2.38−2.33 (m, 1H), 2.30−2.24 (m,
2H), 1.94 (t, J = 12.9 Hz, 1H), 1.86−1.80 (m, 1H), 1.78−1.69 (m, 2H);

13

C NMR (100

MHz, CDCl3)  159.9, 130.6, 127.4, 113.5, 99.2, 83.9, 78.0, 77.2, 73.3, 68.4, 67.7, 55.1,
39.7, 35.1, 15.3. HRMS m/z 288.1361 (calcd for C17H20O4, 288.1362).

(4aR,6R,7aR)-6-((Z)-3-Chlorohepta-3,6-dienyl)-2-(4methoxyphenyl)tetrahydro-4H-furo[3,2-d][1,3]dioxine
(3-96)
A solution of PdCl2 (7.70 mg, 0.04 mmol) and LiCl (12.8
mg, 0.30 mmol) in 4.86 mL acetone:acetic acid (4:1) was
cooled to −78 °C. Alkyne 3-95 (42.0 mg, 0.15 mmol) and then allyl chloride (118 μL,
1.46 mmol) were added neat, allowed to stir for 30 min, then allowed to warm to RT and
stirred for 16 h. The reaction was quenched at the addition of 5.00 mL H2O, and the
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aqueous layer was extracted with EtOAc (3 x 5.00 mL), and the combined organic layers
were washed with brine, dried (MgSO4), filtered through Celite and concentrated under
reduced pressure. Purification by flash chromatography on silica gel using EtOAchexanes for elution provided the title compound as colorless oil (83% yield, 44.0 mg). Rf
0.70 (50% EtOAc/hexanes). 1H NMR (600 MHz, CDCl3)  7.41 (d, J = 8.8 Hz, 2H), 6.87
(d, J = 8.8 Hz, 2H), 5.82−5.75 (m, 1H), 5.54 (t, J = 7.0 Hz, 1H), 5.40 (s, 1H), 5.06 (dq, J
= 17.5, 1.6 Hz, 1H), 4.99 (dq, J = 10.2, 1.5 Hz, 1H), 4.51−4.44 (m, 2H), 4.36 (d, J = 12.9
Hz, 1H), 4.06 (dd, J = 12.9, 2.2 Hz, 1H), 3.82−3.80 (m, 1H), 3.79 (s, 3H), 2.92 (t, J = 6.7
Hz, 2H), 2.53 (ddd, J = 14.6, 9.4, 5.9 Hz, 1H), 2.40 (ddd, J = 14.8, 8.6, 6.4 Hz, 1H), 2.27
(dd, J = 13.5, 5.9 Hz, 1H), 1.86−1.79 (m, 2H), 1.73 (ddd, J = 13.5, 9.7, 3.8 Hz, 1H); 13C
NMR (100 MHz, CDCl3)  160.0, 135.2, 130.7, 127.5, 122.9, 115.3, 113.6, 99.3, 78.4,
77.3, 73.4, 68.0, 55.3, 40.0, 36.3, 34.3, 32.8.

(4aR,6R,7aR)-6-((3Z)-3-Chloroocta-3,6-dienyl)-2-(4methoxyphenyl)tetrahydro-4H-furo[3,2-d][1,3]dioxine
(3-98)
The title compound was obtained from alkyne 3-95 using the
chloropalladation reaction conditions described above in the
procedure to obtain compound 3-96, except 3-chlorobut-1-ene was used instead of allyl
chloride. This procedure provided the title compound as colorless oil (46% yield). Rf 0.18
(20% EtOAc/hexanes). 1H NMR (600 MHz, CDCl3)  7.41 (d, J = 8.8 Hz, 2H), 6.87 (d, J
= 8.8 Hz, 2H), 5.52−5.47 (m, 2H), 5.40 (s, 1H), 5.40−5.35 (m, 1H), 4.51−.4.49 (m, 1H),
4.47−4.44 (m, 1H), 4.36 (d, J = 13.5 Hz, 1H), 4.06 (d, J = 12.9 Hz, 1H), 3.81−3.80 (m,
1H), 3.78 (s, 3H), 2.91 (t, J = 7.0 Hz, 1H), 2.83 (t, J = 6.4 Hz, 1H), 2.52−2.48 (m, 1H),
2.40−2.34 (m, 1H), 2.27 (dd, J = 13.2, 5.6 Hz, 1H), 1.85−1.78 (m, 2H), 1.72 (ddd, J =
13.2, 9.7, 4.1 Hz, 1H), 1.67−1.61 (m, 3H); 13C NMR (100 MHz, CDCl3)  160.0, 134.4,
134.3, 130.7, 127.7, 127.4, 126.9, 126.0, 125.1, 123.9, 123.8, 113.5, 99.3, 78.4, 77.3,
73.4, 67.9, 55.2, 40.0, 36.2, 36.2, 34.4, 34.3, 31.7, 26.6, 17.8. HRMS m/z 378.1605 (calcd
for C21H27ClO4, 378.1598).
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Methyl 2-(hydroxymethyl)acrylate (3-101)
Formaldehyde (5.00 g, 166 mmol) and methyl acrylate (44.0 mL, 498
mmol) in 20.0 mL 1,4-dioxane:H2O (1:1 ratio), was added DABCO
(18.6 g, 166 mol) and the solution was allowed to stir for 16 h at RT. EtOAc (20.0 mL)
and H2O (20.0 mL) were then added and the aqueous layer was extracted with EtOAc (3
x 20.0 mL). The combined organic layers were washed with brine, dried (MgSO4),
filtered through Celite and concentrated under reduced pressure. Purification by flash
chromatography on silica gel using EtOAc-hexanes for elution provided the title
compound as colorless oil (89% yield, 17.1 g). Rf 0.27 (40% EtOAc/hexanes). 1H NMR
(400 MHz, CDCl3)  6.26 (d, J = 1.2 Hz, 1H), 5.83 (d, J = 1.2 Hz, 1H), 4.33 (d, J = 5.9
Hz, 2H), 3.79 (s, 3H), 2.18 (t, J = 6.6 Hz, 1H);

13

C NMR (100 MHz, CDCl3)  166.8,

139.2, 125.9, 62.5, 51.9.

Methyl 2-((tert-butyldimethylsilyloxy)methyl)acrylate (3-102)
The title compound was obtained from alcohol 3-101 using the
standard TBS protection reaction conditions described above in the
procedure to obtain compound 3-67a. This procedure provided the title compound as
colorless oil (100% yield). Rf 0.50 (40% EtOAc/hexanes). 1H NMR (400 MHz, CDCl3) 
6.24 (q, J = 1.9 Hz, 1H), 5.89 (d, J = 2.1 Hz, 1H), 4.35 (t, J =2.2 Hz, 2H), 3.74 (s, 3H),
0.90 (s, 9H), 0.07 (s, 6H); 13C NMR (100 MHz, CDCl3)  166.4, 139.6, 123.9, 61.5, 51.6,
25.9, 18.3, −5.5.

2-((tert-Butyldimethylsilyloxy)methyl)prop-2-en-1-ol (3-103)
Ester 3-102 (9.02 g, 39.4 mmol) in 80.0 mL THF at −78 °C was added
DIBAL (84.7 mL, 84.7 mmol, 1.00 M in Et2O) dropwise. After stirring for 1 h at 0 °C,
the solution was slowly poured into 80.0 mL half saturated aqueous solution of
Rochelle’s salt (Na·K·tartrate) and stirred for 30 min. The mixture was separated and the
aqueous layer was extracted with EtOAc (3 x 60.0 mL). The combined organic layers
were washed with brine, dried (MgSO4), filtered through Celite and concentrated under
reduced pressure. Purification by flash chromatography on silica gel using EtOAchexanes for elution provided the title compound as colorless oil (93% yield, 7.35 g). Rf
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0.74 (50% EtOAc/hexanes). 1H NMR (400 MHz, CDCl3)  5.07 (d, J = 6.6 Hz, 2H), 4.23
(s, 2H), 4.16 (d, J = 5.5 Hz, 2H), 2.00 (t, J = 5.9 Hz, 1H), 0.90 (s, 9H), 0.07 (s, 6H); 13C
NMR (100 MHz, CDCl3)  147.5, 111.1, 65.1, 64.7, 25.9, 18.3, −5.4.

2-((tert-Butyldimethylsilyloxy)methyl)acrylaldehyde (3-104)
The title compound was obtained from alcohol 3-103 after a standard
Swern oxidation, as described above in the procedure to obtain compound
3-67. This procedure provided the title compound as pale yellow oil (96% yield). Rf 0.74
(50% EtOAc/hexanes). 1H NMR (400 MHz, CDCl3)  9.60 (s, 1H), 6.51 (d, J = 1.6 Hz,
1H), 6.09 (d, J = 1.2 Hz, 1H), 4.38 (t, J = 2.2 Hz, 2H), 0.91 (s, 9H), 0.07 (s, 6H);

13

C

NMR (100 MHz, CDCl3)  193.6, 149.5, 132.8, 59.6, 25.8, 18.3, −5.5.

Ethyl 4-((tert-butyldimethylsilyloxy)methyl)-3-hydroxypent-4enoate (rac-3-105)
To iPr2NH (885 μL, 6.26 mmol) in 10.0 mL THF at 0 °C was
added nBuLi (2.18 mL, 5.48 mmol, 2.51 M in hexanes) dropwise. After 15 min at 0 °C,
the solution was cooled to −60 °C and EtOAc (539 μL, 5.48 mmol) was added dropwise.
The solution was allowed to stir for 30 min at −60 °C and then a solution of aldehyde 3104 (980 mg, 4.89 mmol) in 1.00 mL THF was added slowly. The solution was stirred at
−40 °C for 1 h and then the reaction mixture was quenched by 10.0 mL half saturated
NH4Cl. The aqueous layers were then extracted with EtOAc (3 x 10.0 mL), and the
combined organic layers were washed with brine, dried (MgSO4), filtered through Celite
and concentrated under reduced pressure. Purification by flash chromatography on silica
gel using EtOAc-hexanes for elution provided the title compound as colorless oil (83%
yield, 1.17 g). Rf 0.71 (50% EtOAc/hexanes). 1H NMR (400 MHz, CDCl3)  5.13 (s, 2H),
4.63−4.59 (m, 1H), 4.29−4.20 (m, 2H), 4.16 (q, J = 7.2 Hz, 2H), 3.27 (d, J = 5.1 Hz, 1H),
2.66 (s, 1H), 2.64 (d, J = 2.3 Hz, 1H), 1.26 (t, J = 7.0 Hz, 3H), 0.90 (s, 9H), 0.07 (s, 6H);
13

C NMR (100 MHz, CDCl3)  172.3, 148.1, 111.3, 69.6, 64.4, 60.7, 40.7, 25.9, 18.3,

14.2, −5.5.
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(R)-Ethyl-4-((tert-butyldimethylsilyloxy)methyl)-3hydroxypent-4-enoate ((R)-3-105)
To a mixture of 4Ǻ molecular sieves (400 mg), and Ti(OiPr)2 (162
μL, 0.55 mmol) in 5.00 mL CH2Cl2 was added (+)-diethyl tartrate (113 μL, 0.66 mmol)
dropwise at −20 °C. The mixture was stirred at −20 °C for 20 min and then allylic alcohol
rac-3-105 (400 mg, 1.38 mmol) in 1.00 mL CH2Cl2 was added. After 20 min at −20 °C,
the solution was cooled to −40 °C and a solution of tert-butyl hydroperoxide (259 μL,
1.38 mmol, 5.33 M in isooctane) was added dropwise and the resulting solution was
allowed to stir for 24 h at −20 °C. Me2S (101 μL, 1.38 mmol) was added slowly and the
solution was allowed to stir at −20 °C for 30 min before adding tartaric acid (207 mg,
1.38 mmol). The solution was then filtered through Celite and concentrated under
reduced pressure. Purification by flash chromatography on silica gel using EtOAchexanes for elution provided the title compound as colorless oil (42% yield, 190 mg, 60%
ee). All characterization data is the same as the racemic mixture above. The enantiomeric
excess was determined by NMR with the use of chiral shift reagent Eu(hfc)3
(Europium(III)tris[3-hepafluoropropylhydroxymethylene]-d-camphorate).

Ethyl 3-(tert-butyldimethylsilyloxy)-4-((tertbutyldimethylsilyloxy)methyl)pent-4-enoate (3-106)
The title compound was obtained from alcohol (R)-3-105 using the
standard TBS protection reaction conditions described above in the procedure to obtain
compound 3-67a. This procedure provided the title compound as colorless oil (95%
yield). Rf 0.75 (25% EtOAc/hexanes). 1H NMR (400 MHz, CDCl3)  5.11 (s, 2H), 4.67
(dd, J = 8.2, 4.7 Hz, 1H), 4.18 (s, 2H), 4.14-4.06 (m, 2H), 2.57-2.46 (m, 2H), 1.24 (t, J =
7.2 Hz, 1H), 0.90 (s, 9H), 0.85 (s, 9H), 0.06 (s, 6H), 0.02 (s, 3H), 0.00 (s, 3H); 13C NMR
(100 MHz, CDCl3)  171.3, 149.9, 110.3, 71.4, 62.5, 60.4, 43.4, 25.9, 25.7, 18.4, 18.0,
14.2, −4.7, −5.4.

143

144

3-(tert-Butyldimethylsilyloxy)-4-((tertbutyldimethylsilyloxy)methyl)pent-4-enoic acid (3-107)
An aqueous solution of KOH (202 mg, 3.60 mmol, 10.0 M) was
added to a solution of ester 3-106 in 3.00 mL EtOH and allowed to stir for 16 h. After
addition of 1.00 M HCl solution until the solution was pH 4, EtOAc (10.0 mL) was
added. The aqueous layer was then extracted with EtOAc (3 x 10.0 mL). The combined
organic layers were washed with brine, dried (MgSO4), filtered through Celite and
concentrated under reduced pressure provided the title compound as a white solid (96%
yield, 130 mg). Rf 0.07 (25% EtOAc/hexanes). 1H NMR (400 MHz, CDCl3)  5.18-5.15
(m, 2H), 4.73-4.66 (m, 1H), 4.23-4.14 (m, 2H), 2.73-2.63 (m, 2H), 0.90 (s, 9H), 0.88 (s,
9H), 0.09 (s, 3H), 0.07 (s, 3H), 0.05 (s, 3H), 0.03 (s, 3H).

Methyl 3-hydroxy-2-methyleneoct-7-enoate (3-110)
To a stirred solution of hex-5-enal (1.00 g, 10.2 mmol) and methyl
acrylate (919 μL, 10.2 mmol) at room temperature was added DABCO (1.14 g, 10.2
mmol), Sc(OTf)3 (251 mg, 0.51 mmol), and (+)-diethyltartrate (873 μL, 5.10 mmol).
After stirring for 7 days, the thick and homogeneous mixture was diluted with 100 mL
Et2O and washed with 20.0 mL 2% HCl aqueous solution, followed by 20.0 mL H2O.
The organic layer were washed with brine, dried (MgSO4), filtered through Celite and
concentrated under reduced pressure. Purification by flash chromatography on silica gel
using EtOAc-hexanes for elution provided the title compound as colorless oil (49% yield,
920 mg). Rf 0.60 (50% EtOAc/hexanes). 1H NMR (400 MHz, CDCl3)  6.22 (s, 1H),
5.84−5.74 (m, 2H), 5.02−4.93 (m, 2H), 4.40−4.37 (m, 1H), 3.77 (s, 3H), 2.20 (bs, 1H),
2.10−2.05 (m, 2H), 1.69−1.62 (m, 2H), 1.61−1.52 (m, 1H), 1.48−1.39 (m, 1H); 13C NMR
(100 MHz, CDCl3)  167.0, 142.3, 138.5, 125.1, 114.7, 110.0, 71.7, 51.9, 35.6, 33.4,
25.1. HRMS [m/z+H+] 185.1176 (calcd for C10H16O3, 184.1099).

(E)-2-(Methoxycarbonyl)octa-2,7-dienyl 4-nitrobenzoate (3-111)
To a solution of allylic alcohol 3-110 (195 mg, 1.06 mmol) in 10.0
mL THF was added triphenyl phosphine (359 mg, 1.37 mmol) and p-nitrobenzoic acid
(229 mg, 1.37 mmol). The solution was cooled to −40 °C and DIAD (271 μL, 1.37
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mmol) over 10 min. The solution was allowed to warm to −30 °C over 1 h and kept at
that temperature for 3 h. After slowly warming to 0 °C for 15 min, the solution was
concentrated under reduced pressure. The residue was dissolved in 20.0 mL EtOAc and
washed with 20.0 mL H2O followed by 10.0 mL 1.00 M aqueous NaOH solution. The
aqueous layers were then extracted with EtOAc (3 x 20.0 mL), and the combined organic
layers were washed with brine, dried (MgSO4), filtered through Celite and concentrated
under reduced pressure. Purification by flash chromatography on silica gel using EtOAchexanes for elution provided the title compound as pale yellow oil (93% yield, 328 mg).
Rf 0.64 (50% EtOAc/hexanes). 1H NMR (600 MHz, CDCl3)  8.26 (d, J = 8.8 Hz, 2H),
8.16 (d, J = 8.8 Hz, 2H), 7.14 (t, J = 7.6 Hz, 1H), 5.79−5.72 (m, 1H), 5.13 (s, 2H),
5.01−4.96 (m, 2H), 3.79 (s, 3H), 2.39 (q, J = 17.9, 11.9 Hz, 1H), 2.09 (q, J = 7.0 Hz, 1H),
1.59 (p, J = 7.5 Hz, 1H);

13

C NMR (100 MHz, CDCl3)  166.7, 164.4, 150.5, 150.1,

137.6, 135.4, 130.8, 126.7, 123.5, 115.4, 59.4, 52.1, 33.2, 28.2, 27.7. HRMS m/z
333.1209 (calcd for C17H19NO6, 333.1212).

(E)-Methyl 2-(hydroxymethyl)octa-2,7-dienoate (3-112)
A solution of ester 3-111 (220 mg, 0.66 mmol) in 14.0 mL MeOH
and 4.20 mL THF was cooled to 0 °C and K2CO3 (91.0 mg, 0.66 mmol) was added. After
stirring for 2 h at 0 °C, the solvent was removed under reduced pressure and the residue
dissolved in 20.0 mL half saturated brine and 20.0 mL EtOAc. The aqueous layers were
then extracted with EtOAc (3 x 10.0 mL), and the combined organic layers were washed
with brine, dried (MgSO4), filtered through Celite and concentrated under reduced
pressure. Purification by flash chromatography on silica gel using EtOAc-hexanes for
elution provided the title compound as colorless oil (78% yield, 95.0 mg). Rf 0.54 (50%
EtOAc/hexanes). 1H NMR (400 MHz, CDCl3)  6.87 (t, J = 7.8 Hz, 1H), 5.82−5.71 (m,
1H), 5.03−4.91 (m, 2H), 4.31 (s, 2H), 3.77 (s, 3H), 2.30−2.25 (m, 3H), 2.07 (q, J = 7.0
Hz, 2H), 1.55 (p, J = 7.4 Hz, 2H);

13

C NMR (100 MHz, CDCl3)  168.0, 145.5, 137.8,

131.0, 115.2, 57.3, 51.9, 33.1, 27.8, 27.6. HRMS [m/z+H+] 185.1175 (calcd for C10H16O3,
184.1099).
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(E)-Methyl-2-((4-methoxybenzyloxy)methyl)octa-2,7-dienoate
(3-113)
To a solution of alcohol 3-112 (150 mg, 0.81 mmol) and 4-methoxybenzyl-2,2,2trichloroacetimidate (461 mg, 1.63 mmol) in 3.00 mL CH2Cl2, was added 10-CSA (19.0
mg, 0.08 mmol) at RT. The solution was allowed to stir for 16 h and quenched by 10.0
mL half saturated NaHCO3 and 10.0 mL CH2Cl2. The aqueous layers were then extracted
with CH2Cl2 (3 x 10.0 mL), and the combined organic layers were washed with brine,
dried (MgSO4), filtered through Celite and concentrated under reduced pressure.
Purification by flash chromatography on silica gel using EtOAc-hexanes for elution
provided the title compound as colorless oil (87% yield, 216 mg). Rf 0.70 (50%
EtOAc/hexanes). 1H NMR (400 MHz, CDCl3)  7.26 (d, J = 8.6 Hz, 2H), 6.99 (t, J = 7.8
Hz, 1H), 6.87 (d, J = 8.6 Hz, 2H), 5.76 (ddt, J = 17.0, 10.4, 6.6 Hz, 1H), 5.08−4.95 (m,
2H), 4.45 (s, 2H), 4.20 (s, 2H), 3.79 (s, 3H), 3.75 (s, 3H), 2.24 (q, J = 7.7 Hz, 2H), 2.05
(q, J = 7.0 Hz, 2H), 1.56−1.49 (m, 2H);

13

C NMR (100 MHz, CDCl3)  167.6, 159.2,

148.2, 138.0, 130.4, 129.4, 129.2, 115.1, 113.7, 72.1, 63.1, 55.3, 51.8, 33.3, 28.1, 27.8.
HRMS m/z 304.8147 (calcd for C18H24O4, 304.1675).

(E)-2-((4-Methoxybenzyloxy)methyl)octa-2,7-dienal (3-114)
The title compound was obtained from alcohol (Z)-3-125 after a
standard Swern oxidation, as described above in the procedure to
obtain compound 3-67. This procedure provided the title compound as colorless oil (95%
yield). Rf 0.51 (30% EtOAc/hexanes). 1H NMR (600 MHz, CDCl3)  9.42 (s, 1H), 7.23
(d, J = 9.4 Hz, 2H), 7.23 (d, J = 9.4 Hz, 2H), 6.85 (d, J = 8.8 Hz, 2H), 6.68 (t, J = 7.6 Hz,
1H), 5.79-5.72 (m, 1H), 5.01−4.96 (m, 2H), 4.41 (s, 2H), 4.16 (s, 2H), 3.78 (s, 3H), 2.43
(q, J = 7.6 Hz, 2H), 2.07 (q, J = 7.0 Hz, 2H), 1.59 (p, J = 7.5 Hz, 2H);

13

C NMR (100

MHz, CDCl3)  193.8, 159.2, 139.8, 137.7, 130.2, 129.5, 115.3, 113.7, 72.5, 60.6, 55.2,
33.3, 28.6, 27.7.
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Methyl 2-((4-methoxybenzyloxy)methyl)acrylate (3-115)
To a solution of alcohol 3-101 (560 mg, 4.82 mmol) and 4methoxybenzyl-2,2,2-trichloroacetimidate (2.72 g, 9.64 mmol) in 30.0
mL CH2Cl2, was added 10-CSA (111 mg, 0.48 mmol) at RT. The solution was allowed to
stir for 16 h and quenched by 30.0 mL half saturated NaHCO3 and 30.0 mL CH2Cl2. The
aqueous layers were then extracted with CH2Cl2 (3 x 20.0 mL), and the combined organic
layers were washed with brine, dried (MgSO4), filtered through Celite and concentrated
under reduced pressure. Purification by flash chromatography on silica gel using EtOAchexanes for elution provided the title compound as colorless oil (82% yield, 932 mg). Rf
0.63 (40% EtOAc/hexanes). 1H NMR (400 MHz, CDCl3)  7.28−7.25 (m, 2H),
6.89−6.86 (m, 2H), 6.30 (q, J = 1.4 Hz, 1H), 5.91 (q, J = 1.8 Hz, 1H), 4.50 (s, 2H), 4.19
(t, J = 1.6 Hz, 2H), 3.80 (s, 3H), 3.75 (s, 3H). HRMS m/z 236.1050 (calcd for C13H16O4,
236.1049).

2-((4-Methoxybenzyloxy)methyl)prop-2-en-1-ol (3-115b)
The title compound was obtained from ester 3-115 after a DIBAL
reduction, as described above in the procedure to obtain compound (Z)-3-125. This
procedure provided the title compound as colorless oil (86% yield). Rf 0.29 (40%
EtOAc/hexanes). 1H NMR (400 MHz, CDCl3)  7.26−7.24 (m, 1H), 6.89−6.86 (m, 2H),
5.19−5.18 (m, 1H), 5.14−5.12 (m, 1H), 4.45 (s, 2H), 4.18 (d, J = 5.9 Hz, 2H), 4.06 (s,
2H), 3.80 (s, 3H), 1.89 (t, J = 6.1 Hz, 1H); 13C NMR (100 MHz, CDCl3)  159.3, 145.1,
130.0, 129.4, 113.8, 113.5, 72.0, 71.5, 64.6, 55.3. HRMS m/z 208.1098 (calcd for
C12H16O3, 208.1099).

2-((4-Methoxybenzyloxy)methyl)acrylaldehyde (3-116)
The title compound was obtained from alcohol 3-115b after a standard
Swern oxidation, as described above in the procedure to obtain
compound 3-67. This procedure provided the title compound as pale yellow oil (98%
yield). Rf 0.71 (40% EtOAc/hexanes). 1H NMR (400 MHz, CDCl3)  9.58 (s, 1H), 7.24
(d, J = 8.2 Hz, 2H), 6.86 (d, J = 8.8 Hz, 2H), 6.52 (d, J = 1.2 Hz, 1H), 6.11 (d, J = 1.2 Hz,
1H), 4.50 (s, 2H), 4.19 (t, J = 1.8 Hz, 2H), 3.80 (s, 3H); 13C NMR (100 MHz, CDCl3) 
147
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193.3, 159.2, 146.7, 133.9, 129.8, 129.2, 113.7, 72.7, 65.5, 55.1. HRMS m/z 206.0937
(calcd for C12H14O3, 206.0943).

2-((4-Methoxybenzyloxy)methyl)octa-1,7-dien-3-ol (3-117)
Aldehyde 3-116 (100 mg, 0.48 mmol) in 6.00 mL Et2O at 0 °C was
added a solution of pent-4-enylmagnesium bromide (10.0 mL, 0.96 mmol, 0.10 M in
Et2O). After 2 h at RT, the reaction was quenched with 10.0 mL half saturated aqueous
NH4Cl solution. The aqueous layer was then extracted with EtOAc (3 x 10.0 mL), and
the combined organic layers were washed with brine, dried (MgSO4), filtered through
Celite and concentrated under reduced pressure. Purification by flash chromatography on
silica gel using EtOAc-hexanes for elution provided the title compound as colorless oil
(75% yield, 100 mg). Rf 0.53 (40% EtOAc/hexanes). 1H NMR (600 MHz, CDCl3)  7.24
(d, J = 8.2 Hz, 2H), 6.86 (d, J = 8.2 Hz, 2H), 5.77 (ddt, J = 17.1, 10.3, 6.5 Hz, 1H), 5.13
(d, J = 16.9 Hz, 2H), 4.98 (d, J = 16.9 Hz, 1H), 4.92 (d, J = 9.9 Hz, 1H), 4.44 (s, 2H),
4.18−4.14 (m, 1H), 4.09 (d, J = 11.7 Hz, 1H), 4.00 (d, J = 12.3 Hz, 1H), 3.79 (s, 3H),
2.39 (bs, 1H), 2.05 (q, J = 7.4 Hz, 2H), 1.58 (q, J = 12.0, 6.0 Hz, 2H), 1.54−1.48 (m, 1H),
1.41−1.35 (m, 1H);

13

C NMR (100 MHz, CDCl3)  159.3, 147.3, 138.6, 129.9, 129.4,

114.6, 113.8, 113.8, 113.7, 72.1, 71.0, 55.2, 35.1, 33.5, 25.0. HRMS m/z 276.1737 (calcd
for C17H24O3, 276.1725).

2-((4-Methoxybenzyloxy)methyl)octa-1,7-dien-3-yl-4nitrobenzoate (3-119)
The title compound was obtained from alcohol 3-117 using the Mitsunobu reaction
conditions described above in the procedure to obtain compound 3-111. This procedure
provided the title compound as colorless oil (73% yield). Rf 0.75 (40% EtOAc/hexanes).
1

H NMR (600 MHz, CDCl3)  8.24 (d, J = 9.3 Hz, 2H), 8.16 (d, J = 9.4 Hz, 2H), 7.23 (d,

J = 8.8 Hz, 2H), 6.84 (d, J = 8.2 Hz, 2H), 5.76 (ddt, J = 16.9, 10.3, 6.9 Hz, 1H), 5.59 (t, J
= 6.4 Hz, 1H), 5.27 (d, J = 3.5 Hz, 2H), 4.99 (dq, J = 17.4, 1.4 Hz, 1H), 4.96-4.94 (m,
1H), 4.47 (d, J = 11.1 Hz, 1H), 4.40 (d, J = 11.0 Hz, 1H), 4.08 (d, J = 11.9 Hz, 1H), 4.05
(d, J = 11.9 Hz, 1H), 3.79 (s, 3H), 2.10−2.07 (m, 2H), 1.87−1.83 (m, 2H), 1.52−1.46 (m,
2H);

13

C NMR (100 MHz, CDCl3)  163.9, 159.2, 150.5, 143.6, 138.1, 135.8, 130.7,
148

149

130.0, 129.4, 123.5, 115.1, 113.7, 76.5, 71.9, 70.1, 55.3, 33.3, 32.7, 24.7. HRMS m/z
425.1823 (calcd for C24H27NO6, 425.1838).

Hex-5-enyltriphenylphosphonium iodide (3-121)
6-Iodohex-1-ene (9.46 g, 45.0 mmol) and triphenylphosphine
(17.7 g, 67.5 mmol) were dissolved in 220 mL MeCN and the solution was heated to 90
°C for 48 h. The solution was cooled to room temperature and the concentrated under
reduced pressure. Residue triturated with Et2O (2 x 50.0 mL) and minor amounts of
solvent removed under reduced pressure to provide the title compound as white solid
(94% yield, 20.2 g). 1H NMR (600 MHz, CDCl3)  7.84−7.78 (m, 10H), 7.71−7.68 (m,
6H), 5.67 (ddt, J = 17.1, 10.2, 6.9 Hz, 1H), 4.92 (dq, J = 17.1, 1.7 Hz, 1H), 4.88 (dd, J =
9.7, 1.5 Hz, 1H), 3.77−3.72 (m, 2H), 2.08 (q, J = 7.0 Hz, 2H), 1.78 (quin, J = 7.5 Hz,
2H), 1.66−1.60 (m, 2H);

13

C NMR (100 MHz, CDCl3)  135.0, 133.8, 130.5, 130.4,

115.4, 110.0, 32.9, 29.2, 23.2, 21.8.

5-(hex-5-enylidene)-2,2-dimethyl-1,3-dioxane (3-122)
To a solution of hexenyltriphenylphosphonium iodide 3-121 (20.0 g,
42.4 mmol) in 220 mL THF at −78 °C was added nBuLi (18.6 mL, 35.8
mmol, 1.92 M in hexanes) dropwise. After 1 h at −78 °C, 2,2-dimethyl1,3-dioxan-5-one 3-120 (3.67 g, 28.2 mmol) in 30.0 mL THF was added slowly and
stirred at −78 °C for 2 h followed by 30 min at 0 °C. Solution cooled to −78 °C, and
quenched by the addition of 200 mL half saturated aqueous NH4Cl, followed by 100 mL
THF. The mixture was allowed to stir until warmed to room temperature, the layers
separated, and the aqueous layer was extracted with EtOAc (3 x 50 mL). The combined
organic layers were washed with brine, dried (MgSO4), filtered through Celite and
concentrated under reduced pressure. Purification by flash chromatography on silica gel
using EtOAc-hexanes for elution provided the title compound as colorless oil (95% yield,
5.23 g). Rf 0.50 (20% EtOAc/hexanes). 1H NMR (400 MHz, CDCl3)  5.77 (ddt, J =
16.9, 10.4, 6.5 Hz, 1H), 5.22 (t, J = 7.4 Hz, 1H), 4.98 (m, 2H), 4.38 (s, 2H), 4.22 (s, 2H),
2.04 (q, J = 6.6 Hz, 2H), 1.96 (q, J = 7.4 Hz, 2H), 1.42 (s, 8H);
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13

C NMR (100 MHz,

150

CDCl3)  138.4, 131.9, 123.3, 114.8, 99.0, 64.6, 59.9, 41.9, 33.2, 28.5, 26.0, 24.1. HRMS
m/z 196.1485 (calcd for C12H20O2, 196.1463).

2-(Hex-5-enylidene)propane-1,3-diol (3-123)
Acetal 3-122 (1.00 g, 5.09 mmol) in 150 mL MeOH (reagent grade) was
added PPTS (25.0 mg, 0.10 mmol). After 2 h of stirring, NaHCO3 (8.00
mg, 0.10 mmol) was added and the solution was concentrated under reduced pressure.
Purification of the residue by flash chromatography on silica gel using EtOAc-hexanes
for elution provided the title compound as colorless oil (97% yield, 771 mg). Rf 0.15
(40% EtOAc/hexanes). 1H NMR (400 MHz, CDCl3)  5.83−5.73 (m, 1H), 5.54 (t, J = 7.8
Hz, 1H), 5.02−4.94 (m, 2H), 4.30 (s, 2H), 4.21 (s, 2H), 2.12−2.01 (m, 6H), 1.47 (quin, J
= 7.5 Hz, 2H);

13

C NMR (100 MHz, CDCl3)  138.4, 137.2, 130.9, 114.8, 67.7, 60.1,

33.2, 28.7, 26.7. HRMS [m/z+H+] 157.1031 (calcd for C9H16O2, 156.1150).

5-(Hex-5-enylidene)-2-(4-methoxyphenyl)-1,3-dioxane (3-123b)
Diol 3-123 (250 mg, 1.60 mmol) in 15.0 mL CH2Cl2 was added pmethoxybenzaldehyde diethylacetal (350 μL, 1.76 mmol) followed by
10-CSA (37.0 mg, 0.16 mmol). After stirring at room temperature for 16
h, the solution was quenched with 20.0 mL H2O. The mixture was
separated and the aqueous layer was extracted with CH2Cl2 (3 x 10.0
mL). The combined organic layers were washed with brine, dried (MgSO4), filtered
through Celite and concentrated under reduced pressure. Purification by flash
chromatography on silica gel using EtOAc-hexanes for elution provided the title
compound as colorless oil (89% yield, 390 mg). Rf 0.67 (40% EtOAc/hexanes). 1H NMR
(600 MHz, CDCl3)  7.43−7.40 (m, 2H), 6.90−6.87 (m, 2H), 5.79 (ddt, J = 17.1, 10.3, 6.6
Hz, 1H), 5.58 (s, 1H), 5.39 (t, J = 7.6 Hz, 1H), 5.03 (dq, J = 17.2, 1.7 Hz, 1H), 4.99−4.96
(m, 1H), 4.83 (d, J = 12.9 Hz, 1H), 4.50 (d, J = 12.0 Hz, 1H), 4.39−4.32 (m, 2H), 3.78
(m, 3H), 2.15−1.98 (m, 4H), 1.53−1.43 (m, 2H);

13

C NMR (100 MHz, CDCl3)  159.9,

138.2, 130.7, 129.3, 127.3, 126.0, 114.8, 113.5, 101.4, 72.4, 66.2, 55.2, 41.8, 33.0, 28.5,
25.9. HRMS m/z 274.1639 (calcd for C17H22O3, 274,1569).
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2-((tert-Butyldimethylsilyloxy)methyl)octa-2,7-dien-1-ol (3-124)
Diol 3-123 (1.54 g, 9.86 mmol) in 80.0 mL CH2Cl2 was added
imidazole (778 mg, 11.4 mmol) followed by TBSCl (1.56 g, 10.4 mmol). After stirring
for 16 h, 50.0 mL of H2O was added. The mixture was separated and the aqueous layer
was extracted with CH2Cl2 (3 x 30.0 mL). The combined organic layers were washed
with brine, dried (MgSO4), filtered through Celite and concentrated under reduced
pressure. Purification by flash chromatography on silica gel using EtOAc-hexanes for
elution provided the title compound as colorless oil (75% yield brsm (3:1 ratio of E:Z),
1.59 g). Rf 0.66 (40% EtOAc/hexanes). 1H NMR (400 MHz, CDCl3)  5.83−5.73 (m,
1H), 5.47 (t, J = 7.4 Hz, 1H), 5.02−4.93 (m, 2H), 4.33−4.13 (m, 4H), 2.17 (bs, 1H),
2.13−2.02 (m, 4H), 1.46 (quin, J = 7.5 Hz, 2H), 0.90 (s, 9H), 0.08 (s, 6H); 13C NMR (100
MHz, CDCl3)  138.5, 137.0, 129.3, 129.0, 114.7, 68.3, 67.3, 61.1, 60.0, 33.2, 28.8, 28.6,
26.8, 26.7, 25.9, 18.3, −5.4, −5.5. HRMS [m/z+H+] 271.2083 (calcd for C15H30O2Si,
270.2015).

(Z)-2-((4-Methoxybenzyloxy)methyl)octa-2,7-dien-1-ol
((Z)-3-125)
To a solution of ester 3-113 (5.26 g, 17.3 mmol) in 100 mL THF at −78 °C was added
DIBAL (36.3 mL, 36.3 mmol, 1.00 M in Et2O). After 1 h at −78 °C, the reaction mixture
slowly poured into 150 mL half saturated aqueous solution of Rochelle’s salt
(Na·K·tartrate) and stirred for 30 min. The mixture was separated and the aqueous layer
was extracted with EtOAc (3 x 40.0 mL). The combined organic layers were washed with
brine, dried (MgSO4), filtered through Celite and concentrated under reduced pressure.
Purification by flash chromatography on silica gel using EtOAc-hexanes for elution
provided the title compound as colorless oil (76% yield, 3.63 g). Rf 0.49 (50%
EtOAc/hexanes). 1H NMR (400 MHz, CDCl3)  7.25 (d, J = 8.2 Hz, 2H), 6.87 (d, J = 8.6
Hz, 2H), 5.82−5.72 (m, 1H), 5.61 (t, J = 7.4 Hz, 1H), 5.02−4.93 (m, 2H), 4.44 (s, 2H),
4.13 (s, 2H), 4.12 (s, 2H), 3.80 (s, 3H), 2.07−2.00 (m, 4H), 1.75 (bs, 1H), 1.45 (p, J = 7.5
Hz, 1H); 13C NMR (100 MHz, CDCl3)  159.2, 138.4, 135.3, 131.2, 130.0, 129.3, 114.7,
113.8, 72.2, 66.9, 66.5, 55.2, 33.2, 28.6, 26.9. HRMS m/z 275.1638 (calcd for C17H24O3,
276.1725).
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(Z)-2-((4-Methoxybenzyloxy)methyl)octa-2,7-dien-1-ol
((Z)-3-125)
(E)-2-((4-Methoxybenzyloxy)methyl)octa-2,7-dien-1-ol
((E)-3-125)
Acetal 3-123b (337 mg, 1.23 mmol) was dissolved in 6.00 mL Et2O at 0 °C, and DIBAL
(1.00 M in Et2O, 2.70 mL, 2.70 mmol) was added dropwise. After stirring for 3 h at 0 °C,
the solution was slowly poured into 50 mL half saturated aqueous solution of Rochelle’s
salt (Na·K·tartrate) and stirred for 30 min. The mixture was separated and the aqueous
layer was extracted with EtOAc (3 x 15 mL). The combined organic layers were washed
with brine, dried (MgSO4), filtered through Celite and concentrated under reduced
pressure. Purification by flash chromatography on silica gel using EtOAc-hexanes for
elution provided the separable isomers as colorless oils (92% yield, 2:1 dr, 208 mg (Eisomer), 104 mg (Z-isomer). The characterization data for the (Z)-isomer is reported
above, whereas the (E)-isomer data is reported here: Rf 0.46 (40% EtOAc/hexanes). 1H
NMR (400 MHz, CDCl3)  7.27−7.23 (m, 2H), 6.89−6.85 (m, 2H), 5.78 (ddt, J = 17.0,
10.4, 6.6 Hz, 1H), 5.54 (t, J = 7.4 Hz, 1H), 5.03−4.93 (m, 2H), 4.44 (s, 2H), 4.23 (s, 2H),
4.05 (s, 2H), 3.80 (s, 3H), 2.12 (q, J = 7.4 Hz, 2H), 2.08−2.03 (m, 2H), 1.47 (quin, J = 7.5
Hz, 2H); 13C NMR (100 MHz, CDCl3)  159.3, 138.4, 134.9, 132.1, 130.0, 129.4, 114.7,
113.8, 74.7, 71.9, 60.0, 55.2, 33.2, 28.6, 26.8. HRMS m/z 276.1715 (calcd for C17H24O3,
276.1725).

(R,E)-3-Hydroxy-1-((S)-4-isopropyl-2-thioxothiazolidin-3yl)-4-((4-methoxybenzyloxy)methyl)deca-4,9-dien-1-one
(3-126)
TiCl4 (74.0 μL, 0.68 mmol) and NEt(iPr)2 (117 μL, 0.67
mmol) are added sequentially to a solution of auxilliary 3-64 (127 mg, 0.63 mmol) in
2.50 mL CH2Cl2 at −40 °C. After 1.5 h at −40 °C, the solution was cooled to −78 °C, and
the aldehyde 3-114 (104 mg, 0.38 mmol) is added slowly dropwise. After 10 min at −78
°C, the reaction is quenched with the addition of 2.50 mL 1.00 M NaH2PO4·H2O and the
solution was allowed to warm to RT. The aqueous layer was then extracted with CH2Cl2
(3 x 10.0 mL), and the combined organic layers were washed with brine, dried (MgSO4),
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filtered through Celite and concentrated under reduced pressure. Purification by flash
chromatography on silica gel using EtOAc-hexanes for elution provided the title
compound as pale yellow oil (63% yield, 5:1 dr, 144 mg). Rf 0.54 (40% EtOAc/hexanes).
1

H NMR (400 MHz, CDCl3)  7.25 (d, J = 8.6 Hz, 2H), 6.86 (d, J = 8.9 Hz, 2H),

5.81−5.70 (m, 2H), 5.14−5.11 (m, 1H), 5.00−4.92 (m, 2H), 4.62 (dd, J = 8.8, 3.3 Hz,
2H), 4.42 (s, 2H), 4.12−4.05 (m, 2H), 3.79 (s, 3H), 3.69−3.63 (m, 1H), 3.52−3.43 (m,
3H), 2.99 (d, J = 12.5 Hz, 1H), 2.35 (dq, J = 13.5, 6.7 Hz, 1H), 2.09−1.99 (m, 4H), 1.45
(q, J = 7.5 Hz, 2H), 1.04 (d, J = 7.0 Hz, 1H), 0.96 (d, J = 7.0 Hz, 1H);

13

C NMR (100

MHz, CDCl3)  202.8, 173.0, 159.2, 138.4, 135.9, 131.8, 130.1, 129.5, 114.7, 113.8,
72.2, 71.9, 71.5, 65.3, 55.3, 44.4, 33.2, 30.7, 30.4, 28.6, 26.9, 19.1, 17.7. HRMS m/z
477.2001 (calcd for C25H35NO4S2, 477.2007).

(R,E)-1-((S)-4-tert-Butyl-2-thioxothiazolidin-3-yl)-3hydroxy-4-((4-methoxybenzyloxy)methyl)deca-4,9-dien-1one (3-127)
The title compound was obtained from auxilliary 3-65 and
aldehyde 3-114 using the aldol reaction conditions described above in the procedure to
obtain compound 3-126. This procedure provided the title compounds as pale yellow oils
(64% yield, 7:1 dr). Rf 0.49 (40% EtOAc/hexanes). 1H NMR (600 MHz, CDCl3)  7.25
(d, J = 8.2 Hz, 2H), 6.85 (d, J = 8.2 Hz, 2H), 5.79−5.70 (m, 2H), 5.27 (d, J = 8.6 Hz, 1H),
5.00−4.92 (m, 2H), 4.70−4.66 (m, 1H), 4.42 (s, 2H), 4.11 (d, J = 17.9 Hz, 1H), 4.04 (d, J
= 11.9 Hz, 1H), 3.79 (s, 3H), 3.55 (d, J = 5.9 Hz, 2H), 3.49 (dd, J = 11.7, 8.2 Hz, 2H),
3.24 (d, J = 5.1 Hz, 1H), 3.07 (d, J = 11.7 Hz, 1H), 2.08−1.99 (m, 4H), 1.44 (p, J = 7.5
Hz, 2H), 1.01 (s, 9H); 13C NMR (100 MHz, CDCl3)  205.1, 171.9, 159.2, 138.4, 135.8,
131.6, 129.9, 129.4, 114.7, 113.7, 72.3, 72.2, 71.7, 65.4, 55.2, 43.9, 37.8, 33.2, 30.6, 28.6,
26.9, 26.8. HRMS m/z 491.2180 (calcd for C26H37NO4S2, 491.2164).
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(S,E)-((S)-2-Hydroxy-1,2,2-triphenylethyl)-3hydroxy-4-((4-methoxybenzyloxy)methyl)deca-4,9dienoate (3-128)
The title compound was obtained from auxilliary 3-82
and aldehyde 3-114 using the aldol reaction conditions
described above in the procedure to obtain compound 3-84. This procedure provided the
title compound as colorless oil (46% yield, >20:1 dr). Rf 0.29 (30% EtOAc/hexanes). 1H
NMR (400 MHz, CDCl3)  7.54 (m, 2H), 7.35−7.31 (m, 2H), 7.27−7.23 (m, 1H),
7.20−7.07 (m, 10H), 7.02−7.00 (m, 2H), 6.86−6.82 (m, 2H), 6.66 (s, 1H), 5.78−5.70 (m,
1H), 5.55−5.47 (m, 1H), 4.98−4.92 (m, 2H), 4.38−4.32 (m, 3H), 4.00−3.89 (m, 2H), 3.79
(s, 3H), 3.03−2.87 (m, 2H), 2.60−2.48 (m, 2H), 1.99−1.88 (m, 4H), 1.39−1.29 (m, 2H);
13

C NMR (100 MHz, CDCl3)  170.7, 170.6, 159.3, 144.7, 142.5, 138.3, 135.6, 135.5,

131.8, 131.7, 129.8, 129.8, 129.5, 128.4, 128.3, 127.9, 127.7, 127.4, 127.3, 126.9, 126.9,
126.4, 126.4, 126.2, 114.7, 113.8, 80.2, 78.8, 72.3, 71.7, 71.7, 65.1, 55.2, 41.0, 40.9, 33.2,
28.5, 28.4, 26.8.

2-((tert-Butyldimethylsilyloxy)methyl)octa-2,7-dienal (3-129)
Alcohol 3-124 (800 mg, 2.96 mmol) in 20.0 mL EtOAc was added
IBX (1.66 g, 5.92 mmol) and heated to reflux for 3 h. After allowing
the solution to cool to room temperature, the solution was filtered through Celite and
concentrated under reduced pressure, which provided the title compound as colorless oil
as a 3:1 ratio of E:Z inseparable isomers (89% yield, 390 mg). Rf 0.73 (40%
EtOAc/hexanes). 1H NMR (600 MHz, CDCl3)  10.10 (s, 0.75 H), 9.38 (s, 0.25H), 6.74
(t, J = 8.5 Hz, 0.75H), 6.60 (t, J = 7.6 Hz, 0.25H), 5.82−5.72 (m, 1H), 5.04−4.98 (m, 2H),
4.35 (s, 0.50H), 4.31 (s, 1.50H), 2.60 (q, J = 7.4 Hz, 1.50H), 2.52 (q, J = 7.4 Hz, 0.50H),
2.12 (q, J = 7.0 Hz, 2H), 1.61 (quin, J = 7.5 Hz, 2H), 0.91 (s, 9H), 0.07 (s, 6H); 13C NMR
(100 MHz, CDCl3)  190.3, 147.7, 138.7, 137.8, 115.4, 60.2, 54.8, 33.0, 28.6, 25.9, 18.4,
−5.4.
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(R)-4-Benzyl-3-((2R,3S,E)-2-chloro-3-hydroxy-4-((4methoxybenzyloxy)methyl)deca-4,9-dienoyl)oxazolidin-2one (3-131)
The title compound was obtained from auxilliary (R)-3-87 and aldehyde 3-114 using the
aldol reaction conditions described above in the procedure to obtain compound 3-88. This
procedure provided the title compound as colorless oil (75% yield, >20:1 dr). Rf 0.38
(40% EtOAc/hexanes). 1H NMR (600 MHz, CDCl3)  7.33−7.17 (m, 7H), 6.83 (d, J =
8.2 Hz, 2H), 5.88−5.84 (m, 2H), 5.76 (ddt, J = 16.9, 10.3, 6.9 Hz, 1H), 4.98 (dq, J = 16.9,
1.8 Hz, 1H), 4.93 (dd, J = 10.8, 1.5 Hz, 1H), 4.74−4.61 (m, 1H), 4.47−4.44 (m, 1H),
4.41−4.36 (m, 2H), 4.07−4.01 (m, 3H), 3.80−3.74 (m, 1H), 3.77 (s, 3H), 3.21 (dd, J =
13.8, 3.2 Hz, 1H), 3.01 (d, J = 3.5 Hz, 1H), 2.76 (dd, J = 13.5, 9.4 Hz, 1H), 2.09 (q, J =
7.6 Hz, 2H), 2.02 (q, J = 7.0 Hz, 2H), 1.47 (quin, J = 7.5 Hz, 2H); 13C NMR (100 MHz,
CDCl3)  167.5, 159.1, 152.2, 138.2, 136.9, 134.7, 132.4, 129.9, 129.4, 128.9, 128.8,
127.3, 114.7, 113.6, 75.7, 72.3, 65.9, 64.2, 57.7, 55.1, 55.1, 37.0, 33.0, 28.4, 27.0.

(R)-4-Benzyl-3-((R,E)-3-hydroxy-4-((4methoxybenzyloxy)methyl)deca-4,9-dienoyl)oxazolidin-2one (3-132)
The title compound was obtained from alcohol 3-131 using the chloride cleavage reaction
conditions described above in the procedure to obtain compound 3-89. This procedure
provided the title compound as colorless oil (86% yield, 3:1 ratio of products 3-132:3133). Rf 0.34 (40% EtOAc/hexanes). 1H NMR (400 MHz, CDCl3) 7.31−7.22 (m, 5H),
7.18−7.16 (m, 2H), 6.87−6.83 (m, 2H), 5.80−5.70 (m, 2H), 5.00−4.91 (m, 2H), 4.69−4.65
(m, 1H), 4.64−4.60 (m, 1H), 4.46−4.39 (m, 2H), 4.14−4.07 (m, 4H), 3.77 (s, 3H), 3.36
(dd, J = 16.4, 8.9 Hz, 1H), 3.24 (dd, J = 13.3, 3.1 Hz, 1H), 3.16 (dd, J = 16.4, 3.9 Hz,
1H), 2.69 (dd, J = 13.5, 9.6 Hz, 1H), 2.10−1.99 (m, 4H), 1.45 (quin, J = 7.5 Hz, 2H); 13C
NMR (150 MHz, CDCl3)  171.9, 159.1, 153.3, 138.3, 136.0, 135.1, 131.5, 129.9, 129.4,
129.3, 128.8, 127.2, 114.6, 113.7, 72.2, 71.5, 66.0, 65.2, 55.1, 55.0, 41.7, 37.6, 33.1, 28.5,
26.8. HRMS [m/z+H+] 494.2534 (calcd for C29H35NO6, 493.2464).
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(R,Z)-4-Benzyl-3-(4-((4-methoxybenzyloxy)methyl)deca4,9-dien-2-ynoyl)oxazolidin-2-one (3-133)
*Note: The title compound was not confirmed but was only
suspected using the following procedure.*
The suspected title compound was obtained from alcohol 3-131 using the chloride
cleavage reaction conditions described above in the procedure to obtain compound 3-89.
This procedure provided the suspected title compound as colorless oil (86% yield, 3:1
ratio of products 3-132:3-133). Rf 0.54 (40% EtOAc/hexanes). 1H NMR (400 MHz,
CDCl3)  7.09−6.96 (m, 7H), 6.63−6.61 (m, 2H), 5.93 (t, J = 7.8 Hz, 1H), 5.52 (ddt, J =
17.1, 10.3, 6.6 Hz, 1H), 4.78−4.70 (m, 2H), 4.78−4.70 (m, 2H), 4.52−4.46 (m, 1H), 4.25
(s, 2H), 3.96 (s, 2H), 3.94−3.89 (m, 2H), 3.54 (s, 3H), 3.09 (dd, J = 13.3, 3.1 Hz, 1H),
2.54 (dd, J = 13.5, 9.6 Hz, 1H), 1.99 (q, J = 7.8 Hz, 2H), 1.80 (q, J = 7.0 Hz, 2H), 1.27
(quin, J = 7.4 Hz, 2H); 13C NMR (150 MHz, CDCl3)  165.6, 159.2, 153.3, 148.9, 146.9,
138.0, 135.4, 134.6, 130.1, 129.6, 129.4, 128.9, 127.2, 115.8, 115.0, 113.7, 72.4, 66.0,
64.9, 63.7, 55.4, 55.2, 37.9, 33.2, 28.2.

(R,Z)-4-Benzyl-3-(4-(hydroxymethyl)deca-4,9-dien-2ynoyl)oxazolidin-2-one (3-133b)
*Note: The title compound was not confirmed but was only
suspected using the following procedure.*
Suspected ene-yne 3-133 (160 mg, 0.35 mmol) in 8.00 mL CH2Cl2 and 0.80 mL H2O was
added DDQ (157 mg, 0.69 mmol) at RT. After stirring for 2 h at RT, 10.0 mL CH2Cl2
and 10.0 mL H2O was added to the reaction solution. The aqueous layers were then
extracted with CH2Cl2 (3 x 10.0 mL), and the combined organic layers were washed with
brine, dried (MgSO4), filtered through Celite and concentrated under reduced pressure.
Purification by flash chromatography on silica gel using EtOAc-hexanes for elution
provided the suspected title compound as colorless oil (65% yield, 79.5 mg). Rf 0.33
(40% EtOAc/hexanes). 1H NMR (600 MHz, CDCl3)  7.49−7.43 (m, 2H), 7.34−7.31 (m,
2H), 7.27 (d, J = 7.6 Hz, 1H), 7.22 (d, J = 7.6 Hz, 2H), 6.15 (t, J = 7.6 Hz, 1H), 5.79 (ddt,
J = 17.1, 10.3, 6.5 Hz, 1H), 5.02 (d, J = 17.6 Hz, 1H), 4.98 (d, J = 10.5 Hz, 1H),
4.76−4.72 (m, 1H), 4.43 (m, 2H), 4.22−4.15 (m, 2H), 3.35 (dd, J = 13.5, 3.4 Hz, 1H),
156
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2.78 (dd, J = 13.2, 9.7 Hz, 1H), 2.34 (q, J = 7.6 Hz, 2H), 2.09 (q, J = 7.2 Hz, 2H), 1.68
(bs, 1H), 1.56 (quin, J = 7.5 Hz, 2H); 13C NMR (150 MHz, CDCl3)  165.5, 153.5, 148.4,
146.2, 138.0, 136.7, 135.4, 129.4, 128.9, 127.3, 115.7, 115.2, 66.1, 56.9, 55.4, 38.0, 33.2,
28.3, 28.1. HRMS [m/z+H+] 354.7795 (calcd for C21H23NO4, 353.1627).

3-(4-Methoxybenzyloxy)propan-1-ol (3-151b)
The title compound was obtained from 1,3-propanediol using the standard PMB
protection reaction conditions described in the procedure to obtain compound 3-170c.
This procedure provided the title compound as colorless oil (90% yield). Rf 0.36 (40%
EtOAc/hexanes). 1H NMR (600 MHz, CDCl3)  7.25 (d, J = 8.8 Hz, 2H), 6.87 (d, J = 8.8
Hz, 2H), 4.44 (s, 2H), 3.80 (s, 3H), 3.76 (q, J = 5.7 Hz, 2H), 3.63 (t, J = 5.9 Hz, 2H), 2.25
(t, J = 5.6 Hz, 2H), 1.84 (quin, J = 5.7 Hz, 2H);

13

C NMR (100 MHz, CDCl3)  159.3,

130.2, 129.3, 113.8, 72.9, 69.2, 62.1, 55.3, 32.1.

3-(tert-Butyldiphenylsilyloxy)propan-1-ol (3-151c)
The title compound was obtained from 1,3-propanediol using the silyl protection strategy
described above in the procedure to obtain compound 3-67a, except TBDPSCl was used.
This procedure provided the title compound as a white solid (97% yield). Rf 0.41 (20%
EtOAc/hexanes). 1H NMR (600 MHz, CDCl3)  7.89−7.66 (m, 4H), 7.45−7.37 (m, 6H),
3.86−3.82 (m, 4H), 2.36 (d, J = 5.5 Hz, 1H), 1.80 (quin, J = 5.7 Hz, 2H), 1.04 (s, 9H);
13

C NMR (100 MHz, CDCl3)  135.5, 133.2, 129.8, 127.7, 63.3, 62.0, 34.2, 26.8, 19.1.

3-(4-Methoxybenzyloxy)propanal (3-151)
The title compound was obtained from alcohol 3-151b using the
standard IBX oxidation reaction conditions described above in the procedure to obtain
compound 3-76. This procedure provided the title compound as colorless oil (95% yield).
Rf 0.55 (60% EtOAc/hexanes). 1H NMR (400 MHz, CDCl3)  9.78 (t, J = 1.8 Hz, 1H),
7.24 (d, J = 8.6 Hz, 2H), 6.87 (d, J = 8.6 Hz, 2H), 4.45 (s, 2H), 3.79 (s, 3H), 3.80−3.76
(m, 2H), 2.67 (td, J = 6.2, 1.8 Hz, 2H);

13

C NMR (100 MHz, CDCl3)  201.2, 159.3,

129.9, 129.3, 113.8, 72.9, 63.5, 55.3, 43.9.
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(Z)-Ethyl 2-iodo-5-(4-methoxybenzyloxy)pent-2-enoate (3-152)
To a solution of phosphorane41 (388 mg, 2.00 mmol) in 10.0 mL
CH2Cl2 at −20 °C was added NIS (495 mg, 2.20 mmol). After allowing the solution to
stir for 20 min at −20 °C, K2CO3 (691 mg, 5.00 mmol) was added. The reaction mixture
was heated to reflux and aldehyde 3-151 (388 mg, 2.00 mmol) in 1.00 mL CH2Cl2 was
added dropwise. The reaction was held at reflux for 16 h and then cooled to RT. The
reaction mixture was filtered through Celite and concentrated under reduced pressure.
Purification by distillation provided the title compound as colorless oil (88% yield, 686
mg). Rf 0.50 (40% EtOAc/hexanes). 1H NMR (400 MHz, CDCl3)  7.31−7.24 (m, 3H),
6.88−6.86 (m, 2H), 4.46 (s, 2H), 4.25 (q, J = 7.0 Hz, 2H), 3.80 (s, 3H), 3.58 (t, J = 6.5
Hz, 2H), 2.58 (q, J = 6.5 Hz, 2H), 1.31 (t, J = 7.2 Hz, 2H); 13C NMR (100 MHz, CDCl3)
 162.7, 159.3, 150.0, 130.1, 129.3, 113.8, 96.8, 72.7, 67.1, 62.7, 55.3, 37.7, 14.2. HRMS
m/z 390.0313 (calcd for C15H19IO4, 390.0328).

(Z)-2-Iodo-5-(4-methoxybenzyloxy)pent-2-en-1-ol (3-152b)
To a solution of ester 3-152 (471 mg, 1.25 mmol) in 15.0 mL THF at
−78 °C was added DIBAL (3.80 mL, 3.80 mmol, 1.00 M in Et2O). After 4 h at −30 °C,
the reaction mixture slowly poured into 20.0 mL half saturated aqueous solution of
Rochelle’s salt (Na·K·tartrate) and stirred for 30 min. The mixture was separated and the
aqueous layer was extracted with EtOAc (3 x 10.0 mL). The combined organic layers
were washed with brine, dried (MgSO4), filtered through Celite and concentrated under
reduced pressure. Purification by flash chromatography on silica gel using EtOAchexanes for elution provided the title compound as colorless oil (94% yield, 390 g). Rf
0.38 (40% EtOAc/hexanes). 1H NMR (400 MHz, CDCl3)  7.26−7.24 (m, 2H),
6.89−6.86 (m, 2H), 6.00 (t, J = 6.5 Hz, 1H), 4.44 (s, 2H), 4.23 (d, J = 5.9 Hz, 2H), 3.80
(s, 3H), 3.51 (t, J = 6.5 Hz, 1H), 2.46 (q, J = 6.5 Hz, 2H), 1.58 (t, J = 6.6 Hz, 1H); 13C
NMR (100 MHz, CDCl3)  159.2, 133.1, 130.2, 129.3, 113.8, 109.7, 72.6, 71.6, 67.9,
55.3, 36.3. HRMS m/z 348.0211 (calcd for C13H17IO3, 348.0222).
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(Z)-tert-Butyl(2-iodo-5-(4-methoxybenzyloxy)pent-2enyloxy)dimethylsilane (3-153)
The title compound was obtained from alcohol 3-152b using the standard TBS protection
reaction conditions described above in the procedure to obtain compound 3-67a. This
procedure provided the title compound as colorless oil (96% yield). Rf 0.58 (40%
EtOAc/hexanes). 1H NMR (600 MHz, CDCl3)  7.25 (d, J = 6.4 Hz, 2H), 6.87 (d, J = 8.2
Hz, 2H), 6.02 (t, J = 6.7 Hz, 1H), 4.44 (s, 2H), 4.25 (s, 2H), 3.80 (s, 3H), 3.50 (t, J = 6.4
Hz, 2H), 2.47 (q, J = 6.4 Hz, 2H), 0.91 (s, 9H), 0.08 (s, 6H);

13

C NMR (100 MHz,

CDCl3)  159.2, 133.1, 130.2, 129.3, 113.8, 109.7, 72.6, 71.6, 67.9, 55.3, 36.3. HRMS
m/z 462.0991 (calcd for C19H31IO3Si, 462.1087).

(2Z,4E)-Ethyl-4-((tert-butyldimethylsilyloxy)methyl)-7-(4methoxybenzyloxy)hepta-2,4-dienoate (3-149)
Iodide 3-153 (694 mg, 1.50 mmol) and Pd(PPh3)4 (60.0 mg, 0.05
mmol) in 5.00 mL toluene was added vinyl borane43 (678 mg, 3.00 mmol) in 2.50 mL
toluene. A solution of NaOMe (3.75 mL, 1.88 mmol, 0.50 M) in MeOH was then added
and the solution was heated to 68 °C for 12 h. The reaction mixture was cooled to RT and
quenched with 10.0 mL half saturated aqueous NH4Cl. The mixture was separated and
the aqueous layer was extracted with EtOAc (3 x 10.0 mL). The combined organic layers
were washed with brine, dried (MgSO4), filtered through Celite and concentrated under
reduced pressure. Purification by flash chromatography on silica gel using EtOAchexanes for elution provided the title compound as colorless oil (84% yield, 547 mg). Rf
0.74 (40% EtOAc/hexanes). 1H NMR (400 MHz, CDCl3)  7.25−7.22 (m, 2H),
6.87−6.84 (m, 2H), 6.57 (d, J = 12.5 Hz, 1H), 5.87 (d, J = 11.7 Hz, 1H), 5.70 (t, J = 7.0
Hz, 1H), 4.41 (s, 2H), 4.26 (s, 2H), 4.12 (q, J = 7.0 Hz, 2H), 3.79 (s, 3H), 3.45 (t, J = 3.4
Hz, 2H), 2.33 (q, J = 7.0 Hz, 2H), 1.31−1.22 (m, 3H), 0.88 (s, 9H), 0.04 (s, 6H);

13

C

NMR (100 MHz, CDCl3)  159.1, 140.6, 138.0, 137.2, 130.5, 129.2, 125.5, 122.0, 113.7,
72.5, 69.2, 65.7, 60.1, 55.2, 29.3, 25.9, 14.2, −5.3. HRMS m/z 434.2483 (calcd for
C24H38O5Si, 434.2489).
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(E)-5-(3-(4-Methoxybenzyloxy)propylidene)-5,6-dihydro-2H-pyran2-one (3-161)
Ester 3-160 (50.0 mg, 0.12 mmol) in 1.50 mL MeOH was added ptoluenesulphonic acid monohydrate (2.00 mg, 0.01 mmol) and the
reaction mixture was allowed to stir for 2 h. The reaction was quenched with 5.00 mL
half saturated NaHCO3. The mixture was separated and the aqueous layer was extracted
with EtOAc (3 x 5.00 mL). The combined organic layers were washed with brine, dried
(MgSO4), filtered through Celite and concentrated under reduced pressure. Purification
by flash chromatography on silica gel using EtOAc-hexanes for elution provided the title
compound as colorless oil (100% yield, 32.0 mg). Rf 0.34 (40% EtOAc/hexanes). 1H
NMR (600 MHz, CDCl3)  7.31 (d, J = 10.0 Hz, 1H), 7.21 (d, J = 8.2 Hz, 2H), 6.87 (d, J
= 8.2 Hz, 2H), 5.92 (d, J = 10.0 Hz, 1H), 5.82 (t, J = 7.6 Hz, 1H), 4.85 (s, 2H), 4.42 (s,
2H), 3.79 (s, 3H), 3.50 (t, J = 6.4 Hz, 2H), 2.49 (q, J = 6.6 Hz, 2H); 13C NMR (100 MHz,
CDCl3)  159.3, 138.9, 131.7, 130.0, 129.3, 127.5, 119.2, 113.8, 113.8, 72.8, 71.1, 68.3,
55.3, 28.4. HRMS m/z 274.1211 (calcd for C16H18O4, 274.1205).

(E)-5-(3-(4-Methoxybenzyloxy)propylidene)-5,6-dihydro-2H-pyran2-ol (3-161b)
To a solution of lactone 3-161 (32.0 mg, 0.12 mmol) in 2.00 mL CH2Cl2
at −78 °C was added DIBAL (0.15 mL, 0.15 mmol, 1.00 M in Et2O).
After 45 min at −78 °C, the reaction mixture slowly poured into 10.0 mL half saturated
aqueous solution of Rochelle’s salt (Na·K·tartrate) and stirred for 30 min. The mixture
was separated and the aqueous layer was extracted with CH2Cl2 (3 x 10.0 mL). The
combined organic layers were washed with brine, dried (MgSO4), filtered through Celite
and concentrated under reduced pressure. Purification by flash chromatography on silica
gel using EtOAc-hexanes for elution provided the title compound as colorless oil (100%
yield, 32.0 g). Rf 0.23 (40% EtOAc/hexanes). 1H NMR (400 MHz, CDCl3)  7.21 (d, J =
8.9 Hz, 2H), 6.84 (d, J = 8.9 Hz, 2H), 6.58 (d, J = 10.2 Hz, 1H), 5.80 (dt, J = 10.2, 2.3
Hz, 1H), 5.375.35 (m, 2H), 4.52 (d, J = 12.9 Hz, 1H), 4.40 (s, 2H), 4.01 (d, J = 13.3 Hz,
1H), 3.77 (s, 3H), 3.44 (t, J = 6.8 Hz, 2H), 2.97 (d, J = 5.1 Hz, 1H), 2.45 (d, J = 7.6 Hz,
1H), 2.41 (d, J = 7.6 Hz, 1H).
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(E)-6-Methoxy-3-(3-(4-methoxybenzyloxy)propylidene)-3,6-dihydro2H-pyran (3-162)
Lactol 3-161b (390 mg, 1.41 mmol) in 15.0 mL MeOH was added PPTS
(35.0 mg, 0.14 mmol). The solution was allowed to stir for 16 h at RT.
To the reaction mixture was added 1.00 mL NEt3 (7.21 mmol) and the solution was
concentrated under reduced pressure to give the title compound as colorless oil (100%
yield, 385 mg). Rf 0.55 (40% EtOAc/hexanes). 1H NMR (600 MHz, CDCl3)  7.24 (d, J
= 8.8 Hz, 2H), 6.87 (d, J = 8.8 Hz, 2H), 6.60 (d, J = 10.0 Hz, 1H), 5.78 (d, J = 11.7 Hz,
1H), 5.38 (t, J = 7.6 Hz, 1H), 4.89 (d, J = 3.5 Hz, 1H), 4.48 (d, J = 12.9 Hz, 1H), 4.43 (s,
2H), 3.98 (d, J = 12.9 Hz, 1H), 3.79 (s, 3H), 3.46 (t, J = 6.7 Hz, 2H), 3.44 (s, 3H), 2.45
(q, J = 7.0 Hz, 2H);

C NMR (100 MHz, CDCl3)  159.2, 130.5, 130.3, 129.2, 125.6,

13

124.3, 123.9, 113.8, 95.6, 72.6, 69.2, 62.9, 55.3, 55.2, 27.3. HRMS m/z 290.1523 (calcd
for C17H22O4, 290.1518).

(E)-3-(6-Methoxy-2H-pyran-3(6H)-ylidene)propan-1-ol (3-163)
Silyl ether 3-169c (250 mg, 0.61 mmol) was dissolved in 3.00 mL reagent
grade THF and TBAF (1.00 M in THF, 0.92 mL, 0.92 mmol) was added
dropwise. After stirring for 1 h at RT, the solution was diluted with 10.0
mL H2O and 10.0 mL EtOAc. The mixture was separated and the aqueous layer was
extracted with EtOAc (3 x 10.0 mL). The combined organic layers were washed with
brine, dried (MgSO4), filtered through Celite and concentrated under reduced pressure.
Purification by flash chromatography on silica gel using EtOAc-hexanes for elution
provided the title compound as colorless oil (94% yield, 97.0 mg). Rf 0.16 (40%
EtOAc/hexanes). 1H NMR (400 MHz, CDCl3)  6.60 (d, J = 10.2 Hz, 1H), 5.78 (ddd, J =
10.3, 3.0, 1.6 Hz, 1H), 5.36 (t, J = 7.8 Hz, 1H), 4.88 (d, J = 3.1 Hz, 1H), 4.47 (d, J = 11.7
Hz, 1H), 3.98 (d, J = 12.9 Hz, 1H), 3.63 (t, J = 6.3 Hz, 2H), 3.42 (s, 3H), 2.432.37 (m,
2H), 1.98 (bs, 1H); 13C NMR (100 MHz, CDCl3)  131.5, 125.9, 124.2, 123.5, 95.5, 62.8,
61.9, 55.3, 30.1. HRMS m/z 170.0910 (calcd for C9H14O3, 170.0943).
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3-(tert-Butyldiphenylsilyloxy)propanal (3-165)
The title compound was obtained from alcohol 3-151c using the
standard Swern oxidation reaction conditions described above in the procedure to obtain
compound 3-67. This procedure provided the title compound as pale yellow oil (99%
yield). Rf 0.67 (20% EtOAc/hexanes). 1H NMR (400 MHz, CDCl3)  9.81 (t, J = 2.2 Hz,
1H), 7.66−7.64 (m, 4H), 7.43−7.37 (m, 6H), 4.01 (t, J = 6.1 Hz, 2H), 2.59 (td, J = 6.1,
2.3 Hz, 2H), 1.03 (s, 9H);

13

C NMR (100 MHz, CDCl3)  201.9, 135.5, 133.2, 129.8,

127.7, 58.3, 46.4, 26.7, 19.1.

(Z)-Ethyl-5-(tert-butyldiphenylsilyloxy)-2-iodopent-2-enoate
(3-166)
The title compound was obtained from aldehyde 3-165 using the reaction conditions
described above in the procedure to obtain compound 3-152. This procedure provided the
title compound as pale yellow oil (80% yield). Rf 0.56 (10% EtOAc/hexanes). 1H NMR
(400 MHz, CDCl3)  7.67−7.64 ( m, 4H), 7.43−7.35 (m, 7H), 4.27 (q, J = 7.2 Hz, 2H),
3.79 (t, J = 6.5 Hz, 2H), 2.55 (q, J = 6.5 Hz, 2H), 1.32 (t, J = 7.0 Hz, 2H), 1.05 (s, 9H);
13

C NMR (100 MHz, CDCl3)  162.8, 150.2, 135.6, 133.4, 129.7, 127.7, 96.6, 62.6, 61.4,

40.3, 26.8, 19.2, 14.2. HRMS m/z 508.0845 (calcd for C23H29IO3Si, 508.0931).

(Z)-5-(tert-Butyldiphenylsilyloxy)-2-iodopent-2-en-1-ol (3-166b)
The title compound was obtained from ester 3-166 using the
reduction reaction conditions described above in the procedure to obtain compound 3152b. This procedure provided the title compound as colorless oil (92% yield). Rf 0.64
(40% EtOAc/hexanes). 1H NMR (400 MHz, CDCl3)  7.68−7.66 (m, 4H), 7.45−7.37 (m,
6H), 5.96 (t, J = 6.6 Hz, 1H), 4.20 (d, J = 6.6 Hz, 2H), 3.75 (t, J = 6.5 Hz, 2H), 2.44 (q, J
= 6.6 Hz, 2H), 1.90 (t, J = 6.6 Hz, 1H), 1.06 (s, 9H);

13

C NMR (100 MHz, CDCl3) 

135.6, 133.7, 133.2, 129.6, 127.7, 109.6, 71.6, 62.1, 39.1, 26.8, 19.2. HRMS m/z
466.8543 (calcd for C21H27IO2Si, 466.0825).
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(Z)-6-Iodo-2,2,3,3,12,12-hexamethyl-11,11-diphenyl-4,10dioxa-3,11-disilatridec-6-ene (3-167)
The title compound was obtained from alcohol 3-166b using the standard TBS protection
reaction conditions described above in the procedure to obtain compound 3-67a. This
procedure provided the title compound as colorless oil (97% yield). Rf 0.73 (10%
EtOAc/hexanes). 1H NMR (400 MHz, CDCl3)  7.67−7.65 (m, 4H), 7.43−7.35 (m, 6H),
6.06 (tt, J = 6.8, 1.6 Hz, 1H), 4.24 (d, J = 1.6 Hz, 2H), 3.71 (t, J = 6.5 Hz, 2H), 2.44 (q, J
13

= 6.5 Hz, 2H), 1.04 (s, 9H), 0.91 (s, 9H), 0.08 (s, 6H);

C NMR (100 MHz, CDCl3) 

135.6, 133.8, 130.6, 129.6, 127.6, 108.8, 71.5, 62.3, 38.9, 26.8, 25.9, 19.2, 18.4, -5.2 .
HRMS m/z 580.7525 (calcd for C27H41IO2Si2, 580.6887).

(2Z,4E)-Ethyl-4-((tert-butyldimethylsilyloxy)methyl)-7-(tertbutyldiphenylsilyloxy)hepta-2,4-dienoate (3-168)
The title compound was obtained from iodide 3-167 using the
Suzuki reaction conditions described above in the procedure to obtain compound 3-160.
This procedure provided the title compound as colorless oil (80% yield). Rf 0.23 (5%
EtOAc/hexanes). 1H NMR (400 MHz, CDCl3)  7.69−7.66 (m, 4H), 7.44−7.36 (m, 6H),
6.53 (d, J = 12.1 Hz, 1H), 5.85 (d, J = 12.9 Hz, 1H), 5.77 (t, J = 7.2 Hz, 1H), 4.29 (s, 2H),
4.12 (q, J = 7.2 Hz, 2H), 3.68 (t, J = 6.6 Hz, 2H), 2.32 (q, J = 6.6 Hz, 2H), 1.25 (t, J = 7.2
Hz, 3H), 1.06 (s, 9H), 0.90 (s, 9H), 0.06 (s, 6H); 13C NMR (100 MHz, CDCl3)  165.7,
140.5, 137.1, 135.5, 133.9, 129.5, 127.6, 125.8, 121.8, 65.6, 63.1, 60.1, 32.1, 26.8, 25.9,
19.1, 18.4, 14.1, −5.3. HRMS m/z 551.3039 (calcd for C32H48O4Si2, 552.3091).

(E)-5-(3-(tert-Butyldiphenylsilyl)propylidene)-5,6-dihydro-2Hpyran-2-one (3-169)
The title compound was obtained from ester 3-168 using the
cyclization reaction conditions described above in the procedure to
obtain compound 3-161. This procedure provided the title compound as colorless oil
(99% yield). Rf 0.60 (40% EtOAc/hexanes). 1H NMR (400 MHz, CDCl3)  7.647.62
(m, 4H), 7.467.36 (m, 6H), 7.21 (d, J = 9.8 Hz, 1H), 5.90 (dd, J = 9.9, 1.8 Hz, 1H), 5.76
(t, J = 7.8 Hz, 1H), 2.462.41 (m, 2H), 1.04 (s, 9H);
163
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C NMR (100 MHz, CDCl3) 
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168.0, 139.0, 135.5, 133.4, 131.7, 129.8, 127.7, 119.0, 71.0, 62.5, 31.0, 26.8, 19.1.
HRMS m/z 392.7631 (calcd for C24H28O3Si, 392.1808).

(E)-5-(3-(tert-Butyldiphenylsilyloxy)propylidene)-5,6-dihydro-2Hpyran-2-ol (3-169b)
The title compound was obtained from lactone 3-169 using the
reduction reaction conditions described above in the procedure to
obtain compound 3-161b. This procedure provided the title compound as colorless oil
(99% yield). Rf 0.45 (40% EtOAc/hexanes). 1H NMR (400 MHz, CDCl3)  7.65 (d, J =
7.4 Hz, 4H), 7.447.35 (m, 6H), 6.49 (d, J = 10.2 Hz, 1H), 5.78 (d, J = 10.2 Hz, 1H),
5.405.35 (m, 2H), 4.53 (d, J = 12.9 Hz, 1H), 4.02 (d, J = 12.9 Hz, 1H), 3.68 (t, J = 6.3
Hz, 2H), 2.79 (d, J = 5.9 Hz, 1H), 2.40 (q, J = 7.0 Hz, 2H), 1.04 (s, 9H); 13C NMR (100
MHz, CDCl3)  135.6, 133.8, 130.4, 129.6, 127.6, 126.3, 124.6, 124.3, 89.3, 63.2, 63.2,
30.2, 26.8, 19.2. HRMS m/z 394.2028 (calcd for C24H30O3Si, 394.1964).

(E)-tert-Butyl(3-(6-methoxy-2H-pyran-3(6H)ylidene)propoxy)diphenylsilane (3-169c)
The title compound was obtained from lactol 3-169b using the reaction
conditions described above in the procedure to obtain compound 3162. This procedure provided the title compound as colorless oil (94% yield). Rf 0.68
(40% EtOAc/hexanes). 1H NMR (600 MHz, CDCl3)  7.65 (d, J = 6.4 Hz, 4H),
7.437.40 (m, 2H), 7.387.36 (m, 4H), 6.47 (d, J = 9.9 Hz, 1H), 5.73 (ddd, J = 9.9, 2.9,
1.8 Hz, 1H), 5.45 (t, J = 7.6 Hz, 1H), 4.88 (d, J = 2.9 Hz, 1H), 4.45 (d, J = 12.9 Hz, 1H),
3.95 (d, J = 12.9 Hz, 1H), 3.67 (t, J = 6.7 Hz, 2H), 3.43 (s, 3H), 2.39 (q, J = 6.7 Hz, 2H),
1.03 (s, 9H);

13

C NMR (100 MHz, CDCl3)  135.6, 133.8, 130.7, 129.6, 127.6, 125.4,

124.5, 124.0, 95.6, 63.3, 62.9, 55.3, 30.1, 26.8, 19.2. HRMS m/z 408.3647 (calcd for
C25H32O3Si, 408.2121).

2-(tert-Butyldimethylsilyloxy)ethanol (3-170b)
The title compound was obtained from ethylene glycol using the standard TBS protection
reaction conditions described above in the procedure to obtain compound 3-67a. This
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procedure provided the title compound as colorless oil (98% yi eld). Rf 0.50 (40%
EtOAc/hexanes). 1H NMR (400 MHz, CDCl3)  3.70-3.68 (m, 2H), 2.63-3.61 (m, 2H),
2.09 (bs, 1H), 0.09 (s, 9H), 0.06 (s, 6H); 13C NMR (100 MHz, CDCl3)  64.1, 63.7, 25.9,
18.3, −5.4.

2-(4-Methoxybenzyloxy)ethanol (3-170c)
Ethylene glycol (1.74 mL, 31.1 mmol) in 70.0 mL THF was added NaH
(753 mg, 31.4 mmol) portionwise at 0 °C and allowed to stir for 1 h at that temperature.
To the cold solution, Bu4NI (1.14 g, 3.11 mmol) was added, followed by PMBBr and
allowed to stir at RT for 2 h. The reaction was quenched by the addition of 70.0 mL H2O.
The aqueous layer was then extracted with EtOAc (3 x 50.0 mL), and the combined
organic layers were washed with brine, dried (MgSO4), filtered through Celite and
concentrated under reduced pressure. Purification by flash chromatography on silica gel
using EtOAc-hexanes for elution provided the title compound as colorless oil (87% yield,
4.92 g). Rf 0.33 (40% EtOAc/hexanes). 1H NMR (600 MHz, CDCl3)  7.26 (d, J = 8.8
Hz, 2H), 6.88 (d, J = 8.8 Hz, 2H), 4.49 (s, 2H), 3.80 (s, 3H), 3.74−3.73 (m, 2H),
3.57−3.56 (m, 2H);

13

C NMR (100 MHz, CDCl3)  159.3, 130.0, 129.4, 113.8, 73.0,

71.0, 61.9, 55.3.

2-(tert-Butyldimethylsilyloxy)acetaldehyde (3-171)
The title compound was obtained from alcohol 3-170b using the standard
IBX oxidation reaction conditions described above in the procedure to obtain compound
3-76. This procedure provided the title compound as colorless oil (98% yield). Rf 0.70
(40% EtOAc/hexanes). 1H NMR (400 MHz, CDCl3)  9.69 (s, 1H), 4.21 (s, 2H), 0.91 (s,
9H), 0.09 (s, 6H); 13C NMR (100 MHz, CDCl3)  207.7, 75.0, 31.2, 23.8, 0.0.

2-(4-Methoxybenzyloxy)acetaldehyde (3-173)
The title compound was obtained from alcohol 3-170c using the standard
IBX oxidation reaction conditions described above in the procedure to obtain compound
3-76. This procedure provided the title compound as colorless oil (97% yield). Rf 0.50
(60% EtOAc/hexanes). 1H NMR (600 MHz, CDCl3)  9.68 (s, 1H), 7.27 (d, J = 8.8 Hz,
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2H), 6.88 (d, J = 8.2 Hz, 2H), 4.54 (s, 2H), 4.05 (s, 2H), 3.79 (s, 3H);

13

C NMR (100

MHz, CDCl3)  200.5, 159.5, 129.7, 128.8, 74.9, 73.2, 55.2.

(S)-4-Benzyl-3-((2S,3R)-2-chloro-3-hydroxy-3-(4methoxyphenyl)propanoyl)oxazolidin-2-one (3-176)
The title compound was obtained from auxilliary (S)-3-87 and
aldehyde 3-173 using the aldol reaction conditions described above in the procedure to
obtain compound 3-88. This procedure provided the title compound as colorless oil
(64%). Rf 0.50 (40% EtOAc/hexanes). 1H NMR (400 MHz, CDCl3)  7.27−7.23 (m, 5H),
6.99−6.97 (m, 2H), 6.87−6.83 (m, 2H), 5.87−5.83 (m, 1H), 4.72−4.66 (m, 1H), 4.25−4.21
(m, 1H), 4.15−4.13 (m, 1H), 3.76 (s, 3H) 3.45 (dd, J = 13.7, 7.8 Hz, 1H), 3.14 (dd, J =
13.7, 7.0 Hz, 1H), 3.07 (dd, J = 13.7, 3.1 Hz, 1H), 2.64 (dd, J = 13.7, 8.9 Hz, 1H);

13

C

NMR (100 MHz, CDCl3)  168.7, 158.9, 152.5, 134.5, 130.8, 129.3, 128.9, 127.8, 127.4,
114.0, 66.2, 55.3, 55.2, 54.5, 39.7, 37.4.

2-(4-Methoxyphenoxy)ethanol (3-177b)
NaOH (2.48 g, 62.1 mmol) in 25.0 mL H2O was added 4-methoxyphenol
(8.48 g, 62.1 mmol) followed by 2-chloroethanol (448 mg, 7.06 mmol) and the solution
was allowed to stir for 24 h at RT. The reaction was quenched by the addition of 25.0 mL
EtOAc. The aqueous layer was then extracted with EtOAc (3 x 20.0 mL), and the
combined organic layers were washed with brine, dried (MgSO4), filtered through Celite
and concentrated under reduced pressure. Purification by flash chromatography on silica
gel using EtOAc-hexanes for elution provided the title compound as a white solid (88%
yield, 1.04 g). Rf 0.32 (40% EtOAc/hexanes). 1H NMR (600 MHz, CDCl3)  6.87−6.82
(m, 4H), 4.04−4.02 (m, 2H), 3.94−3.91 (m, 2H), 3.76 (s, 3H), 2.01 (t, J = 6.4 Hz, 1H);
13

C NMR (100 MHz, CDCl3)  154.1, 152.7, 115.6, 114.7, 69.9, 61.6, 55.7.

2-(4-Methoxyphenoxy)acetaldehyde (3-178)
The title compound was obtained from alcohol 3-177b using the standard
IBX oxidation reaction conditions described above in the procedure to obtain compound
3-76. This procedure provided the title compound as colorless oil (95% yield). Rf 0.33
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(40% EtOAc/hexanes). 1H NMR (600 MHz, CDCl3)  9.77 (s, 1H), 6.81 (bs, 4H), 4.47
(s, 2H), 3.72 (s, 3H); 13C NMR (100 MHz, CDCl3)  199.8, 115.7, 114.9, 73.5, 55.7.

(S)-4-Benzyl-3-((2S,3R)-2-chloro-3-hydroxy-4-(4methoxyphenoxy)butanoyl)oxazolidin-2-one (3-179)
The title compound was obtained from auxilliary (S)-3-87 and
aldehyde 3-178 using the aldol reaction conditions described above in the procedure to
obtain compound 3-88. This procedure provided the title compound as pale yellow oil
(74% yield, >20:1 dr). Rf 0.27 (40% EtOAc/hexanes). 1H NMR (400 MHz, CDCl3) 
7.36−7.26 (m, 3H), 7.22−7.20 (m, 2H), 6.87−6.79 (m, 4H), 5.96 (d, J = 4.3 Hz, 1H),
4.71−4.66 (m, 1H), 4.53−4.49 (m, 1H), 4.22−4.15 (m, 2H), 4.12 (d, J = 5.9 Hz, 2H), 3.75
(s, 3H), 3.28 (dd, J = 13.5, 3.3 Hz, 1H), 2.83 (dd, J = 13.7, 9.4 Hz, 1H); 13C NMR (100
MHz, CDCl3)  168.3, 154.3, 152.1, 134.5, 129.4, 129.1, 127.5, 115.6, 114.7, 70.2, 68.6,
66.4, 56.1, 55.7, 55.3, 37.2. HRMS m/z 419.1132 (calcd for C21H22ClNO6, 419.1136).

(S)-4-Benzyl-3-((S)-3-hydroxy-4-(4methoxyphenoxy)butanoyl)oxazolidin-2-one (3-180)
The title compound was obtained from alcohol 3-179 using the
chloride cleavage reaction conditions described above in the procedure to obtain
compound 3-89. This procedure provided the title compound as pale yellow oil (93%
yield). Rf 0.14 (40% EtOAc/hexanes). 1H NMR (400 MHz, CDCl3)  7.34−7.23 (m, 3H),
7.21−7.19 (m, 2H), 6.87−6.81 (m, 4H), 4.72−4.66 (m, 1H), 4.48−4.53 (m, 1H), 4.23−4.16
(m, 2H), 4.03−3.97 (m, 2H), 3.75 (s, 3H), 3.36−3.22 (m, 3H), 3.19 (bs, 1H), 2.79 (dd, J =
13.5, 9.6 Hz, 1H);

13

C NMR (100 MHz, CDCl3)  171.8, 154.1, 153.4, 152.6, 135.0,

129.4, 129.0, 127.4, 115.6, 114.6, 71.5, 66.7, 66.3, 55.7, 55.0, 39.4, 37.7. HRMS m/z
385.1518 (calcd for C21H23NO6, 385.1525).

(S)-3-Hydroxy-N-methoxy-4-(4-methoxyphenoxy)-Nmethylbutanamide (3-181)
The title compound was obtained from alcohol 3-180 using the
auxilliary cleavage reaction conditions described above in the procedure to obtain
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compound 3-90. This procedure provided the title compound as colorless oil (91% yield).
Rf 0.26 (70% EtOAc/hexanes). 1H NMR (400 MHz, CDCl3)  6.84−6.77 (m, 4H),
4.41−4.34 (m, 1H), 3.99−3.90 (m, 3H), 3.72 (s, 3H), 3.66 (s, 3H), 3.17 (s, 3H), 2.82−2.69
(m, 2H);

13

C NMR (100 MHz, CDCl3)  172.9, 153.9, 152.6, 115.3, 114.5, 71.3, 66.6,

61.2, 55.6, 34.9, 31.7. HRMS m/z 269.1261 (calcd for C13H19NO5, 269.1263). All of the
auxiliary ((S)-3-86) was also recovered from the reaction mixture.

(S)-5-Hydroxy-6-(4-methoxyphenoxy)hex-1-en-3-one (3-182)
The title compound was obtained from amide 3-181 using the
Grignard addition conditions, as described above in the procedure to obtain compound 370. This procedure provided the title compound as colorless oil (72% yield). Rf 0.47
(70% EtOAc/hexanes). 1H NMR (400 MHz, CDCl3)  6.85−6.80 (m, 4H), 6.37 (dd, J =
16.0, 12.0 Hz, 1H), 6.27 (dd, J = 16.0, 1.2 Hz, 1H), 5.91 (d, J = 11.3 Hz, 1H), 4.47 (dq,
J = 10.8, 5.4 Hz, 1H), 3.94 (d, J = 5.1 Hz, 1H), 3.75 (s, 3H), 3.19 (d, J = 4.3 Hz, 1H),
3.95−3.93 (m, 2H);

13

C NMR (100 MHz, CDCl3)  200.1, 154.1, 152.6, 136.6, 129.4,

115.5, 114.6, 71.5, 66.4, 55.7, 42.4. HRMS m/z 236.1042 (calcd for C13H16O4, 236.1049).

(2S,4R)-1-(4-Methoxyphenoxy)hex-5-ene-2,4-diol (3-183)
The title compound was obtained from ketone 3-182 using the
Prasad reduction reaction conditions, as described above in the procedure to obtain
compound 3-72. This procedure provided the title compound as colorless oil (95% yield).
Rf 0.20 (40% EtOAc/hexanes). 1H NMR (600 MHz, CDCl3)  6.85−6.80 (m, 4H), 5.89
(ddd, J = 17.0, 10.8, 5.9 Hz, 1H), 5.28 (dt, J = 17.2, 1.4 Hz, 1H), 5.12 (dt, J = 10.5, 1.2
Hz, 1H), 4.46−4.41 (m, 1H), 4.26−4.20 (m, 1H), 3.88−3.82 (m, 2H), 3.75 (s, 3H), 3.37
(bs, 1H), 3.14 (bs, 1H), 1.18−1.69 (m, 2H); 13C NMR (100 MHz, CDCl3)  154.1, 152.6,
140.3, 115.5, 114.8, 114.7, 72.8, 72.6, 70.3, 55.7, 39.3. HRMS m/z 238.1196 (calcd for
C13H18O4, 238.1205).

168

169

(2R,3R,5S)-2-(Hydroxymethyl)-5-((4-methoxyphenoxy)
methyl)tetrahydrofuran-3-ol (3-184)
To a flask charged with Co(nmp)2 (6.00 mg, 0.01 mmol) and
iPrOH (1.30 mL) was added tBuOOH (5.74 M, 2.00 L, 0.01 mmol). The reaction was
heated to 55 °C under oxygen for 1 h, and the solvent was removed completely under
reduced pressure (rotary evaporator followed by 5 min under 0.1 mm Hg vacuum while
stirring to ensure that all traces of peroxide have been removed). Diol 3-183 (25.0 g, 0.10
mmol) was added as a solution in 1.00 mL iPrOH to a flask charged with preactivated
Co(nmp)2 under 1 atm of O2 (balloon). The resulting solution was heated at 55 °C for 16
h. The solution was cooled to RT, and the solvent was removed completely under
reduced pressure (rotary evaporator followed by 5 min under 0.1 mm Hg vacuum while
stirring). The resulting residue was then dissolved in 5.00 mL EtOAc and filtered through
a pad of Celite and washed with 10.0 mL EtOAc. Solvent removal under reduced
pressure provided the title compound as colorless oil (87% yield, 23.0 mg). Rf 0.03 (40%
EtOAc/hexanes). 1H NMR (400 MHz, CDCl3)  6.84−6.79 (m, 4H), 4.66−4.61 (m, 1H),
4.59−4.55 (m, 1H), 4.00−3.89 (m, 5H), 3.74 (s, 3H), 3.74 (bs, 1H), 3.03 (bs, 1H),
2.14−2.11 (m, 1H), 2.04−2.02 (m, 1H);

13

C NMR (100 MHz, CDCl3)  153.9, 152.8,

115.6, 114.6, 81.2, 76.6, 74.0, 71.1, 61.7, 55.7, 38.2. HRMS m/z 254.1144 (calcd for
C13H18O5, 254.1154).

tert-Butyl(((2R,3R,5S)-3-(tert-butyldimethylsilyloxy)-5-((4methoxyphenoxy)methyl)tetrahydrofuran-2-yl)methoxy)
dimethylsilane (3-185)
Diol 3-183 (45.0 mg, 0.18 mmol) in 0.50 mL DMF was added imidazole (61.0 mg, 0.90
mmol) followed by TBSCl (80.0 mg, 0.90 mmol). After stirring for 16 h, 10.0 mL of H2O
was added. The mixture was separated and the aqueous layer was extracted with EtOAc
(3 x 10.0 mL). The combined organic layers were washed with brine, dried (MgSO4),
filtered through Celite and concentrated under reduced pressure. Purification by flash
chromatography on silica gel using EtOAc-hexanes for elution provided the title
compound as colorless oil (90% yield). Rf 0.45 (10% EtOAc/hexanes). 1H NMR (600
MHz, CDCl3)  6.86−6.79 (m, 4H), 4.55−4.51 (m, 1H), 4.46−4.42 (m, 1H), 3.97−3.92
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(m, 3H), 3.84−3.79 (m, 1H), 3.76−3.73 (m, 1H), 3.75 (s, 3H), 2.02−1.94 (m, 2H), 0.90 (s,
9H), 0.88 (s, 9H), 0.08 (s, 6H), 0.05 (s, 6H); 13C NMR (150 MHz, CDCl3)  153.9, 153.2,
115.5, 114.5, 83.8, 76.1, 72.2, 71.2, 61.3, 55.7, 38.5, 26.0, 25.8, 18.1, −4.7, −5.1, −5.3.
HRMS m/z 482.2878 (calcd for C25H46O5Si2, 482.2884).
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